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  2Abstract 
 
 
Antibody directed enzyme prodrug therapy (ADEPT) is a drug delivery system 
developed for the treatment of cancer. ADEPT uses a systemically administered 
antibody, tethered to an enzyme, to localize enzyme in tumour deposits. When 
the antibody-enzyme has cleared from the circulation, a low-toxicity prodrug is 
given. The prodrug is converted by the tumour-bound enzyme into an active 
cytotoxic drug. The system has potential to generate a highly potent cytotoxic 
agent at the tumour site. 
 
A clinical ADEPT system using MFECP1, a recombinant fusion protein 
consisting of an anti-carcinoembryonic antigen single chain Fv antibody and the 
bacterial enzyme carboxypeptidase G2, in combination with a bis-iodo phenol 
mustard prodrug (BIP) has been developed. A previous phase I/II clinical trial 
established the maximum tolerated dose of a single treatment cycle of this 
ADEPT system. 
 
In-vivo models with human tumour xenografts indicate that repeated ADEPT 
treatment with MFECP1/BIP led to greater efficacy without increased toxicity. 
This thesis aims to establish conditions required for safe and effective ADEPT 
when using MFECP1/BIP in man. This was achieved by conducting a phase I/II 
clinical trial of repeat-treatment ADEPT and comparing and combining the 
results with data from the single-treatment trial. The combined dataset provided 
mechanistic and clinical information on 43 patients. 
 
Multiple parameters were investigated to examine the likely cause of toxicity and 
clinical risk factors for its occurrence. Efficacy was evaluated using CT, FDG-
PET and serum tumour markers. The nature of the immune response to 
MFECP1 was investigated and possible strategies to reduce immunogenicity 
were developed.  
 
Results showed that repeated therapy was feasible in man and did not increase 
the risk of MFECP1 infusion reactions. At the maximum tolerated total prodrug 
dose for 2 ADEPT treatments, one of three patients experienced tumour 
response on FDG-PET imaging. This MD (Res) thesis significantly increases 
understanding of the conditions required for safe and effective ADEPT. 
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  21Chapter 1 
 
Introduction 
 
1.1 Drug treatment of cancer 
Improving cancer treatment is a formidable international challenge. In 
many cancer types the prognosis of patients with metastatic disease is 
measured in months rather than years and worldwide annual cancer 
mortality is estimated to be 7 million (Kamangar et al., 2006). 
 
Systemic drug therapy is an important component of the contemporary 
multi-modality treatment of cancer. Efficacy has been demonstrated in a 
number of tumour types both against early disease (i.e. adjuvant therapy) 
and against metastatic disease. Systemic treatment can be broadly 
divided into cytotoxic chemotherapy (principally acting by disrupting DNA 
function) and targeted biological therapy. In patients with metastatic solid 
tumours the efficacy of cytotoxic chemotherapy has varied markedly 
between tumour types. For example in patients with testicular germ cell 
tumours (which are usually very sensitive to cytotoxic chemotherapy) 
metastatic disease can frequently be eliminated (Honecker et al, 2009). 
 
However in most solid tumours cytyotoxic drugs cannot eliminate 
metastatic disease and benefit is typically measured in modest 
improvements of median survival. In the most resistant tumour types e.g. 
hepatocellular carcinoma, cytotoxic chemotherapy has failed to improve 
median survival. 
 
A major limitation to the effectiveness of conventional chemotherapy is 
their relative non-selectivity between malignant and non-malignant cells. 
Toxicity to non-malignant cells can cause significant side effects e.g. 
myelosuppression, stomatitis. Hence it may not be possible to deliver the 
  22ideal drug concentration to a tumour because the systemic effects of such 
a concentration would cause excessive toxicity. 
 
Targeted therapy aims to overcome these limitations by destroying 
tumour while sparing normal tissue. Therapeutic monoclonal antibodies 
(mAbs) and small molecule drugs (small non-protein compounds) have 
both demonstrated anti-tumour efficacy. For example small molecule 
drugs e.g. sunitinib, can be used to inhibit intracellular pathways that 
promote cancer cell survival (Motzer et al, 2007). Small molecule drugs 
are already playing an important role in oncology but their specificity can 
be limited by inhibition of multiple targets.  
 
1.1.1 Antibody therapy of cancer  
The exquisite specificity of antibodies provides an ideal mechanism for 
targeted cancer therapy. The earliest use of antibodies to treat human 
disease was developed by Emil Behring and Paul Ehrlich at the end of 
the 19
th century. They developed a treatment for diphtheria by 
immunizing sheep and horses with an attenuated form of the causative 
agent of diphtheria. Serum from the animals was administered to patients 
in order to provide the patients with a passive immunization of polyclonal 
antibodies against diphtheria toxin. The success of this serum therapy led 
to Behring receiving the Nobel Prize for Physiology/Medicine in 1901. 
However the administration of non-human serum to patients caused 
some recipients to develop serum sickness characterised by joint pain, 
rash and enlarged lymph nodes (von Pirquet and Schick, 1905).  
 
In 1975 Kohler and Milstein described an immortal clone of cells that 
produced antibodies with a single specificity i.e. a monoclonal antibody, 
produced by fusing an antibody generating mouse spleen cell with a 
myeloma cell (Kohler and Milstein, 1975). The ability to produce 
antibodies with a single specificity has produced a revolution in cancer 
therapy. The structure of immunoglobulin G (IgG), the most abundant 
form of antibody in serum, is shown in Figure 1.1. 
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Figure 1.1 
Schematic representation of intact immunoglobulin G (IgG). Each IgG molecule consists 
of 2 identical heavy chains and 2 identical light chains held together with disulfide bonds. 
Each chain consists of a variable region and a constant region (the heavy chain constant 
region is sub-divided into CH1, CH2 and CH3). Spatial complementarity between antibody 
and antigen allows non-covalent binding of the two molecules. VH: variable heavy region, 
VL: variable light region, CH: constant heavy region, CL: constant light region. For 
simplicity the variable and constant regions are labelled on one side only of the molecule.  
 
 
1.1.2 The development of monoclonal antibodies for cancer therapy 
The production of mAbs by Kohler and Milstein soon led to mAbs being 
used to target cancer cells. Bernstein and colleagues demonstrated that 
the survival of mice with leukaemia was increased by the administration 
of a murine mAb targeting thymus cell differentiation antigen on 
leukaemia cells (Bernstein et al, 1980). Similarly clinical trials 
demonstrated that mAbs could bring benefits to patients. For example 
administration of a murine IgG mAb targeting GD3 (a disialoganglioside 
expressed on melanomas) to 21 patients with metastatic melanoma, 
  24produced a significant reduction in tumour size in 4 patients (Vadhan-Raj 
et al, 1988). However 14 patients developed an urticarial skin reaction 
and 20 of the 21 patients developed specific antibodies against the 
administered murine mAb i.e. human anti-mouse antibodies (HAMA). 
These HAMA are generated because foreign murine mAbs are 
immunogenic i.e. they induce a specific immune response by 
components of the acquired immune system. The generation of HAMA 
can increase the risk of anaphylactic reactions, alter mAb clearance and 
reduce or abolish efficacy. Hence the immunogenicity of murine mAbs 
significantly limits their therapeutic usefulness.  
 
Over the last two decades recombinant technology has been used to 
progressively reduce immunogenicity by replacing murine sequences with 
human sequences, while retaining antigen specificity (Figure 1.2).  
 
The first development in this process of humanization was the generation 
of chimeric mAbs which consist of a murine variable region combined 
with a human constant region (Morrison et al, 1984). Several antibodies 
licensed for the treatment of cancer have a chimeric structure e.g. 
rituximab and cetuximab. In a phase I study of cetuximab in patients with 
solid tumours anti-drug antibodies (ADAs) were produced in 5% of 
patients i.e. 1 of 19 (Baselga et al, 2000). In general, patients who receive 
a chimeric mAb are less likely to produce ADAs than patients who receive 
a murine mAb (Hwang and Foote, 2005). 
 
The murine component of a mAb can be further reduced by the 
production of humanized mAbs in which the entire antibody has human 
sequences except for the complementarity determining regions (CDRs) 
which remain murine (Jones et al, 1986). Several humanized mAbs have 
been licensed for the treatment of cancer e.g. trastuzumab and 
bevacizumab. The percentage of patients producing ADAs to humanized 
antibodies is generally low. For example in a total of 37 patients treated 
with bevacizumab in two phase I clinical trials no patients produced ADAs 
(Gordon et al, 2001) and (Margolin et al, 2001). However humanized 
  25mAbs can remain immunogenic. In patients with colon cancer who 
received the unconjugated humanized mAb A33, 20 of 28 (71%) 
produced ADAs (Ritter et al, 2001). 
 
 
 
 
Figure 1.2 
Schematic representation of murine, chimeric, humanized and fully human IgG. Murine 
sequences are shown in pink and human sequences are shown in blue. In chimeric IgG 
the variable regions are murine whereas in humanized IgG only the CDRs are murine. VH: 
variable heavy region, VL: variable light region 
 
 
Two different approaches have successfully led to the development of 
entirely human mAbs. The first has been to create in vitro recombinant 
human antibody libraries (Marks et al, 1991). Libraries can be generated 
using light-chain variable domain (VL) genes and heavy-chain variable 
domain (VH) genes derived from human B-lymphocytes and incorporated 
into a selection platform such as phage display. Each phage particle 
expresses a unique antibody on its surface and recombinant antibody 
  26libraries can contain billions of different antibodies. Phage display 
technology was used to generate adalimumab, a human antibody that 
targets tumour necrosis factor. Adalimumab is licensed for the treatment 
of rheumatoid arthritis and psoriatic arthritis (Weinblatt et al, 2003; Mease 
et al., 2005). Human mAbs can also be produced using transgenic mice 
in which the mouse germ line has been manipulated by introducing 
human heavy and light chain genes while the endogenous murine 
antibody genes have been disrupted (Lonberg et al, 1994: Green et al, 
1994). The transgenes function in a manner comparable to native 
immunoglobulin genes i.e. they can undergo V(D)J joining, heavy-chain 
class switching and somatic mutation. Panitumumab is a fully human anti-
EGFR mAb generated from transgenic mice (Yang et al, 2001). 
Administration of panitumumab to 88 patients with advanced renal cell 
carcinoma did not cause any ADA formation or hypersensitivity reactions 
(Rowinsky et al, 2004). 
 
The advent of recombinant technology has also allowed the production of 
a wide variety of antibody derived molecules (Figure 1.3). The structure of 
these molecules can be tailored to a particular clinical need. For example 
single chain Fv antibodies (scFv) are univalent recombinant antibody 
fragments consisting of a variable heavy (VH) chain joined to a variable 
light (VL) chain by a polypeptide linker (Chester et al, 1994; Huston et al, 
1988; Begent et al, 1996).  
 
Single chain Fv antibodies (27 kDa) are smaller than intact IgG (150 
kDa). Dimers consisting of two scFv molecules (diabodies) can be 
produced by reducing the length of the polypeptide linker between VH and 
VL which inhibits intramolecular VH and VL interaction and instead favours 
dimer formation. Furthermore fusion proteins can be produced by joining 
the gene for a recombinant antibody fragment (e.g. scFv) with the gene 
for a second protein. Fusion proteins can create antibody-like molecules 
with multiple biological functions. Hence using hybridoma technology, 
antibody libraries, transgenic mice and recombinant technology high 
  27affinity mAbs and antibody-derived molecules can be produced against 
an extensive range of targets.  
 
 
Figure 1.3 
Schematic representation of IgG and smaller antibodies produced by enzymatic cleavage 
(e.g. F(ab’)2 and Fab’) or recombinant technology (e.g. minibody, diabody and scFv). 
scFv: single chain fragment variable antibody, VH: variable heavy region, VL: variable light 
region, CH: constant heavy region, CL: constant light region. 
 
 
1.1.3 Delivering a therapeutic antibody to cancer cells 
A further consideration in the design of mAb therapy is ensuring that 
there is sufficient delivery of antibody to the tumour. Antibody delivery to 
the peripheral rim of the tumour mass is usually good because this region 
is well perfused by relatively normal blood vessels from adjacent tissue. 
However the centre of a tumour is frequently poorly perfused and this 
limits antibody delivery. Furthermore antibody is required to diffuse 
throughout the tumour mass. Several characteristics of the antibody can 
affect this process, e.g. size, affinity and valency. These factors affect the 
total quantity of antibody targeted to a tumour, the tumour to normal 
  28tissue antibody ratio, the depth of tumour penetration and the time course 
of tumour targeting / antibody clearance. Yokota and colleagues 
demonstrated that small antibody formats e.g. scFv (27kDa) penetrate 
more deeply and rapidly into the tumour mass than larger antibody 
formats e.g. Fab’ (55kDa), F(ab’)2 (110kDa) and 150kDa IgG (Yokota et 
al, 1992). Although small antibodies achieve rapid tumour penetration 
they are also cleared quickly from the systemic circulation. Single chain 
Fv antibodies for example, undergo first pass renal clearance. This fast 
clearance can reduce the proportion of injected antibody that reaches 
each gram of tumour tissue. For example Milenic and colleagues 
demonstrated that 24 hours after administration, the percentage of 
injected antibody per gram of tumour tissue (%IDg
-1) was less with scFv 
or Fab’ than with IgG or F(ab’)2 (Milenic et al, 1991). The ideal affinity of 
an antibody appears to be complex since low affinity antibodies may 
achieve reduced tumour localization whereas very high affinity antibodies 
may fail to diffuse from the perivascular region (Adams et al, 1998; 
Adams et al, 2001). Adams and colleagues have also demonstrated that 
for antibodies of similar size increased valency increases tumour 
retention (Adams et al, 2006). 
 
1.1.4 Unconjugated antibodies 
There are two broad mechanisms by which an unconjugated mAb can 
inhibit or kill a cancer cell. The first is that antibody binding to antigen can 
disrupt the biological function of the antigen. The second is that bound 
antibody can interact with components of the immune system leading to 
an immunological assault on a targeted cell. These two mechanisms 
reflect the dual action of naturally occurring antibodies i.e. target 
recognition and interaction with complement and immune cells. The 
target antigen may be an antigen only found on cancer cells (tumour 
specific antigen) or an antigen that is over-expressed on malignant tissue 
but present to a lesser extent on normal tissue (tumour associated 
antigen). For example the mAb cetuximab targets the tumour associated 
antigen EGFR (epidermal growth factor receptor). An alternative strategy 
has been to target a soluble growth factor that promotes tumour survival. 
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tumour and stimulates angiogenesis. Bevacizumab is a humanised mAb 
that binds to VEGF and inhibits angiogenesis. Bevacizumab was the first 
anti-angiogenesis mAb to increase survival in cancer patients (Hurwitz et 
al, 2004). 
 
Mabs can also kill cancer cells by effects exerted through the Fc 
(fragment crystalizable) portion of the antibody. After binding to a target 
cell the CH2 and CH3 regions of the mAb can bind to Fc-gamma 
receptors (FcR) on immune cells (e.g. natural killer cells, neutrophils, 
macrophages) leading to antibody dependent cellular cytotoxicity 
(ADCC). Similarly following mAb-antigen binding, the interaction of two or 
more CH2 regions with the complement component C1q can activate the 
complement cascade resulting in complement dependent cytotoxicity 
(CDC). Activation of ADCC and CDC appears to be important in the 
mechanism of action of the anti-CD20 mAb rituximab which is licensed for 
the treatment of lymphoma. The response rate and time to disease 
progression of patients receiving rituximab for follicular lymphoma are 
significantly higher in individuals with certain FcRIIa and FcRIIIa 
polymorphisms (Weng et al, 2003). Furthermore in mice injected with 
lymphoma cells the therapeutic effect of rituximab is dependent on the 
animals having a functioning complement system. In knockout mice that 
are deficient in the complement component C1q the activity of rituximab 
is completely abolished (Di Gaetano et al, 2003). ADCC also appears to 
be important in the mode of action of the anti-HER2 mAb trastuzumab. In 
mice bearing human breast cancer xenografts the efficacy of trastuzumab 
is enhanced in mice deficient in the inhibitory Fc receptor FcRIIb and 
reduced in mice deficient in activating Fc receptors (Clynes et al, 2000). 
 
1.1.5 Conjugated antibodies 
It is possible to combine a mAb to a second entity so that the resulting 
conjugate mAb has a second biological function not present on naturally 
occurring antibodies e.g. radioactivity. Conjugated mAbs therefore consist 
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of an antibody component for tumour targeting and a payload that is 
responsible for cytotoxicity. Monoclonal antibodies can be conjugated to a 
variety of effectors including radioisotopes, cytotoxic drugs, enzymes or 
immunotoxins. Conjugation of the two entities can be achieved via a 
chemical bond or by production of a recombinant fusion protein. Two 
radioimmunotherapy conjugates are licensed for the treatment of 
lymphoma. Both use a β-emitting radioisotope and target the cell surface 
molecule CD20, which is expressed on normal and malignant B cells. 
Yttrium-90 ibritumomab tiuxetan (Zevalin
®) consists of the murine anti-
CD20 mAb ibritumomab (the murine version of rituximab) covalently 
bound via the chelator tiuxetan to 
90Y (Gordon et al, 2004; Witzig et al, 
2002). Tositumomab (Bexxar
®) is an 
131iodine labelled anti-CD20 murine 
IgG mAb (Kaminski et al, 2005). Cytotoxic drugs can also be conjugated 
to antibodies to selectively deliver the cytotoxic agent to a tumour. 
Gemtuzumab ozogamicin (Mylotarg
®) is a humanised anti-CD33 mAb 
conjugated with the cytotoxic calicheamicin. When gemtuzumab 
ozogamicin binds to CD33 the resulting complex is internalized into the 
cell and the cytotoxic calicheamicin moiety is released by hydrolysis of 
the mAb-calicheamicin link (Larson et al, 2005). Several unconjugated 
and conjugated mAbs are licensed to treat haematological or solid 
tumours (Table 1.1). 
 
1.2 ADEPT 
Antibody Directed Enzyme Prodrug Therapy (ADEPT) uses an antibody-
enzyme conjugate to deliver an enzyme to a tumour. When the antibody-
enzyme conjugate has bound to the tumour and cleared from the 
circulation, a low-toxicity prodrug is given that is converted by the tumour-
bound enzyme into an active cytotoxic (Figure 1.4). Many molecules of 
the active cytotoxic drug can be produced by each targeted enzyme.  
 Table 1.1 
Monoclonal antibodies approved for the treatment of cancer 
Antibody type Generic 
name 
Trade 
name  Target Murine/human 
composition 
Oncology 
indication 
Proposed 
mechanism of action 
Year of 
FDA 
approval 
Reference 
Rituximab  MabThera, 
Rituxan  CD20  Chimeric  NHL, CLL  ADCC, CDC  1997 
Coiffier et al., 2002; 
Forstpointner et al., 2004; 
Marcus et al., 2005; 
Byrd et al., 2003. 
Trastuzumab Herceptin HER-2 Humanized  Breast  cancer 
Interferes with receptor 
signal transduction, 
ADCC 
1998 
Slamon et al., 2001; 
Piccart-Gebhart et al., 
2005 
Romond et al., 2005 
Alemtuzumab Campath  CD52  Humanized  CLL  Uncertain: possibly 
CDC  2001 Elter et al., 2005 
Bevacizumab Avastin VEGF Humanized 
CRC, Breast 
cancer, NSCLC, 
RCC 
Inhibits angiogenesis  2004 
Hurwitz et al., 2004 
Sandler et al., 2006 
Yang et al., 2003 
Cetuximab Erbitux  EGFR Chimeric  CRC 
SCCHN  
Interferes with receptor 
signal transduction  2004  Cunningham et al., 2004 
Bonner et al., 2006 
Unconjugated
Panitumumab Vectibix EGFR  Human  CRC  Interferes with receptor 
signal transduction  2006 Van  Custem et al., 2007 
Gemtuzumab 
ozogamicin  Mylotarg CD33  Humanized  AML  Conjugated to the toxin 
calicheamicin.  2000 Larson et al., 2005 
Ibritumomab 
tiuxetan  Zevalin CD20  Murine  NHL  Conjugated with 
90Yttrium.  2002  Gordon et al., 2004 
Witzig et al., 2002  Conjugated 
Tositumomab Bexxar  CD20  Murine  NHL  Conjugated with 
131Iodine.  2003 Kaminski et al., 2005 
VEGF: vascular endothelial growth factor, EGFR: epidermal growth factor receptor, CRC: colorectal carcinoma, NSCLC: non-small cell lung cancer, RCC: renal cell carcinoma, SCCHN: 
squamous cell carcinoma of head and neck, NHL: non-Hodgkins lymphoma, CLL: chronic lymphocytic leukaemia,  AML:  acute myeloid leukaemia, ADCC: Antibody Dependent Cellular 
Cytotoxicity, CDC: Complement-Dependent Cytotoxicity, FDA: United States food and drug administration. 
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Figure 1.4 
Antibody directed enzyme prodrug therapy (ADEPT). ADEPT delivers an antibody-
enzyme conjugate to tumour. When the antibody-enzyme conjugate has cleared from the 
systemic circulation, a low toxicity prodrug is given that is converted by the tumour-bound 
enzyme into an active cytotoxic. The figure shows an antibody-enzyme composed of a 
single chain Fv antibody (scFv) however other antibody formats could in principle be 
used. 
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The aim of ADEPT is to maximize the dose of cytotoxic drug in tumour 
and to minimize the concentration of cytotoxic drug in non-tumour. The 
principle of ADEPT is generic and could be applied to a variety of tumour 
associated antigens using a number of possible enzyme/prodrug 
combinations.  
 
Results from pre-clinical experiments and ADEPT clinical trials have 
explored the principal requirements of ADEPT. These include: 
 
  A suitable antigen target  
  An antibody to selectively delivery antibody-enzyme to 
tumour  
  Clearance of unbound antibody-enzyme from the circulation 
  A prodrug that is converted by the enzyme into a cytotoxic 
drug 
  An active drug that causes minimal systemic toxicity 
  Patient safety and clinical efficacy 
  Minimal immunogenicity of the antibody-enzyme so that 
treatment can be given repeatedly 
 
These requirements are discussed in more detail below, drawing 
particular attention to the results of ADEPT clinical trials. Details of 
ADEPT clinical trials are also shown in Table 1.2. 
 
1.2.1 Antigen target for ADEPT 
Pre-clinical in vivo ADEPT experiments have targeted a variety of tumour 
associated antigens including carcinoembryonic antigen (CEA) (Sharma 
et al, 2005), L6 antigen (Senter et al, 1989), CD20 (Senter et al, 1989), 
Ep-CAM1 (Wolfe et al, 1999), seminoprotein (Hao et al, 2006), β-human 
chorionic gonadotrophin (Springer et al, 1991) and TAG-72 (Alderson et 
al, 2006).  
 
 
  
Table 1.2 
Components of clinical ADEPT trials 
 
Antigen Target  Antibody-
enzyme product  Enzyme  Clearing 
antibody  Prodrug Reference(s) 
CEA 
F(ab’)2 fragment of 
murine mAb (A5B7) 
chemically conjugated 
to CPG2 
CPG2 
Galactosylated murine 
mAb (SB43-gal) binds 
and inactivates CPG2 
Benzoic acid mustard 
prodrug (CMDA) 
Bagshawe et al, 1995. 
Bagshawe and 
Begent, 1996. 
CEA  ‘’ ‘’  ‘’  ‘’  Napier et al, 2000 
CEA  ‘’ ‘’  No 
Bis-iodo phenol 
mustard prodrug (BIP 
prodrug) 
Francis et al, 2002 
CEA 
Glycosylated 
recombinant fusion 
protein (MFECP1) 
composed of scFv 
and CPG2 
‘’  No 
Bis-iodo phenol 
mustard prodrug (BIP 
prodrug) 
Mayer et al, 2006 
 
ADEPT: antibody directed enzyme prodrug therapy, mAb: monoclonal antibody, CPG2: carboxypeptidaseG2, 
CEA: carcinoembryonic antigen, scFv: single chain variable antibody fragment 
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al, 1995; Bagshawe and Begent, 1996; Napier et al, 2000; Francis et al, 
2002; Mayer et al, 2006). CEA is an oncofoetal antigen and is expressed 
by a variety of adenocarcinomas in particular colorectal carcinomas. 
Normal expression of CEA in adult tissue is confined to the luminal 
surface of the gut, where it is inaccessible to antibodies given into the 
circulation, provided that IgA is not used. 
 
A feature of ADEPT systems is that activated prodrug can kill not only the 
antigen positive cell to which the antibody-enzyme is bound, but also 
other nearby tumour cells. This is known as the bystander-effect. There is 
in vivo evidence for killing of antigen negative tumour cells following 
ADEPT treatment (Cheng et al, 1999). This effect may help overcome the 
challenges of heterogeneous antigen distribution and inadequate tumour 
penetration by therapeutic mAbs.  
 
1.2.2 Antibody component of antibody-enzyme product 
The antibody component of the antibody-enzyme product aims to 
selectively target all regions of the tumour. Initial in vivo ADEPT 
experiments used intact IgG (Senter et al, 1988) or a F(ab’)2 fragment 
(Bagshawe et al, 1988) chemically conjugated to an enzyme. A chemical 
conjugate of a F(ab’)2  and enzyme has been used in clinical trials 
(Bagshawe et al, 1995; Bagshawe and Begent, 1996; Napier et al, 2000; 
Francis et al, 2002). However chemical conjugation can create difficulties 
in producing a uniform product. This challenge can be overcome by 
creating a recombinant fusion protein produced by fusing the gene 
encoding a selected scFv with the gene for a chosen enzyme. The fusion 
protein allows production of a uniform therapeutic. Furthermore using 
recombinant technology the amino acid sequence can be modified to 
meet clinical requirements. A recombinant fusion protein (MFECP1) that 
combines an anti-CEA scFv and the enzyme carboxypeptidease G2 
(CPG2), has been an important development in ADEPT clinical trials 
(Mayer et al, 2006). To produce MFECP1 a library of scFvs was 
produced from the spleen cells of mice immunised with CEA and high 
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The scFv MFE-23 was chosen for clinical use and successful tumour 
localisation of MFE-23 was demonstrated in patients by 
radioimmunoscinitgraphy (Begent et al, 1996) and a trial of radioimmuno-
guided surgery (Mayer et al, 2000).  
 
1.2.3 Clearance of antibody-enzyme from the circulation 
At the time of prodrug administration it is necessary that there is 
adequate antibody-enzyme on the tumour (to achieve efficacy) and as 
little antibody-enzyme as possible in non-tumour tissue (to minimize off-
target prodrug activation). The quantity of antibody-enzyme at any 
particular location varies with time. After intravenous administration of 
antibody-enzyme its concentration falls in the circulation as it is cleared. 
In the tumour, antibody-enzyme concentration rises following its 
administration (as the product diffuses into the tumour) and then 
subsequently falls. Hence the timing of prodrug administration is crucial; 
too soon and off-target activation may occur, too late and the absolute 
quantity of antibody-enzyme on the tumour may be inadequate.  
 
One strategy to reduce antibody-enzyme in the circulation is to administer 
a clearing antibody. A clearing antibody is given after the antibody-
enzyme and is used to neutralize antibody-enzyme that has not bound to 
tumour and remains in the bloodstream. This technique has been used in 
clinical trials (Bagshawe et al, 1995; Bagshawe and Begent, 1996; Napier 
et al, 2000). In one phase I clinical trial administration of antibody-enzyme 
(an anti-CEA F(ab’)2 chemically conjugated to CPG2) was followed by a 
clearing antibody capable of neutralizing the catalytic activity of CPG2 
(Napier et al, 2000). Tumour biopsies were taken on 5 patients following 
administration of clearing antibody and immediately before prodrug 
administration. The median tumour to plasma ratio of enzyme activity was 
>10,000 to 1. The importance of the clearing antibody can be seen from 
the results of a subsequent phase I clinical trial in which the same 
antibody-enzyme was used but a clearing antibody was not used. In this 
trial the median tumour to plasma ratio of enzyme was 0.4 to 1 (Francis et 
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mechanism for achieving high tumour to non-tumour enzyme ratios. 
However the use of a clearing antibody also made ADEPT more complex. 
 
An alternative strategy was the development of MFECP1 a novel 
antibody-enzyme fusion protein that cleared more rapidly. This was 
achieved by production of MFECP1 in the yeast Pichia pastoris which 
resulted in mannosylation of the fusion protein. Mannose structures on 
MFECP1 bind to mannose receptors on cells in the liver and spleen 
resulting in faster clearance of the fusion protein (Kogelberg et al, 2007). 
In mice bearing human xenografts mannosylated fusion protein achieved 
a greater tumour to plasma ratio than non-mannosylated fusion protein 
(Medzihradszky et al, 2004). Furthermore maximal tumour targeting 
occurred sooner with mannosylated fusion protein than non-
mannosylated fusion protein i.e. 4hours versus 48 hours.  
 
1.2.4 Enzyme in ADEPT systems 
Enzymes from a variety of sources have been examined during in vivo 
testing of ADEPT systems. One approach is to construct an antibody-
enzyme product that contains a human enzyme. Administration of the 
antibody-enzyme product is then followed by a prodrug that is activated 
by the human enzyme. The system aims to achieve a significantly higher 
concentration of the human enzyme in tumour compared to non-tumour 
tissue. 
 
Several ADEPT systems using human enzymes have been examined in 
vivo i.e. alkaline phosphatase (Senter et al, 1988; Senter et al, 1989; 
Wallace et al, 1991; Haisma et al, 1992), carboxypeptidase-A (Hao et al, 
2006) and β-glucuronidase (Bosslet et al, 1994; Houba et al, 1996; 
Houba et al, 2001; Biela et al, 2003). These systems have never been 
tested in patients. The concern with using a human enzyme is that a 
patient’s endogenous enzyme could activate prodrug in non-tumour 
tissue. In theory this challenge can be overcome if the endogenous 
enzyme is confined intracellularly and the prodrug is incapable of 
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environment it is difficult to be certain that the situation would be so 
absolute. Even low concentrations of the enzyme in blood could cause 
significant prodrug activation.  
 
In ADEPT the ideal enzymatic scenario is one in which prodrug can only 
be catalysed by the tumour bound antibody-enzyme i.e. prodrug cannot 
be catalysed by the patient’s naturally occurring enzymes. The most 
frequently applied method to achieve this is to use a bacterial enzyme 
with no mammalian homologue such as cytosine deaminase (Wallace et 
al, 1994), β-lactamase or CPG2. 
 
The bacterial enzyme β-lactamase has been incorporated into several in 
vivo ADEPT systems (Meyer et al, 1993; Vrudhula et al, 1993; Rodrigues 
et al, 1995; Kerr et al, 1999; Cortez-Retamozo et al, 2004; Alderson et al, 
2006). Alderson and colleagues used a fusion protein of a scFv (targeting 
the tumour associated antigen TAG-72) and β-lactamase (Alderson et al, 
2006). Cleavage of a cephalosporin-melphalan prodrug by β-lactamase 
released the cytotoxic drug melphalan. In mice bearing human colorectal 
carcinoma xenografts (LS174T) tumour to plasma activity ratios of 1000 
to 1 were achieved. In mice that received fusion protein followed by 
prodrug at 300mg/kg, tumour volume was significantly less than control 
mice and there was a reduction in tumour volume compared to pre-
treatment. (In contrast minimal efficacy was observed following the 
systemic administration of the licensed cytotoxic drug irinotecan alone.) 
However the ADEPT system caused significant toxicity in the mice i.e. 
following a prodrug dose of 300mg/kg the mice lost 14% of their body 
mass. The extent of the weight loss was much greater following ADEPT 
than following prodrug alone and this suggested that leak-back of 
melphalan into non-tumour tissue was responsible for most of the toxicity. 
This system has not undergone clinical testing. It is possible that toxicity 
due to leak-back of melphalan could also occur in patients, since the 
terminal half life of melphalan in patients is 108 minutes +/- 21 minutes 
(melphalan summary of product characteristics, GlaxoSmithKline). 
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and is the only enzyme to have been used in ADEPT clinical trials. CPG2 
is a metalloenzyme produced by the bacteria Pseudomonas sp. strain 
RS16. It is a homodimer and each subunit of the dimer has a catalytic 
domain containing two zinc ions (Rowsell et al, 1997). CPG2 cleaves the 
C-terminal glutamate from folic acid and its analogues e.g. the cytotoxic 
drug methotrexate. Recombinant CPG2 is used in oncology in two 
scenarios. 
 
One use of CPG2 is the emergency treatment of excessively high 
methotrexate levels in patients receiving high-dose methotrexate. In this 
indication CPG2 (which is also known by the international nonproprietary 
name glucarpidase) is used to cleave methotrexate in patients with 
delayed methotrexate excretion (Buchen et al, 2005).  
 
CPG2 has also been extensively used in ADEPT systems. CPG2 is 
useful in ADEPT for 2 reasons. Firstly it has no human enzyme 
equivalent with the same substrate specificity. Secondly it can cleave the 
C-terminal glutamate from benzyl nitrogen mustards prodrugs. CPG2 has 
been used in all ADEPT clinical trials. Initially it was used with the prodrug 
CMDA (Bagshawe et al, 1995; Bagshawe and Begent, 1996; Napier et al, 
2000) and subsequently with a bis-iodo phenol mustard prodrug (BIP 
prodrug) (Francis et al, 2002; Mayer et al, 2006). 
 
The principal challenge of using CPG2 in the clinic is that it frequently 
causes a specific immune response in patients. This is because CPG2 is 
a bacterial enzyme and it is recognized by the immune system of patients 
as being foreign. The immune response to foreign proteins is 
characterized by the activation of specific T-helper lymphocytes (Th 
lymphocytes) and the production of human antibodies directed against 
the protein. ADAs to non-human therapeutic proteins can neutralize the 
biological activity of the protein, alter the clearance of the protein and 
increase the risk of adverse events. Immunological issues are an 
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response to ADEPT using CPG2 is discussed in detail in Chapter 5. 
 
1.2.5 Prodrug in ADEPT systems 
There are a number of characteristics required in an ideal prodrug: 
 
  prodrug is stable in vivo and water soluble 
  prodrug is non-toxic 
  prodrug is readily activated into cytotoxic drug by the 
antibody-enzyme product 
  activated prodrug is many times more toxic than the prodrug 
  activated prodrug has a steep dose-cytotoxicity curve i.e. the 
increased dose of cytotoxic drug generated by ADEPT should 
lead to increased efficacy. 
  minimal leak-back of activated prodrug into non-tumour 
tissue 
 
Many different prodrugs have been used in pre-clinical ADEPT testing. 
These prodrugs can be divided into two categories, prodrugs of licensed 
cytotoxic drugs and prodrugs of bespoke cytotoxic drugs developed for 
ADEPT. For example prodrugs of methrotrexate (Hao et al, 2006), 
doxorubicin (Biela et al, 2003) and melphalan (Alderson et al, 2006) have 
been investigated in vivo. However prodrugs of licensed cytotoxic drugs 
have never been used in ADEPT clinical trials. The relatively long half 
lives of licensed cytotoxic drugs may increase the risk of side-effects 
caused by drug leaking back into non-tumour tissue. 
 
ADEPT clinical trials have used prodrugs of bespoke alkylating agents. 
Alkylating agents were chosen because in vitro they maintain a log-linear 
tumour cell kill over a wide range of doses, whereas with non-alkylating 
agents there was a plateau of cell kill at higher doses (Frei et al, 1988). 
Hence ADEPT is designed to produce tumour-localized high-dose 
chemotherapy. Whether the ADEPT approach to high-dose 
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that non-ADEPT high-dose chemotherapy regimes have not increased 
survival in common solid epithelial cancers (Hortobagyi, 2004). 
 
The first prodrug used in ADEPT clinical trials was CMDA, a benzoic acid 
mustard prodrug that was converted by CPG2 into the alkylating agent 
CJS11 (Bagshawe et al, 1995; Bagshawe and Begent, 1996; Napier et al, 
2000). Napier and colleagues reported on 10 patients with advanced CEA 
expressing malignancy who were treated with a chemical conjugate (anti-
CEA F(ab’)2 combined with CPG2) followed by a clearing antibody and 
subsequently CMDA prodrug  (Napier et al, 2000). Although no active 
enzyme was found in plasma at the time of prodrug administration, 40% 
of patients experienced grade 3/4 neutropaenia and thrombocytopaenia. 
The half life of the activated prodrug was 36 minutes +/- 14 minutes 
(Martin et al, 1997). It is likely that myelosuppression was caused by leak-
back of activated prodrug into non-tumour tissues.  
 
To address these challenges a new prodrug for ADEPT clinical trials was 
selected. This BIP prodrug (previously referred to as ZD2767P) was 
chosen based on effective conversion of BIP prodrug by CPG2 and the 
very short half life of the activated prodrug (Springer et al, 1995).  
 
BIP prodrug has since been used in 2 ADEPT clinical trials (Francis et al, 
2002; Mayer et al, 2006). Unactivated BIP prodrug appears to cause little 
toxicity since when it was given to 3 patients (without antibody-enzyme) 
only grade 1 adverse events occurred (Francis et al, 2002). 
 
1.3 Single ADEPT treatment with MFECP1 and BIP prodrug 
It was hypothesized that MFECP1 could produce a high tumour to plasma 
enzyme activity ratio without the use of a clearing antibody, due to its 
rapid clearance from the circulation. Furthermore by combining MFECP1 
with BIP prodrug it was hypothesized that adverse events could be 
reduced and efficacy increased. 
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(anti-CEA scFv and CPG2) and BIP prodrug were investigated in nude 
mice bearing human colon carcinoma xenografts (Sharma et al, 2005). 
The half life of the fusion protein in mice bearing LS174T xenografts was 
30 minutes. Six hours after administration of fusion protein the tumour to 
plasma ratios of CPG2 activity in LS174T and SW1222 xenografts were 
1400 to 1 and 339 to 1 respectively. The lowest tumour to non-tumour 
CPG2 activity ratio at 6 hours was 43 to 1 (tumour versus spleen in mice 
with SW1222 xenografts). Selective localization of CPG2 in tumour tissue 
was also demonstrated by immunohistochemistry 6 hours after fusion 
protein administration. A single ADEPT treatment consisting of 
intravenous fusion protein followed by BIP prodrug (given at 6, 7 and 8 
hours intra-peritoneally) significantly delayed growth of LS174T and 
SW1222 xenografts compared to no treatment. Administration of fusion 
protein alone or BIP prodrug alone did not slow tumour growth. The mean 
percentage weight loss following a single ADEPT treatment was <2%.  
 
1.3.1 Phase I clinical trial of a single ADEPT treatment with MFECP1 
and BIP prodrug 
Following these encouraging pre-clinical results a phase I clinical trial of 
single ADEPT treatments, using MFECP1 and BIP prodrug, was 
conducted (Mayer et al, 2006). The trial recruited 31 patients with 
advanced CEA expressing malignancy; all had received previous 
chemotherapy. Gamma camera imaging of patients who received 
MFECP1 labelled with 
123I or 
131I showed that MFECP1 cleared rapidly 
through the liver. The pharmacokinetics of MFECP1 was measured after 
administration of 3000U/m
2  (α half life 0.44h, β half life 1.96h) and 
5000U/m
2 (α half life 0.52h, β half life 4.6h). Adverse events related to 
MFECP1 were mild i.e. grade 1 only. Analysis of tumour biopsies by 
immunohistochemistry with anti-CPG2 antibodies showed MFECP1 up to 
15hours after 3000U/m
2 and up to 19hours after 5000U/m
2. The median 
half life of the BIP prodrug was 10 minutes. Details of treatment received 
are shown in Table 1.3. 
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Table 1.3 
Treatment received in phase I trial of single-treatment ADEPT 
with MFECP1 and BIP prodrug 
 
Number of treatments 
MFECP1 
dose per 
treatment 
(U/ml) 
 
Total 
prodrug 
dose 
(mg/m
2) 
 
Number of  
patients 
treated 
 
37 6 
48 3 
63 2 
101 2 
202 2 
5000 
 
403 1 
806 4 
1613 2 
3226 1 
806 3 
3000 
1613 2 
1 
1500 600  3 
Data from Mayer A et al., 2006 and CRUK database 
 
 
Three dose-levels of MFECP1 were evaluated: 5000U/m
2, 3000U/m
2 and 
1500U/m
2. At an MFECP1 dose of 5000U/m
2 and with prodrug 
administered when serum CPG2 activity ≤ 0.005 U/ml, total prodrug dose 
(TPD) was escalated from 37.26mg/m
2 to 3225.6 mg/m
2. DLT occurred in 
a patient who received a TPD of 3225.6 mg/m
2 (grade 4 elevation of AST, 
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were reversible but temporary haemodialysis was required. 
 
One patient (patient 3) received prodrug when serum CPG2 activity was 
> 0.005 U/ml
 (serum CPG2 activity 0.0167 U/ml). The patient received a 
total prodrug dose of 37mg/m
2 and developed grade 3 neutropaenia and 
thrombocytopaenia. (Initial patients had been permitted to receive 
prodrug when serum CPG2 activity was <0.05U/ml.) Following this 
toxicity at the lowest prodrug dose level, the serum CPG2 activity that 
permitted prodrug administration was lowered from 0.05U/ml to 
0.005U/ml. 
 
In patients who received MFECP1 5000U/m
2 and prodrug when serum 
CPG2 activity was ≤ 0.005U/ml the median time interval between end of 
MFECP1 infusion and start of prodrug was 19.1 hours (range 4.9 to 37.2 
hours). However in mice studies favourable tumour to normal tissue 
MFECP1 ratios were seen 6 hours after administration of MFECP1. In 
order to investigate whether a reduced dose of MFECP1 would permit 
earlier prodrug administration, MFECP1 doses of 3000U/m
2 and 
1500U/m
2 were evaluated. 
 
When MFECP1 was given at 3000U/m
2 and prodrug was given at a 
serum CPG2 activity ≤ 0.005U/ml the median time interval between end 
of MFECP1 infusion and start of prodrug was reduced to 13.0 hours 
(range 11.6 to 14.9 hours). At a TPD of 806mg/m
2 no grade 3 or 4 
toxicities occurred. At a TPD of 1613mg/m
2, DLT occurred (grade 4 
elevations of ALT and AST, grade 3 fatigue). 
 
MFECP1 at 1500U/m
2 was investigated at a TPD of 600mg/m
2 in 3 
patients. Prodrug was given at a median of 8.4 hours (range 7.9 to 23.8 
hours) after the end of the MFECP1 infusion.
 Grade 3 thrombocytopaenia 
and fatigue occurred in 1 of the 3 treated patients. 
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determined as MFECP1 3000U/m
2 followed by a TPD of 806mg/m
2, given 
when
 serum CPG2 activity ≤ 0.005U/ml.
 With this regime no grade 3 or 4 
toxicities occurred and tumour biopsies showed evidence of MFECP1 
localization and cross-linking of tumour DNA consistent with exposure to 
activated prodrug (Mayer et al, 2006).
 
 
The presence of human anti-CPG2 antibodies (HACPA) was measured 
before and during follow up. Complete HACPA data was available on 30 
patients (no follow up HACPA data was available on patient 31 due to 
clinical deterioration because of disease progression). Twelve of 30 
patients became HACPA positive (40%). 
 
No complete or partial responses were seen on computerized 
tomography (CT) imaging by RECIST criteria (Response Evaluation 
Criteria in Solid Tumours; Therasse et al, 2000). One patient with 
metastatic peritoneal carcinoma had a 9% reduction in tumour size by 
RECIST methods on Day 29 on CT imaging. 
 
1.4 Repeat ADEPT treatment using MFECP1 and BIP prodrug 
How can the efficacy of ADEPT using MFECP1 and BIP prodrug be 
increased? One possibility is to give repeat ADEPT treatments. Evidence 
to support the technique of repeatedly treating a cancer with a cytotoxic 
drug comes from in vitro experiments using murine L1210 leukaemia cells 
(Skipper, 1971). The results demonstrate that a cytotoxic drug displays 
logarithmic cell kill kinetics i.e. when cells receive repeated chemotherapy 
treatments a constant percentage of tumour cells are killed per treatment, 
rather than a constant number of cells. In a drug-sensitive cell line all the 
cancer cells can be eliminated following repeat treatments. The model 
simplifies a complex in vivo system where there may be heterogeneity of 
drug delivery and heterogeneity of cell sensitivity. However it emphasizes 
the principle that when a cytotoxic system is unable to kill all cancer cells 
with a single treatment, repeat treatments are necessary to achieve the 
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dominance of repeat treatment schedules in oncology. 
 
1.4.1 Pre-clinical investigation of repeat ADEPT treatment 
Pre-clinical in vivo testing of repeat treatments of ADEPT was performed 
in nude mice bearing human colon carcinoma xenografts (Sharma et al, 
2005). Each treatment consisted of intravenous glycosylated fusion 
protein followed by BIP prodrug given at 6, 7 and 8 hours intra-
peritoneally. Mice bearing LS174T xenografts received 9 ADEPT 
treatments over 3 weeks and mice bearing SW1222 xenografts received 
10 ADEPT treatments over 4 weeks. Control mice received repeat 
treatment of prodrug alone, repeat treatment of fusion protein alone, a 
single ADEPT treatment or no treatment. Therapeutic efficacy was 
significantly greater with repeat treatments compared to a single 
treatment in both types of xenograft. Repeat ADEPT treatments induced 
growth delay in LS174T xenografts and tumour regression in SW1222 
xenografts. Weight loss following repeat ADEPT treatments was <2% in 
both xenograft types. 
 
1.4.2 Phase I/II clinical trial of repeat ADEPT treatment with MFECP1 
and BIP prodrug 
It is hypothesized that in patients, repeat ADEPT treatments will also 
deliver greater efficacy compared to a single ADEPT treatment. However 
to date, no patient has ever received more than one treatment of ADEPT 
with MFECP1 and BIP prodrug. 
 
This MD (Res) thesis aims to investigate repeat ADEPT treatments and 
to increase understanding of the immune response to MFECP1. Hence at 
the centre of this thesis is a phase I/II clinical trial of repeat ADEPT 
treatments using MFECP1 and BIP prodrug. In addition laboratory 
experiments were conducted to increase understanding of the immune 
response to MFECP1. 
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1)  Can repeat ADEPT be given safely? 
 
2)  Is there preliminary evidence that repeat ADEPT has efficacy and 
how is this best measured? 
 
3)  What clinical factors affect toxicity and efficacy? 
 
4)  What is the nature of the immune response to MFECP1 and is this 
affected by repeat administration of ADEPT?  
 
1.5 Safety of repeat ADEPT treatment 
The principal aim of the phase I/II clinical trial is to investigate whether 
repeat ADEPT treatments can be given safely. At the MTD of a single 
ADEPT treatment (3000U/m
2 MFECP1 with a TPD of 806mg/m
2) the 
most severe grade of adverse event was grade 2 (Table 1.4). 
 
Table 1.4 
Most severe adverse events (all grade 2) at the maximum tolerated 
dose of a single ADEPT treatment with MFECP1 and BIP prodrug 
 
Adverse event  Number of patients (%) 
Fatigue 2  (66%) 
Nausea 1  (33%) 
Vomiting 1  (33%) 
Leucocytes (total WBC)  1 (33%) 
Neutrophils / granulocytes  1 (33%) 
Haemoglobin 1  (33%) 
Data on patients 26, 27 and 28. Data from CRUK database 
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may occur after repeat ADEPT treatments. It is possible that repeat 
treatment could increase the severity or frequency of the toxicities seen 
following a single treatment. In addition new adverse events, not seen 
with single treatment, could emerge. 
 
This MD (Res) thesis aims to use safety data from the repeat-treatment 
ADEPT clinical trial to answer important clinical questions: What is the 
maximum number of tolerated treatments? What is the maximum 
tolerated total prodrug dose? 
 
Understanding ADEPT toxicity is likely to be more complex than 
understanding toxicity in a conventional single-agent phase I clinical trial. 
This is due to two reasons. Firstly more than one drug is administered i.e. 
MFECP1 and BIP prodrug. Furthermore a third drug (activated prodrug) 
is generated. Hence any toxicity could be due to MFECP1, BIP prodrug 
or activated prodrug. 
 
Secondly the use of more than one drug creates multiple variables, all of 
which could affect toxicity: 
 
1. Dose of MFECP1 
2. Serum CPG2 activity at time of prodrug administration 
3. Time interval between MFECP1 and prodrug 
4. Total prodrug dose 
5. Number of ADEPT treatments 
 
In addition toxicity may also be dependent on patient characteristics e.g. 
organ function. 
 
Hence it is desirable to identify principles underlying ADEPT toxicity.  This 
would be very useful clinically and would allow the design of safer 
treatment schedules. In view of the large number of variables it is 
desirable to analyse data from as many patients as possible. Hence this 
  49MD (Res) aims to perform a combined analysis on all available safety 
data i.e. single-treatment and repeat-treatment patients. Combined 
analysis aims to answer important clinical questions: Which dose 
schedules predispose to hepatic toxicity? What factors increase the risk 
of myelosuppression? 
 
1.6 Efficacy of repeat ADEPT treatment 
The principle aims of a phase I trial are to establish a safe dose, the 
toxicity profile and the pharmacokinetic profile. In addition it is also 
desirable to confirm that the drug is having the desired biological effect on 
target tissue. 
 
If a novel investigational agent can satisfy the requirements of a phase I 
trial then the drug may progress to a phase II trial. The principal aim of 
the phase II trial is to investigate efficacy in a larger number of patients, 
using the dose and schedule established in the phase I trial. 
 
Although efficacy is formally assessed in a phase II trial it is desirable to 
detect some evidence of efficacy in a phase I trial since it may provide an 
early indication of which dose/schedule, tumour types or patient 
characteristics are associated with efficacy. 
 
1.6.1 CT imaging 
Perhaps the simplest method to assess efficacy is to measure the size of 
tumours before and after treatment. In a meta-analysis of data from over 
3000 patients who received cytotoxic chemotherapy for metastatic 
colorectal cancer, tumour response (based on reduction in tumour size) 
was a highly significant predictor of survival (Buyse et al, 2000). This 
effect was independent of the patient’s performance status.  
 
CT imaging is the most widely used technique to measure tumour size. 
The international use of RECIST criteria has provided a common 
language to consistently describe efficacy assessment. Since the 
activated prodrug in ADEPT is a cytotoxic agent it is appropriate to 
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may cause tumour shrinkage. Hence CT imaging and RECIST criteria will 
be used to assess efficacy in the current trial of repeat ADEPT 
treatments. 
 
1.6.2 FDG-PET imaging 
Whereas CT measures the size of tumour positron emission tomography 
(PET) is designed to examine the activity of tumour. The most frequently 
used positron emitting isotope is 
18F which can be incorporated into the 
glucose analogue 2-[
18F] fluoro-2-deoxy-D-glucose (FDG). FDG is taken 
into cells and phosphorylated by hexokinase. However unlike glucose 
FDG is not significantly further metabolized and hence becomes trapped 
in the cell. Many tumours have increased rates of aerobic glycolysis 
compared to non-tumour tissue and hence tumour tissue can be identified 
by a region of increased FDG uptake. FDG-PET imaging can be used to 
measure response to systemic anti-cancer drugs. In these situations the 
reduction in FDG uptake in tumour following treatment, can be caused by 
a reduction in the number of viable tumour cells or by a reduction in the 
uptake/metabolism of glucose per cell. 
 
Unike CT anatomical imaging, there is still wide variation between 
investigators regarding the methods used to quantify tumour activity and 
the criteria used to assess response to therapy. The most frequently used 
method to quantify FDG activity in tumour is to calculate the tumour’s 
standardized uptake value (SUV). This is the FDG uptake relative to the 
injected dose of radioactivity. The injected dose is normalized to body 
mass, lean body mass or body surface area. There is no standard 
technique for defining the region of interest (ROI) of the tumour i.e. the 
region where the SUV is measured. A variety of different methods are 
currently used e.g. hand-drawing, fixed dimension ROI including the pixel 
with highest activity, volume-growing algorithms that define ROI based on 
the increased uptake of tumour compared to normal tissue. 
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FDG-PET can be useful in measuring the response of gastrointestinal 
carcinomas to chemotherapy. For example a clinical trial evaluated the 
usefulness of FDG-PET imaging in patients with adenocarcinoma of the 
oesophago-gastric junction undergoing chemotherapy followed by 
resection (Ott et al, 2006). FDG-PET imaging was performed before 
chemotherapy and 14 days after starting chemotherapy. Patients 
subsequently underwent surgical resection. ROI was defined as a circle 
of fixed diameter placed onto the tumour on the slice of maximal FDG 
uptake. FDG-PET response was defined a priori as a > 35% reduction in 
tumour SUV. A histopathological response occurred in 44% of patients 
who had a FDG-PET response and only 5% of patients who did not have 
a FDG-PET response (p=0.001). Median survival was significantly longer 
in patients who had a FDG-PET response compared to those who did 
not.  
 
Other groups have developed volume-growing algorithms to attempt to 
measure total activity in the tumour volume i.e. total lesion glycolysis. For 
example Green and colleagues have developed a technique which 
begins with the investigator selecting a point on a visualized tumour 
lesion (Green et al, 2008). Computer software then runs a volume-
growing algorithm to define the volume of interest and calculate the total 
number of counts in the volume. The technique can be applied to multiple 
lesions within a patient so that the total number of counts in the target 
lesions can be calculated. The clinical validity of this semi-automatic 
drawing method was investigated in 20 patients who underwent 1
st or 2
nd 
line standard chemotherapy for metastatic or locally advanced solid 
tumours. Fourteen of the 20 patients had gastrointestinal carcinomas. 
Tumour response was assessed by CT and FDG-PET prior to treatment. 
Following treatment patients underwent FDG-PET (at 2 - 4 weeks and 9 – 
12 weeks) and CT (at 9 - 12 weeks). Response on FDG-PET was defined 
as a reduction of >15% in the total number of counts or disappearance of 
all target lesions, disease progression (PDPET) was an increase of >10% 
in the total number of counts and stable diease (SDPET) was defined as 
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images was assessed by RECIST criteria. Patients with a response by 
FDG-PET at 2-4 weeks or 9-12 weeks lived significantly longer than 
patients with (SDPET) or (PDPET). In the 9 patients who had SD on CT 
imaging 4 patients had a response on FDG-PET. Hence in this small 
group of patients response based on the volume-growing algorithm of 
Green and colleagues was positively associated with an important clinical 
end-point i.e. survival. 
 
Francis and colleagues have used the same algorithm to assess FDG-
PET response after one cycle of chemotherapy in patients with 
mesothelioma (Francis et al, 2007). Risk of death was significantly less in 
patients in whom there was a ≥ 10% reduction in total number of counts 
in the volume of interest.  
 
Hence in addition to efficacy assessment by CT (which will be performed 
in all patients), assessment by FDG-PET will be offered to patients. FDG-
PET images will be quantified using the semi-automatic drawing method 
described by Green and colleagues. 
 
1.6.3 Serum tumour markers 
Elevation of serum tumour-associated antigen is associated with a 
number of solid tumours. For example more than 80% of patients with 
metastatic colorectal cancer have an elevated value of CEA. In addition 
serum CA 19-9 can be elevated in carcinomas of the gastrointestinal tract 
and biliary region. Measurement of serum tumour markers can provide 
clinically relevant information in patients with gastrointestinal carcinoma. 
For example the serum CEA kinetic (a measure of the change of serum 
CEA over at least 3 CEA values) was measured on patients with 
metastatic colorectal cancer undergoing chemotherapy (Iwanicki-Caron et 
al, 2008). The serum CEA kinetic values for patients with progressive 
disease, stable disease and responsive disease (measured by CT 
imaging) were significantly different. Furthermore high CEA kinetic values 
were significantly correlated with reduced disease free survival. 
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serum CEA, serum CA19-9 is examined rather than serum CEA. 
 
1.7 Immune response to MFECP1  
The fusion protein MFECP1 combines targeting and enzymatic functions. 
The bacterial enzyme CPG2 was chosen since it has no human enzyme 
equivalent with the same substrate specificity. However the use of non-
human proteins can also have disadvantages. This is because the 
administration of a non-human protein to a patient can induce a specific 
immune response directed against the therapeutic protein i.e. the protein 
is immunogenic. One important consequence of immunogenicity is the 
production of ADAs. 
 
1.7.1 Clinical relevance of immune response to therapeutic proteins 
derived from non-human proteins 
Studying the immune response to therapeutic proteins derived from non-
human proteins is important because the immune response can cause 
significant clinical effects. Immunological responses (including the 
formation of ADAs) can cause serious adverse events (e.g. serum 
sickness and anaphylaxis), reduce clinical effectiveness and alter 
clearance. 
 
Serum sickness is characterised by joint pain, rash and enlarged lymph 
nodes. The mechanism is believed to be due to antibody-drug complexes 
lodging in small blood vessels. Serum sickness can occur after the first 
dose of a drug, (when it typically presents 8-13 days after drug 
administration) or after repeated doses. Serum sickness has been 
reported in patients receiving the chimeric mAb rituximab (Todd and 
Helfgott, 2007), the murine radiolabelled mAb Zevalin
® (DeMonaco and 
Jacobs, 2007) and the bacterial protein streptokinase (Proctor et al, 
1994). The clinical symptoms and signs are usually self-limiting provided 
that administration of the causative drug stops. 
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drug or its epitopes, and is characterized by an excessive secondary 
immunological response. The reaction begins with drug molecules 
binding to IgE on the surface of mast cells. This leads to cross-linking of 
surface IgE resulting in the release of pre-formed granules (containing a 
variety molecules including histamine) and the synthesis of arachidonic 
acid metabolites. The clinical features of severe anaphylaxis are the very 
rapid onset of urticarial rash, bronchospasm and hypotension. Severe 
anaphylaxis can be fatal within minutes of drug administration. For 
example retreatment with the murine mAb muromonab-CD3 (Orthoclone 
OKT
®3), can cause life-threatening anaphylaxis due to the presence of 
anti-muromanab-CD3 IgE in serum (Abramowicz et al, 1992). In patients 
with rheumatoid arthritis receiving the mAb infliximab, ADA levels were 
significantly higher in patients who discontinued treatment due to an 
infusion reaction, than patients whose therapy was not stopped due to 
adverse events (Bendtzen et al, 2006). 
 
Anti-drug antibodies can also reduce drug efficacy if the antibodies 
neutralize the active site of the drug i.e. neutralizing antibodies (NAbs). 
For example ADAs against the therapeutic enzyme L-asparaginase, 
derived from Escherichia coli (E.coli) can neutralize the enzyme activity of 
L-asparaginase (Avramis et al, 2002).  
 
Furthermore there is some evidence that neutralization of a drug can 
affect clinical effectiveness. The most convincing evidence comes from 
longitudinal studies in which the efficacy of a drug in individual patients is 
examined during antibody negative and antibody positive periods i.e. 
each patient acts as their own control. Sorensen and colleagues 
examined the presence of NAbs in 541 multiple sclerosis patients who 
were treated with recombinant human interferon beta (Sorensen et al, 
2003). The odds ratio for risk of relapse was significantly higher (p<0.03) 
during NAb positive periods than during NAb negative periods. 
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non-human proteins 
The immunological reaction to a therapeutic derived from a foreign 
protein is modelled on the immune response to a pathogen or 
vaccination. The most fundamental determinant of neo-antigen 
immunogenicity is whether a therapeutic protein can activate B-
lymphocytes and CD4+ Th lymphocytes. B-lymphocytes and T-
lymphocytes recognize antigen in different ways. 
 
Each B-lymphocyte produces antibody with a single specificity and many 
copies of this antibody are expressed on its cell surface. When antigen 
encounters a B-lymphocyte with surface antibody that is complimentary to 
it, the antigen binds the surface antibody causing activation of the B-
lymphocyte. This induces clonal proliferation and differentiation leading to 
the production of plasma cells capable of making antibody specific to that 
particular antigen.  
 
In contrast T-lymphocytes do not recognize antigen directly. T-
lymphocytes require antigen to be presented to them by specialized 
antigen presenting cells (APCs). APCs e.g. dendritic cells, take up 
antigen, process it into short peptide fragments and display it with cell-
surface major histocompatibilty complex (MHC) molecules. A naïve T-
lymphocyte can be activated if there is complimentarity between the T-
cell receptor (TCR) and the presented peptide-MHC. Each T-lymphocyte 
expresses a TCR with a single specificity. Activation of T-lymphoctytes 
leads to clonal proliferation and maturation. Non-naive lymphocytes can 
be activated by peptide-MHC on other cell types e.g. macrophages and 
B-lymphocytes. 
 
Hence B-lymphocytes recognize surface epitopes whereas T-
lymphocytes recognize linear peptide sequences. 
 
Although antibodies are produced by plasma cells derived from activated 
B-lymphocytes, Th lymphocytes are essential in the production of an 
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necessary for the production of high affinity, class switched antibodies 
and memory responses, which are all characteristics of ADA immune 
responses.  
 
For example a TCR on a Th lymphocyte can bind to a MHC class II-
peptide complex on the surface of B-lymphocyte. This interaction leads to 
release of cytokines from Th lymphocyte and upregulation of IL-4 
receptors on the B-lymphocytes. These signals promote clonal 
proliferation of the B-lymphocytes and allow immunoglobulin class 
switching e.g. change of production from IgM to IgG. In addition activation 
of the B-lymphocyte leads to somatic hypermutation of immunoglobulin 
variable regions, which is essential for the production of novel 
immunoglobulins with higher antigen affinity i.e. affinity maturation.  
 
1.7.3 ADEPT and immunogenicity 
Early ADEPT clinical trials used the antibody-enzyme A5B7-CPG2. This 
chemical conjugate was immunogenic since it combined a F(ab’)2 
fragment of a murine mAb (A5B7) and the bacterial enzyme CPG2. 
Hence patients frequently produced HAMA against the murine F(ab’)2 
fragment and HACPA against CPG2. 
 
For example in a phase I trial of a single ADEPT treatment using A5B7-
CPG2, 100% of patients developed HAMA and 96% developed HACPA 
(Francis et al, 2002). The median time to develop HACPA was 15 days 
(range 7 to 50). 
 
Subsequently the chemical conjugate A5B7-CPG2 has been replaced by 
MFECP1. Following a single infusion of MFECP1 40% of patients 
became HACPA positive (CRUK ADEPT trials database). Adverse events 
considered related to the infusion were mild i.e. Common Toxicity Criteria 
(CTC) grade 1 only.  
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positive was day 14 (range 7 to 42). Since these antibodies formed after 
the treatment period they would not have affected the efficacy of single 
ADEPT treatment. 
 
1.7.4 Repeat ADEPT treatment and immunogenicity 
Repeated infusions of MFECP1 may cause more undesirable 
immunological consequences. For example if a patient who developed 
HACPA received a further MFECP1 infusion, HACPA could bind to 
MFECP1 and alter clearance. There is evidence from pre-clinical ADEPT 
systems that clearance can become accelerated after repeat treatments. 
Sharma and colleagues investigated clearance of the antibody-enzyme 
A5B7-CPG2 in mice (Sharma et al, 1996). Clearance was measured in 
treatment-naive mice and in mice who had received a dose of A5B7-
CPG2 10 days before. Clearance was faster in mice that have previously 
been exposed to A5B7-CPG2 compared to mice who had never 
previously received A5B7-CPG2. It was demonstrated that following 
exposure to A5B7-CPG2 mice produced anti-CPG2 antibodies. The 
authors hypothesized that the rapid clearance of A5B7-CPG2 in pre-
treated mice was caused by the presence of anti-CPG2 antibodies. 
Similarly it is possible that HACPA production in patients could neutralize 
the enzymatic activity of CPG2. 
 
These issues could significantly affect the repeat treatment trial since the 
current evidence (from the single treatment trial) indicates that HACPA 
production is common i.e. 40% of patients. Furthermore the repeat 
administration of MFECP1 may increase the percentage of patients who 
become HACPA positive. 
 
Importantly, increasing the number of MFECP1 infusions could also 
increase the incidence of symptomatic adverse events, since the immune 
response to a foreign protein may be significantly greater on the 2nd (or 
subsequent) exposure compared with the first exposure. An example of 
this can be seen with the drug streptokinase, a protein produced by the 
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acute myocardial infarction. When a single treatment of streptokinase is 
given the frequency of allergic reactions is <5% (ISIS-2 collaborative 
group, 1988; GISSI-1 collaborative group, 1986). However when 8 
patients received re-treatment with streptokinase, 4 patients (50%) 
experienced allergic reactions (White et al, 1990). The streptokinase re-
treatment was given a median of 4 days (range 3 to 7) after the first 
treatment.  
 
1.7.5 Managing the immunogenicity of repeat ADEPT treatment 
Patient safety is of paramount importance in a phase I clinical trial. It is 
likely that the risk of an immunological adverse event would be 
significantly higher in HACPA positive patients compared to HACPA 
negative patients. Furthermore HACPA could significantly alter MFECP1 
pharmacokinetics (e.g. accelerated clearance) and/or reduce the 
biological activity of CPG2. To reduce the risk of such problems patients 
in the repeat-treatment ADEPT phase I/II trial that became HACPA 
positive will be ineligible for further ADEPT treatment. 
 
An important consequence of this is that for many patients i.e. those who 
become HACPA positive, there is likely to be a relatively short time during 
which repeat ADEPT treatments can be given. This may limit the number 
of treatments that can be given and hence could compromise efficacy. It 
is therefore desirable to reduce the immunological response to MFECP1. 
 
There are a variety of methods that could in principle be used to reduce 
the probability of ADA formation against MFECP1. Some of these are 
already performed i.e. vigorous quality control of MFECP1 production to 
Good Manufactoring Practice (GMP) standards and administration by the 
intravenous route. Early clinical trials of ADEPT (using the chemical 
conjugate A5B7-CPG2) used immunosupression with ciclosporin. 
Although ciclosporin appeared to delay HACPA formation ciclosporin 
produced significant adverse events in some patients (Bagshawe et al, 
1995; Napier et al, 2000). 
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itself either by removing B-lymphocyte epitopes (B-cell epitopes) or by 
removing amino acid sequences that are recognized by T-lymphocytes 
(T-cell epitopes). 
 
1.7.6 B-cell epitopes 
An important determinant of immunogenicity is whether a drug can 
activate B-lymphocytes. Attempts to disrupt B-cell epitopes can be 
divided into techniques that mask the epitope and techniques that remove 
the epitope. The aim of masking is to physically shield an epitope from B-
lymphocytes without disrupting the therapeutic active site of the drug. 
Masking can be achieved by coating the surface of the molecule, via 
covalent bonds, with polyethylene glycol (PEG). In a randomized clinical 
trial pegylated asparaginase caused asparagine depletion as effectively 
as unpegylated asparaginase. Furthermore the pegylated drug induced 
ADAs in significantly fewer patients than the unpegylated drug (Avramis 
et al, 2002). However pegylation can have additional effects on the drug, 
such as altering absorption and serum half life. 
 
An alternative is to identify and selectively remove B-cell epitopes. This 
approach has been demonstrated with the therapeutic enzyme 
staphylokinase which is derived from E.coli and induces NAbs in the 
majority of patients. Interaction analysis with a panel of murine mAbs 
identified three immunodominant epitopes (Collen et al, 1996). Epitopes 
were then disrupted by substitution of charged amino acids with alanine 
to form staphylokinase mutants. ADAs from patients treated with wild-
type staphylokinase bound to the mutant enzyme less than wild-type 
enzyme. However the enzyme activity of mutants was significantly 
reduced. Subsequently comprehensive site-directed mutagenesis 
produced a mutant with retained enzyme activity and reduced Nab 
production when given to patients (Laroche et al, 2000). 
 
Spencer and colleagues have investigated surface B-cell epitopes on 
CPG2 in ADEPT (Spencer et al, 2002). Using a phage display library of 
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spectrometry and the crystal structure of CPG2 a discontinuous epitope 
at the C-terminus of CPG2 was identified. A novel antibody-enzyme 
fusion protein was produced and mutants synthesized containing site-
specific mutations to eliminate the identified epitope. ADAs from patients 
who had received A5B7-CPG2, bound significantly less to the mutant 
fusion protein compared to wild-type fusion protein. Subsequently, it has 
been demonstrated that a C-terminal histamine-tag (His-tag) on MFECP1 
(which was added to MFECP1 for immobilized metal affinity 
chromatography purification) also significantly reduces the binding of 
ADAs from ADEPT patients to the epitope (Mayer et al, 2004). It was 
hypothesized that the His-tag masks a B-cell epitope.  
 
1.7.7 T-cell epitopes 
Despite the presence of the C-terminal His-tag on MFECP1, a single 
treatment of ADEPT using MFECP1 produced HACPA in 40% of patients. 
Since the development of an antibody response to foreign proteins is 
driven by Th lymphocytes examining the Th lymphocyte response to 
MFECP1 is clinically important. Furthermore identifying and removing 
immunodominant Th lymphocyte epitopes appears to be a promising 
approach to reducing MFECP1 immunogenicity.  
 
Identification of Th lymphocyte epitopes requires identification of the 
amino acid sequences within the molecule that are responsible for Th 
lymphocyte activation. One approach is to investigate whether a peptide 
is likely to bind to a given class II MHC molecule. This can be done using 
in-silico  prediction methods that are available for a limited number of 
class II MHC molecules. Alternatively in vitro class II MHC binding assays 
can be used to measure peptide binding. These techniques are frequently 
used in combination (Warmerdam et al., 2002). However both these 
techniques do not take into account the role of antigen processing. 
Furthermore they may over-estimate epitopes since not all peptides that 
bind class II MHC can bind the TCR. 
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therapeutic proteins. For example Tangri and colleagues used short 
peptides (15mers, overlapping by 10 amino acids) spanning the entire 
sequence of erythropoietin to investigate the location of Th lymphocyte 
epitopes on erythropoietin (Tangri et al., 2005). They identified 2 peptides 
that bound to a large number of human leucocyte antigen (HLA) types in 
vitro and caused activation of peripheral blood mononuclear cells 
(PBMCs) from healthy donors. Mutation of these peptides was used to 
produce two variant erythropoietin proteins which retained function and 
stimulated Th lymphocytes significantly less than wild type erythropoietin. 
 
The phase I/II clinical trial of repeat ADEPT patients also offers an 
opportunity to investigate Th lymphocyte response in blood from treated 
patients. Are untreated patients truly naive to the epitopes on MFECP1 or 
have patients been exposed to CPG2 epitopes naturally e.g. through 
contact with CPG2 from Pseudomonas? Although ADEPT patients are 
confirmed as being HACPA negative before treatment it is possible that 
patients have been exposed to CPG2 sufficiently long ago that HACPA 
levels have fallen to undetectable. These patients would retain specific 
memory T-lymphocytes capable of stimulating a rapid secondary 
response. 
 
Due to limited availability of PBMCs from healthy volunteers and very 
limited availability of patient blood, it is desirable to use a model system 
using animal T-lymphocytes. However the use of laboratory animals for 
pre-clinical immunogenicity testing is of limited value due to differences in 
MHC molecules between animals and humans. Hence a Th lymphocyte 
response in mice may not reflect the response in humans. 
 
The development of mice that are transgenic for human MHC (and do not 
express murine MHC) may provide a suitable model in which to conduct 
pre-clinical immunogenicity investigation. Altmann and colleagues 
developed HLA-DR1 transgenic mice by inserting genomic constructs for 
the  α-chain of HLA-DR (HLA-DRA1*0101) and a β-chain of HLA-DR 
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molecules (Altmann et al., 1995). Responses in these HLA-DR1 
transgenic mice to HLA II restricted peptides were consistent with 
conventional experimental tools e.g. class II MHC binding assays (Depil 
et al., 2006). Mice transgenic for human MHC are used in vaccine 
development and may be suitable for pre-clinical investigation of protein 
therapeutics (De Groot et al., 2008).  
 
In  chapter 5 the nature of the immune response to MFECP1 is 
examined. Firstly the clinical aspects of MFECP1 administration is 
investigated, including the incidence of MFECP1 related adverse events. 
Data on all patients (single-treatment and repeat treatment patients) is 
analysed to examine whether repeat infusions of MFECP1 increase the 
risk of an infusion reaction. The frequency of HACPA production is 
measured and the effect of repeat infusions on HACPA production 
assessed. 
 
Secondly the in vitro response of Th lymphocytes from healthy volunteers 
and an ADEPT patient to MFECP1 is examined. T-cell epitope mapping 
is performed on CPG2 using PBMCs from 20 healthy volunteers. 
Furthermore the suitability of mice transgenic for human MHC as a 
possible source of lymphocytes for immunogenicity experiments is 
examined. 
 
1.8 Aims of MD (Res) thesis 
The overall aim of this MD thesis is to improve the safety and efficacy of 
ADEPT. The phase I/II clinical trial of repeat ADEPT treatments, 
described in this MD thesis, aims to investigate the safety of repeat 
treatments, obtain early evidence of efficacy and increase understanding 
of the immune response to MFECP1. A phase I/II clinical trial of repeat 
ADEPT has never been conducted before and therefore this MD (Res) 
thesis aims to significantly increase understanding of ADEPT. 
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 1) Investigate the safety of repeat ADEPT treatments  
In Chapter 3 the safety profile of repeat ADEPT treatment is examined. 
The phase I/II trial aims to establish the maximum number of tolerated 
treatments and the maximum tolerated TPD. Analysis of data from all 
patients who have received MFECP1 (during the single and repeat 
treatment phase I trials) aims to identify risks factors for toxicity. 
 
2) Investigate whether there is preliminary evidence of efficacy with 
repeat ADEPT treatments  
In Chapter 4 evidence of efficacy is examined using CT, FDG-PET and 
serum CA19-9. Combined data from single and repeat treatment patients 
is used to examine the relationship between efficacy and the 
dose/schedule of ADEPT.  
 
3) Investigate the nature of the immune response to MFECP1  
Chapter 5 aims to examine the immunological response to MFECP1. The 
effect of repeat administration of MFECP1 on infusion reactions and 
HACPA production is examined. The mechanisms leading to the clinical 
immune response are examined. Lymphocytes from healthy volunteers, 
an ADEPT patient and mice transgenic for human MHC are used to 
examine the in vitro response to MFECP1 and the possible identity of T-
cell epitopes. 
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Materials and Methods 
 
2.1 ADEPT phase I/II clinical trial  
 
2.1.1 Trial conduct and regulation 
The study was sponsored and monitored by Cancer Research UK 
(CRUK) Drug Development Office. The principal investigator (PI) was 
Professor RHJ Begent (UCL Cancer Institute, The Paul O’Gorman 
Building, University College London, Gower Street, London WC1E 6BT, 
UK). All drug administration, in-patient and out-patient activities were 
performed at the Royal Free Hospital, Pond Street, London NW3 2QG. 
The study was conducted in compliance with the protocol, the European 
Union Clinical Trials Directive, principles of the International Conference 
on Harmonization of Good Clinical Practice guidelines and the 
Declaration of Helsinki. The study was conducted under a Clinical Trials 
Authorisation with approval from the Medicines and Healthcare products 
Regulatory Agency (MHRA) and the appropriate research ethics 
committee. A license for the administration of radioactive substances was 
obtained from the Administration of Radioactive Substances Advisory 
Committee. 
 
2.1.2 Study drugs 
MFECP1 was produced in Pichia pastoris in the GMP facility in the 
Department of Oncology at the Hampstead Site of University College 
London. BIP prodrug was manufactured and supplied by Astra Zeneca 
(Macclesfield, UK). Each vial of BIP prodrug contained 610mg of 
crystalline BIP prodrug hydroiodide (equivalent to 500mg of BIP prodrug 
free base). 
 
  652.1.3 Study design 
Each ADEPT treatment consisted of an infusion of MFECP1 followed by 
3 bolus administrations of BIP prodrug. MFECP1 was given in the 
evening and prodrug given the following day, provided that serum CPG2 
activity was < 0.002 U/ml. The starting prodrug dose was 200mg/m
2 and 
the first cohort of patients received 2 treatments i.e. TPD of 1200mg/m
2. 
The number of treatments was increased by one per cohort. The first 
cohort consisted of 3 patients and subsequent cohorts consisted of a 
minimum of one patient. In the event that grade 2 or higher toxicity 
occurred (ADEPT-related) the cohort would be expanded to 3 patients. 
 
In the event of a dose limiting toxicity (DLT) when less than 8 treatments 
per patient had been given, the cohort was to be expanded to 6 patients. 
Absence of a second patient experiencing a DLT allowed a new cohort to 
open. In the event of a second patient experiencing a DLT then the dose 
of BIP prodrug in the next cohort was reduced by 25%. In the event of a 
DLT when 8 or more treatments per patient were given, the cohort was to 
be expanded to 6 patients but a new cohort was not opened. The daily 
treatment schedule for patients receiving 2 or 3 treatments is shown in 
Table 2.1. The treatment schedule for additional ADEPT treatments is 
shown in Appendix 1. 
 
For patients in the same cohort an interval of 3 weeks was required 
between a patient completing scheduled treatment and the next patient 
starting treatment. This interval was increased to 4 weeks when the next 
patient was in a new cohort. 
 
Treatment with MFECP1 and BIP prodrug could be repeated on a 4-6 
weekly basis after the final scheduled treatment if there was no evidence 
of progression and the patient remained HAMA and HACPA negative. 
Patients could be given ciclosporin immunosupression to attempt to 
reduce HACPA formation. Intravenous ciclosporin (5mg/kg) was started 2 
days before MFECP1 and given for 7 days. (The dose of intravenous 
ciclosporin was adjusted to maintain blood levels between 150-350ng/ml.) 
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divided doses for 7 further days. 
 
 
Table 2.1 
Treatment schedule for patients that received 2 or 3 ADEPT 
treatments 
 
Study drug 
Treatment 
number  Day  Cohort 1 
 
Cohort 2 
 
1  MFECP1 MFECP1 
2 
1 
Prodrug x3  Prodrug x3 
3  MFECP1 MFECP1 
4 
2 
Prodrug x3  Prodrug x3 
5      
6      
7      
8   MFECP1 
9 
3 
 Prodrug  x3 
 
 
2.1.4 Eligibility criteria 
Eligible patients had metastatic, unresectable or locally recurrent 
histologically proven CEA expressing carcinoma and had been offered 
standard treatment. The other inclusion criteria were a plasma CEA level 
between 10µg/L and 1000µg/L (or if serum CEA < 10µg/l then CEA had 
to be demonstrated by immunohistochemistry on tumour blocks), 
measurable disease on RECIST criteria, an age of ≥ 18 years, life 
expectancy ≥ 4 months, World Health Organization (WHO) performance 
status of 0, 1 or 2, adequate haematological function (neutrophil count ≥ 
2x10
9/l, platelet count ≥ 100x10
9/l and haemoglobin ≥ 10g/dl), adequate 
renal function (plasma creatinine ≤ 120 µmol/l or EDTA/urine creatinine 
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30µmol/l, ALT/AST ≤ 2x upper limit of normal (ULN), (5x ULN in the 
presence of liver metastases), INR ≤ 1.5 (or within the therapeutic range 
for patients on anti-coagulation) and written informed consent. Patients 
were excluded if they had received radiotherapy (except for palliative 
reasons to non-target lesions), chemotherapy, endocrine therapy, or 
immunotherapy during the 4 weeks prior to study treatment, were 
pregnant or lactating, serologically positive for Hepatitis B, C or HIV, were 
considered poor medical risk because of non-malignant systemic 
disease, had a second current malignancy, had undergone major surgery 
within 4 weeks, were HAMA or HACPA positive or had a history of allergy 
to iodine or mouse proteins. All toxic manifestations of previous treatment 
must have resolved (excluding alopecia or grade 1 toxicities that in the 
opinion of the PI and CRUK should not exclude the patient). All patients 
were treated in the Department of Oncology at the Royal Free 
Hampstead NHS Trust, London. 
 
2.1.5 Pre-treatment evaluation 
Before beginning ADEPT all patients underwent complete history, 
performance status assessment, physical examination, ECG, full blood 
count, chemistry profile, creatinine phosphokinase, clotting, serum CEA, 
serum CA 19-9, HLA typing, storage of PBMCs, comet assay, urinalysis 
and chest X-ray. Disease assessment was performed by CT. Patients 
were offered the possibility of additional disease assessment using FDG-
PET imaging.  
 
2.1.6 Drug administration 
MFECP1 was administered intravenously at a fixed dose of 3000U/m
2 
over 2 hours in a total volume of 300ml of 0.9% sodium chloride. Each 
vial of BIP prodrug was reconstituted with 10ml sodium bicarbonate 
solution and filtered through a 0.22m filter. The three BIP prodrug bolus 
administrations were each separated by 1 hour. Each bolus was given 
into a fast running drip of 5% w/v dextrose through a Hickman Line 
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patients was 200mg/m
2 per bolus i.e. 600mg/m
2 per treatment. 
 
2.1.7 Measurement of serum CPG2 activity 
Serum CPG2 was measured by Dr Surinder Sharma, Dr Hassan 
Shahbakhti and Natalie Griffin. 
 
Serum CPG2 activity was measured by high performance liquid 
chromatography 5 minutes after completion of MFECP1 infusion and then 
up to hourly until serum CPG2 activity was < 0.002U/ml. 
 
2.1.8 Pharmacokinetics of BIP prodrug 
Pharmacokinetic measurement and analysis was performed by Professor 
Caroline Springer’s laboratory (Institute of Cancer Research, Sutton, UK). 
 
Plasma samples for analysis of BIP prodrug concentrations were taken at 
2, 5, 10, 15, 30 and 60 minutes following the 3
rd prodrug bolus. Plasma 
BIP prodrug concentrations were quantified by HPLC. Concentration of 
BIP prodrug extrapolated back to time zero (C0), volume of distribution at 
steady state (Vss),  area under the curve extrapolated to infinity (AUCINF), 
rate of clearance and elimination half-life were determined using a non-
compartmental model and WinNonlin software. 
 
Pharmacokinetic profile of the activated prodrug was not possible 
because the activated prodrug has a half life in the order of seconds. 
 
2.1.9 Prodrug activation  
Single cell comet assays were performed by Dr Janet Hartley 
(Department of Oncology, UCL, UK). Comet assays were used to 
indirectly measure DNA interstrand crosslinks, which was used as a 
surrogate marker for prodrug activation. Blood for comet assay was taken 
approximately 60 minutes after the last prodrug administration. Comet 
assays were performed on peripheral blood lymphocytes and tumour 
tissue (where available). 
  692.1.10 Post treatment evaluation 
Patients were followed up until Day 58 of treatment. History, physical 
examination, performance status assessment, HAMA and HACPA were 
performed weekly. Toxicity was assessed according to the National 
Cancer Institute CTC. Full blood count and chemistry profile were 
examined twice weekly in the fist 4 weeks and weekly thereafter. Serum 
creatinine kinase was measured 4-6 hours after the first prodrug bolus of 
each treatment and was also measured the day after prodrug 
administration. Serum CEA and serum CA 19-9 were measured every 2 
weeks from Day 16. Blood clotting was measured on days 30 and 58. 
ECG was recorded on Day 23. A blood sample on day 37 was used to 
extract PBMCs in order to assess Th lymphocyte response to MFECP1.  
 
Patients were evaluated for response by CT on Days 29 and 57. 
Response was assessed according to RECIST criteria. Optional disease 
assessment with FDG-PET imaging was performed on Days 23 and 54. 
Response was assessed by semi-automatic volume of interest drawing 
(Green et al., 2008). A significant reduction in tumour activity was defined 
as >15% reduction in total counts in the volume(s) of interest. 
 
2.1.11 Measurement of HACPA 
HACPA was measured by Dr Surinder Sharma, Dr Hassan Shahbakhti 
and Natalie Griffin. 
 
Blood was assessed for HACPA formation before treatment and weekly 
during follow up period. HACPA were measured by ELISA. 96 well ELISA 
plates were coated with CPG2.  (96 well ELISA plates were supplied by 
Nunc-Immuno™. CPG2 was supplied by Centre for Applied Microbiology 
Research (Porton Down, Sutton, UK). Serum samples were added to the 
plates at dilutions of 1:100 and 1:1000. Peroxidase-labelled goat anti-
human IgG F(ab’)2 was used as a secondary antibody. (Peroxidase-
labelled goat anti-human IgG F(ab’)2 was supplied by Sigma-Aldrich: Ref 
A2290). After adding substrate results were quantified using a plate 
reader. Plates were read using a Thermo Labsystems Opsys MR Dynex 
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absorbance of 0.2 at 490nm wavelength. The cut-off value was obtained 
by assaying 50 pre-treatment serum samples at 1:100 dilutions and 
taking the cut-off as 3x the standard deviation above the mean 
absorbance. A serum sample from a previous patient that had been found 
to be HACPA positive was used as the positive control. 
 
2.2. Materials and methods for immunogenicity experiments 
Experiments were performed at: 
1.  The Department of Infectious Diseases and Immunity, 
Hammersmith Hospital, Du Cane Road, London, United Kingdom 
in collaboration with Professor Daniel Altmann (Professor of 
Immunology). 
2.  The Department of Oncology, 1st floor, Royal Free Hospital, Pond 
Street, London, United, Kingdom. 
3. Biovation Ltd / Antitope Ltd, Babraham Research Campus, 
Babraham, Cambridge, United Kingdom. 
 
All experiments were done in accordance with COSHH (control of 
substances hazardous to health). Radioactive work was done in 
accordance with Radiation Protection guidelines.  All animal work was 
carried out in accordance with  the guidelines of the United Kingdom 
Coordinating Committee on Cancer Research (UKCCCR) and the Animal 
(Scientific Procedures) Act 1986.  Blood samples were taken from 
members of staff and students in the Commonwealth Building, Imperial 
College (Hammersmith campus) with specific ethics committee approval. 
Blood samples were taken from ADEPT patients for analysis of T-cell 
immunogenicity on patients 35 to 43 inclusive. Ethics committee approval 
was granted as part of the ADEPT protocol amendment of 4
th April 2006. 
 
2.2.1. Extraction of PBMCs from peripheral blood 
A blood sample (12ml from healthy volunteer and 50ml from an ADEPT 
patient) was taken from a peripheral vein into sodium heparin vacutainer 
tubes (BD Diagnostics, USA). Blood samples were taken by an 
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to a microbiological safety cabinet. The blood was mixed with an equal 
volume of sterile phosphate buffered saline (PBS) pH 7.4 (Invitrogen, 
USA). 20ml of the blood/PBS/heparin mixture was very slowly layered 
onto 15ml of Histopaque (Sigma-Aldrich, USA) in a 50ml centrifuge tube. 
This was repeated so that all the blood/PBS/heparin mixture was layered 
onto Histopaque. Density gradient centrifugation was performed by 
centrifuging samples at 1500rpm for 25 minutes at room temperature with 
no brake. The PBMCs were seen as a buffy layer and this layer was 
removed using a sterile plastic disposable pipette. The PBMCs were 
placed into a new 50ml centrifuge tube and the tube filled to a total 
volume of 50ml with AIM-V media (Invitrogen, USA). The sample was 
centrifuged at 1500rpm for 10 minutes at room temperature with brake 
on. The supernatant was discarded, the pellet resuspended in the small 
residual volume and the centrifuge tube filled to 50ml with AIM-V
 media. 
The sample was centrifuged again (1500rpm, 10 minutes, room 
temperature, brake on). The supernatant was discarded, the pellet 
resuspended in the small residual volume and 10mL AIM-V
 media added. 
 
2.2.2 Calculating the concentration of lymphocytes in a cell 
suspension 
The sample was mixed to prevent settling of cells. A 10l sample of cell 
suspension was removed and mixed with 90l of 0.2% trypan blue 
solution (Sigma-Aldrich, USA). A 10l sample of the dye/cell suspension 
mixture was placed onto a plastic microscope slide with quantitative grid 
(Hycor Biomedical, USA). The sample was inspected at 20x magnification 
using a microscope. The number of viable lymphocytes in 4 large squares 
was counted (viable cells appear as large, rounded, white cells) and this 
value divided by 4 to obtain the mean number of viable cells per large 
square. The cell concentration was calculated as follows: 
 
Cell concentration in 
cell suspension 
mixture 
 
= 
mean number of viable 
cells per large square  x  10
5 
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cell concentration was different to the required cell concentration. When 
the concentration was too high additional media was added to bring the 
cell concentration to the desired figure. When the concentration was too 
low the sample was centrifuged at 1500 revolutions per minute (rpm) for 
10 minutes at room temperature with brake on. The supernatant was 
discarded and the cell pellet resuspended in the small residual volume. 
The appropriate volume of media was then added to create the required 
cell concentration. 
 
2.2.3 Mice: immunization and lymphocyte extraction 
All DRB1*0101 transgenic mice were kindly supplied by Professor Daniel 
Altmann. Immunization material consisted of MFECP1 immunization (i.e. 
MFECP1 solution and adjuvant) or control immunization (i.e. sterile PBS 
and adjuvant). The adjuvant was TiterMax
®Gold (CytRx Corporation, 
USA). MFECP1 immunization material was prepared by thoroughly 
mixing equal volumes of MFECP1 solution and adjuvant. The 
concentration of MFECP1 stock solution varied according to the batch 
number and therefore the quantity of MFECP1 injected per mouse is 
described in the results. (The volume injected per mouse was constant 
i.e. 50l). A single batch of MFECP1 was used for each immunization 
experiment. Control immunization material was prepared by thoroughly 
mixing equal volumes of sterile PBS and adjuvant. Immunization material 
was mixed using a 1ml syringe and an orange needle. Mice were each 
immunized with 50l of immunization material into the foot pad of the left 
hind foot. The day of immunization was described as Day 0. 
 
Mice were culled between days 10 and 13. The mice were killed by 
cervical dislocation. The popliteal lymph node from the left hind leg of 
each mouse was identified and removed. Each lymph node was placed 
into a 50ml Falcon tube containing 5ml of murine media. Murine media 
was HL1 media (Lonza, Switzerland), plus 1% L-glutamine (Invitrogen, 
USA), 1% penicillin/streptomycin and 0.7% 2-mercaptoethanol (VWR 
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of a 1ml syringe and filtered through a 70m nylon cell strainer (BD 
Biosciences, USA). Each cell suspension was placed into a separate 
15ml centrifuge tube and centrifuged at 1500rpm for 15 minutes at room 
temperature with brake on. For each tube the supernatant was discarded, 
the pellet resuspended in the residual volume and 1ml of murine media 
added to each tube. The cell concentration was then calculated as per 
section 2.2.2. 
 
2.2.4 T-cell proliferation assays 
T-cell proliferation assays were performed in 96 well clear flat-bottom cell 
culture plates (Corning, USA). Plates were prepared by placing 100l of 
MFECP1 solution (50µg/ml), negative control solution (media only) or 
positive control solution into the appropriate wells.  
 
Media for human Th lymphocytes was AIM-V
® media and media for 
murine Th lymphocytes was HL1 media plus 1% L-glutamine, 1% 
penicillin/streptomycin and 0.7% 2-mercaptoethanol. MFECP1 was 
diluted with the appropriate media to produce a solution of 50µg/ml. 
Positive controls were Staphylococcal enterotoxin B (SEB) 20ng/ml 
(Sigma-Aldrich, USA) and Tuberculin Purified Protein Derivative (PPD) 
1000U/ml (Chiron Vaccines Evans, USA). SEB and PPD were diluted in 
the appropriate media according to whether the Th lymphocytes were 
human or murine. 
 
An equal volume (100l) of cell solution was added to each well. Hence 
the final “in-well” concentration of MFECP1 was 25µg/ml and the final “in-
well” concentration of SEB and PPD was 10ng/ml and 500U/ml 
respectively. 
 
Each experimental condition was performed in triplicate i.e. performed in 
3 wells. 100μL of cell suspension at a concentration of 3.5 x10
6 cells/ml 
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oC 
with 5% CO2 for 5 days.  
 
After 5 days of incubation a 37MBq/ml / 1mCi/ml (methyl-
3H) thymidine 
solution  (GE Healthcare, USA) was diluted 1 in 100 with the appropriate 
media (depending on whether cells were human or murine). Ten micro 
litres of the (methyl-
3H) thymidine/media mixture was placed in each well 
so that each well was pulsed with 1Ci. The cells were incubated for 8 
hours at 37
0C with 5% CO2. Plates were then either harvested 
immediately or frozen at -20
0C and harvested within 5 days (half life of 
(methyl-
3H) thymidine is 12.3 years). 
 
Plates that had been frozen were defrosted. The plates were harvested 
onto glass fibre filtermats (PerkinElmer Life Sciences, USA) using a cell 
harvester (Mach IIIm, Tomtec). The filtermats were dried in a standard 
electric oven at 125
0C until completely dry (approximately 10 minutes). 
Each filtermat was placed into a plastic sample bag (PerkinElmer Life 
Sciences, USA) and enough scintillation liquid (PerkinElmer Life 
Sciences, USA) added to soak the filtermat (approximately 10ml). Each 
sample bag was sealed and the filtermats read on a beta scintillation 
counter (PerkinElmer Life Sciences, USA). 
 
The raw results of each well were described as counts per minute (cpm). 
The mean cpm for each experimental condition was calculated. 
Stimulation indices (S.I.) for antigens were calculated as: 
 
S.I.  = 
mean cpm 
with antigen 
÷ 
 
mean cpm 
with negative 
control 
 
 
 
  752.2.5 Peptide experiments 
T-cell epitope mapping of CPG2 was performed by Biovation Ltd. (now 
Antitope Ltd) by Dr Matthew Baker. 
 
Individual peptides spanning the amino acid sequence of CPG2 were 
incubated  in vivo with PBMCs from 20 healthy volunteers. T-cell 
proliferation assays were used to measure T-cell stimulation. 
 
2.2.5.1 Peptides 
Peptides (Mimotopes, Australia) spanning the amino acid sequence of 
CPG2 were used. The peptides were 15 amino acids long (15mers) and 
each overlapped the adjacent peptide by 12 amino acids (Figure 2.1). 
The amino acid sequences of the 128 peptides are shown in Appendix 2. 
The peptides, which were supplied as a freeze-dried product, were 
dissolved in DMSO to produce a stock-solution of 5mM. 
 
Peptide 
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NA  D  V  RYARNEDFDA  A        
Peptide 
88 
      V R Y A R N E D F D A A M K T
 
Figure 2.1 
Example of overlapping 15 mer peptides. 
 
 
2.2.5.2 Preparation of PBMCs from volunteer blood samples 
(Method from Biovation Ltd.) 
PBMCs were isolated from whole blood. Blood samples from healthy 
volunteers were obtained from the National Blood Service, Long Road, 
Cambridge. Extraction of PBMCs was performed in a class II 
microbiological safety cabinet. Blood was centrifuged in falcon tubes at 
1500rpm for 10 minutes at room temperature. The upper layer (plasma) 
was removed using a sterile disposable Pasteur pipette and disposed. 
Each falcon tube was filled to 50ml with sterile PBS and the sample 
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Ficoll-Paque PLUS (GE Healthcare, USA). Each falcon tube was 
centrifuged at 400 x g for 30 minutes at room temperature with no brake. 
The buffy layer (PBMCs) was removed from each sample using a sterile 
plastic disposable pipette and placed in a new falcon tubes. Each 20ml of 
PBMCs was washed with 30ml of PBS. Samples were centrifuged at 
1500rpm for 10 minutes at room temperature. The supernatant was 
carefully poured off and disposed. Cells were resuspened in PBS and 
carefully layered onto 10ml of Ficoll-Pacque PLUS. Each sample was 
centrifuged at 2000rpm for 30minutes at room temperature with no brake. 
The buffy layer was removed from each sample using a sterile plastic 
disposable pipette and placed in a single new falcon tube. The PBMCs 
were washed with at least 1x volume of PBS. The sample was 
centrifuged at 1500rpm for 10 minutes at room temperature. The 
supernatant was poured off and disposed. Cells were resuspened in 50ml 
PBS. The sample was centrifuged at 1500rpm for 10 minutes at room 
temperature. The supernatant was poured off and disposed. Cells were 
resuspened in 30ml AIM-V media.  
 
A 10µL sample was taken and the cells counted (see section 2.2.2) so 
that the total number of cells in the 30ml sample could be calculated. The 
30ml sample was centrifuged at 1500rpm for 10 minutes at room 
temperature. The supernatant was poured off and disposed. Cells were 
resuspended in AIM-V media to a concentration of 2 x 10
7 cells per ml. 
 
2.2.5.3 T-cell proliferation assays in peptide experiments 
PBMCs (5 x 10
8 cells) were incubated in a flat bottom flask for 1 hour at 
37
oC. Non-adherent (responder) cells were removed and the flask rinsed 
with 10ml AIM V media. Responder cells were pelleted and frozen at –
80
oC. 15ul GM-CSF (800units/ml) and 15ul of IL-4 (500 units/well) were 
added to adherent (stimulator cells) cells and incubated at 37
oC with 5% 
CO2. After 3 days of culture 0.5ml AIM V containing 15ul GM-CSF 
(800U/ml) and 15ul IL-4 (500U/ml) were added and cells were cultured for 
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Cells were collected and washed twice in 10-20 ml AIM V media.  
 
Stimulator cells were thawed and washed in AIM V and resuspended in 
1ml AIM V, Mitomycin C was added at a final concentration of 50ug/ml. 
Cells were incubated at 37
oC, washed 3x in AIM V and resuspended 
(4x10
5 cells/ml). 
 
T-cell proliferation assays were performed in 96 well plates. 100ul of 
peptide solution (5μM) was added to the appropriate wells. Each peptide 
was tested in triplicate. In negative control wells 100ul of AIM V was 
added. Positive control was Keyhole limpet hemocyanin (KLH) supplied 
by Thermo Fisher Scientific (USA). KLH was dissolved in AIM-V to 
produce a solution of 200µg/ml and 100ul was added to positive control 
wells. 50ul of stimulator cells was added to each well and plates were 
incubated at 37
 oC for 1 hour. 50ul of responder cells (4 x 10
6cells/ml) 
was added to each well, plates were incubated for 48 hours and 10U IL 2 
added. Cells were incubated for a further 6 days, then pulsed with 
3H-
thymidine for 18 hours, plates harvested and read on a beta scintillation 
counter. Stimulation indices were calculated (see section 2.2.4) for each 
peptide and control. 
 
2.2.6 Cytokine secretion assay and fluorescence-activated cell 
sorting (FACS) 
A 15ml blood sample was taken from each healthy volunteer into sodium 
heparin tubes. This 15ml sample was referred to as the “experimental 
sample”. In one volunteer an additional 5ml of blood was taken to 
calibrate the flow cytometry machine. This 5ml sample was referred to as 
the “calibration sample”. The 15ml experimental sample was divided 
equally into 3 centrifuge tubes. Each 5ml blood sample was incubated 
with MFECP1, SEB or media. The concentration of MFECP1 in the 
blood/MFECP1 mixture was 10g/ml. The concentration of SEB in the 
blood/SEB mixture was 1g/ml. In each 5ml sample 76l of blood was 
first removed. 76l of MFECP1 solution (0.66mg/ml), 76l of SEB solution 
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samples. (The cells were human and therefore the media used to dilute 
SEB stock to 66g/ml was AIM-V). The 5ml calibration blood sample was 
incubated with media (AIM-V) i.e. 76l of blood was first removed and 
then 76l of media was added. Each sample was incubated for 13 hours 
at 37
OC with 5% CO2.  
 
After the 13 hour incubation period, 45ml of 1x erythrocyte lysing solution 
(ELS) was added to each 5ml blood sample. ELS (10x) was prepared 
with 41.4g NH4Cl (Sigma-Aldrich, USA), 5g KHCO3 (Sigma-Aldrich, 
USA), 1ml 0.5M EDTA (VWR International, USA) and made up to 500ml 
with distilled water. The pH of the ELS (10x) solution was adjusted to 7.3 
using concentrated NaOH or concentrated HCl as appropriate. The pH of 
the solution was measured with an electronic pH meter (Spectronic 
analytical instruments, UK). ELS (1x) was prepared by mixing 50ml ELS 
(10x) with 450ml distilled water. 
 
The mixtures of blood, ELS and antigen (or media negative control) were 
incubated at room temperature for 10 minutes and each sample mixed 
several times during the 10 minutes. The samples were then centrifuged 
at 1200rpm for 10 minutes with brake on. The supernatant was removed 
with a sterile disposable plastic pipette. Each cell pellet was resuspended 
in 15ml of cold buffer (4
OC). Buffer was prepared with 495.5ml PBS and 
2.5ml of 0.5% foetal bovine serum (Autogen Bioclear, UK). 
 
The samples were centrifuged at 1200rpm for 10 minutes at 4
OC with 
brake on. The supernatant was removed with a sterile disposable plastic 
pipette. Each cell pellet was resuspended in 160μl of cold medium (4
OC). 
Medium was prepared with 64ml RPMI (Invitrogen, USA) and 16ml 
human serum albumin type AB (Cambrex Corporation,USA). 
 
Interferon gamma (IFN-γ) secretion assay kit was supplied by Miltenyi-
Biotec, Germany. 20μl of Cytokine Catch Reagent was added to all 
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 OC) was 
added to the calibration sample. The samples were incubated on ice for 5 
minutes. 7ml of warm medium (37
OC) was added to each sample. All 
samples were incubated at 37
 OC for 45 minutes and the sample was 
turned every 5 minutes. The tubes were removed from the incubator and 
placed on ice. 8ml of cold buffer (4
OC) was added to each sample. The 
samples were centrifuged at 1200rpm for 10 minutes at 4
OC with brake 
on. The supernatant was removed with a sterile disposable plastic 
pipette. The cell pellet of each experimental sample was resuspended in 
160μl of cold buffer (4
OC). The cell pellet of the calibration sample was 
resuspended in 400μl of cold buffer (4
OC). 80 μl of each experimental 
sample (i.e. not the calibration sample) was placed into FACS tubes. 10μl 
of cytokine detection antibody on PE, 10μl of anti-CD3 on FITC 
(Immunotech, France) and 10μl anti-CD4 on PE-CY5 (BD Biosciences, 
USA) were added to each FACS tube. 
 
The calibration sample was divided into 4 and each 100μL added to a 
FACS tube labeled “Calibration 1”, “Calibration 2”, “Calibration 3” and 
“Calibration 4”. Nothing was added to Calibration 1. 5μl of anti-CD3 on 
FITC was added to Calibration 2. 5μl of anti-CD3 on PE (BD Biosciences, 
USA) was added to Calibration 3. 5μl of anti-CD3 on PE-CY5 (BD 
Biosciences, USA) was added to Calibration 4.  
 
All the FACS tubes were then incubated in the dark and on ice for 10 
minutes. 3ml of cold buffer (4
OC) was added to each FACS tube. Each 
sample was centrifuged at 1200rpm for 10 minutes at 4
OC with brake on. 
The supernatant was removed with a sterile disposable plastic pipette. 
Each cell pellet was resuspended in 100μl of cell fix (1x) (BD 
Biosciences, USA). The samples were kept in the dark at 4
OC until they 
were ready to be analysed (later the same day). 
 
Flow cytometry was kindly performed by Dr Rebecca Ingram using a 
FACSCalibur machine and Flow Jo software. 
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Treatment, pharmacokinetics and 
toxicity of ADEPT with MFECP1 
and BIP prodrug (Phase I/II trial). 
 
3.1 Introduction  
Successful ADEPT therapy has a number of requirements. These include 
a suitable antigen target, a suitable antibody-enzyme product (safe, 
minimally immunogenic, can be uniformly manufactured), a high 
concentration of enzyme on tumour, a very low concentration of enzyme 
on non-tumour, a prodrug that is safe and catalysed efficiently by the 
targeted enzyme and an active cytotoxic drug that causes minimal 
systemic side-effects. These design criteria provide for a safe system that 
can be given more than once, is clinically effective and practically 
feasible. 
 
ADEPT is complex and a number of clinical trials have been conducted to 
develop the system (Table 1.2). The most recent clinical trial used a 
single treatment of ADEPT using MFECP1 and BIP prodrug (Mayer et al., 
2006). Thirty one patients were treated with a single treatment of ADEPT. 
The MTD was MFECP1 3000U/m
2 followed at a median of 13 hours (from 
the end of the MFECP1 infusion) by a total prodrug dose of 806.4mg/m
2 
when serum CPG2 enzyme activity was <0.002U/ml. MFECP1 
localization was demonstrated on tumour biopsies up to 15 hours after 
administration of MFECP1 3000U/m
2. Three patients were treated at the 
MTD (patients 26, 27, 28) in whom no grade 3 or 4 treatment related 
adverse events occurred. All adverse events at the MTD for a single 
ADEPT treatment are shown in Table 3.1. 
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Table 3.1 
Treatment related adverse events at the maximum tolerated dose of 
a single ADEPT treatment with MFECP1 and BIP prodrug 
 
Number of patients (%) 
Adverse event 
CTC Grade 1  CTC Grade 2 
Nausea  1 (33%)  1 (33%) 
Vomiting  1 (33%)  1 (33%) 
Fatigue  1 (33%)  2 (66%) 
Constitutional – other*  1 (33%)  0 (0%) 
Platelets  1 (33%)  0 (0%) 
Leucocytes (total WBC)  0 (0%)  1 (33%) 
Neutrophils/Granulocytes 0 (0%)  1 (33%) 
Haemoglobin  1 (33%)  1 (33%) 
AST  1 (33%)  0 (0%) 
Data shown is from 3 patients (patients 26, 27 and 28) who were all treated at the 
maximum tolerated dose (MTD) of a single ADEPT treatment using MFECP1. MTD was 
MFECP1 3000U/m
2 followed by a total prodrug dose of 806.4mg/m
2.
 Adverse events 
shown were possibly, probably or almost certainly related to ADEPT. All data from 
Cancer Research UK database. Adverse events described according to common toxicity 
criteria (CTC) version 2. ADEPT: antibody directed enzyme prodrug therapy, WBC: 
white blood cells, AST: aspartate aminotransferase *pyrexial (maximum 37.9
OC) onset 3 
hours after prodrug, completely resolved after 15 hours. 
 
 
In mice bearing human carcinoma xenografts repeated treatments of 
ADEPT produced increased efficacy compared with a single ADEPT 
treatment (Sharma et al., 2005). It is hypothesized that a similar effect 
occurs in patients i.e. that repeat treatment will produce more anti-tumour 
efficacy than a single treatment. Since repeat treatments of ADEPT with 
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was to assess the safety of repeat treatments. A principal objective of this 
thesis therefore is to conduct and analyse a phase I/II clinical trial of 
repeat ADEPT using MFECP1. In particular the aims of the trial are to 
investigate toxicity and to identify the maximum number of tolerated 
treatments and the maximum tolerated TPD. Toxicity results are 
presented in this chapter and anti-tumour activity is discussed in Chapter 
4. 
 
3.2 Patient characteristics 
Between April 2005 and November 2007 twelve patients were registered 
onto the study and all patients received at least two ADEPT treatments. 
Patient characteristics are listed in Table 3.2. Eleven patients completed 
the follow-up period. One patient (patient 41) died as a consequence of 
disease progression on Day 25 (serum CA19-9 increased 84% from Day 
1 to Day 19). The study was completed in January 2008. 
 
3.3 Treatment received 
Details of treatment received are shown in Table 3.3. CPG2 enzyme 
levels were <0.002U/ml at the time of prodrug administration for all 
treatments.  
 
Patients in the first cohort (patients 32, 33 and 34) each received 2 
scheduled treatments. Each treatment consisted of MFECP1 (3000U/m
2) 
followed by prodrug at 200mg/m
2 x3. (Patient 32 remained HACPA 
negative after the first 2 ADEPT treatments. This patient was therefore 
eligible for further treatment which was given on days 43/44 and 45/46.) 
No DLTs occurred in the first cohort (2 treatments) and therefore the next 
patient (patient 35) received 3 treatments at a prodrug dose of 200mg/m
2 
x3 per treatment. 
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Table 3.2 
Patient characteristics in repeat-treatment ADEPT phase I/II trial 
 
Characteristic 
 
 
Number of 
patients 
(n=12) 
 
% 
 
 
Sex 
   
  Male  10  83 
  Female  2  17 
       
 
Age (years) 
  
 Median  66 
  Range  36 – 77 
      
 
Type of cancer 
   
  Adenocarcinoma colon  7  58 
  Adenocarcinoma oesophagus  2 
 
17 
  Adenocarcinoma pancreas  1  8 
  Adenocarcinoma gallbladder  1  8 
  Carcinoma of unknown primary  1  8 
       
 
Number of previous chemotherapy 
regimes (including adjuvant) 
  
 Median  2 
  Range  1 – 3 
      
 
WHO Performance status 
   
  0  4  33 
  1  8  67 
       
 
Sites of Metastases 
  
 Lung  9   
  Distant lymph node  8   
 Liver  5   
  Local nodal disease  2   
 Soft  tissue  3   
 Bone  1   
 Peritoneum  1   
 Adrenal  gland  1   
 Spleen  1   
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Table 3.3 
ADEPT treatment received in repeat-treatment ADEPT phase I/II trial 
 
    Day 1  Day 2  Day 3  Day 4  Day 8  Day 9 
 
Patient 
 
Total 
prodrug 
dose 
(mg/m
2) 
 
MFECP1
 
Prodrug 
(mg/m
2) 
 
MFECP1
 
Prodrug 
(mg/m
2) 
 
MFECP1 
 
 
Prodrug 
(mg/m
2) 
 
32  1200 
    600    600 NA NA 
33  1200 
    600    600 NA NA 
34  1200 
    600    600 NA NA 
35  1800 
    600    600    600 
36  900 
    450    450    ND* 
37  1350 
    450    450    450 
38  900 
    300    300    300 
39  300 
    150    150    ND** 
40  450 
    150    150    150 
41  450 
    150    150    150 
42  900 
    300    300    300 
43  700 
    300    300    100*** 
 
= MFECP1 3000U/m
2 per treatment administered. NA: not applicable, ND: not done. 
Patients 32, 33, 34, 36 and 39 completed 2 scheduled treatments. Patient 32 received 2 
additional treatments (MFECP1 3000U/m
2 per treatment and prodrug 600mg/m
2 per 
treatment) on days 43/44 and 45/46 (details not shown on table). 
Patients 35, 37, 38, 40, 41, 42 and 43 completed 3 scheduled treatments. 
* Patient 36 did not complete the 3
rd treatment; MFECP1 was administered but prodrug 
was not given because the patient developed a symptomatic pulmonary embolus. 
** Patient 39 did not complete the 3
rd treatment; MFECP1 was administered but prodrug 
was not given due to very slow MFECP1 clearance. 
** In patient 43 only 1 bolus of prodrug was given following the 3
rd MFECP1 infusion  
because the patient was found to be thrombocytopaenic (after the 1
st bolus of prodrug 
was given) and therefore no further prodrug was given. 
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of platelets as prophylaxis against haemorrhage. Patient 35 also 
experienced grade 4 neutropaenia and grade 3 febrile neutropaenia. Both 
the grade 4 thrombocytopaenia requiring platelet transfusion and the 
febrile neutropaenia constituted a DLT. Following the significant 
myelosuppression in patient 35 the PI decided that expanding the cohort 
and treating further patients at the same dose should not be performed as 
this could harm patient safety.  
 
In order to attempt to reduce the risk of myelosuppression a substantial 
protocol amendment was approved by the MHRA in April 2006 and 
contained 3 features. Firstly the next cohort of patients would receive 3 
treatments at a reduced dose of 150mg/m
2 x3. Secondly if further DLT 
occurred the cohort could be expanded or a new cohort opened with a 
reduced prodrug dose. Following a dose reduction the new cohort would 
continue with the same number of treatments as the previous cohort. In 
the event that toxicity was less than grade 2 a new cohort would open 
and the number of treatments would be increased by one. Thirdly the 
definition of DLT relating to thrombocytopaenia was changed from grade 
4 thrombocytopaenia of ≥ 5 days or requiring platelet transfusion to any 
grade 3 thrombocytopaenia (this was changed at the request of CRUK in 
order to harmonize the definition with that used in other CRUK sponsored 
phase I trials). 
 
Patient 36 was scheduled to receive 3 treatments, each with a prodrug 
dose of 150 mg/m
2 x3. However, only 2 treatments were completed 
because the patient developed a pulmonary embolus on day 9 before the 
prodrug (of the 3
rd treatment) had been given. The PI decided not to 
proceed with prodrug. Patient 36 experienced a grade 2 
thrombocytopaenia and therefore the cohort was expanded. Patient 37 
received 3 treatments at 150 mg/m
2 x3. This patient experienced DLT 
(febrile neutropaenia and grade 4 thrombocytopaenia.) The PI and CRUK 
decided to open a new cohort with a reduced prodrug dose of 100 mg/m
2 
x3. 
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2 x3 and experienced grade 
3 thrombocytopaenia. Under the new definition of DLT (substantial 
protocol amendment 2006) the grade 3 thrombocytopaenia constituted a 
DLT. To further lower the risk  of myelosuppression the PI and CRUK 
decided to open a new cohort with a reduced prodrug dose of 50 mg/m
2 
x3. Patient 39 was scheduled to receive 3 treatments at a prodrug dose 
of 50 mg/m
2 x3. However following the 3
rd MFECP1 infusion, serum 
CPG2 enzyme activity did not fall <0.005U/ml until 59.5 hours after the 
end of the infusion. Prodrug was not given following this 3rd MFECP1 
infusion because MFECP1 retention on tumour was unlikely to be 
adequate after this length of time (Mayer et al., 2006). Hence patient 39 
only completed 2 ADEPT treatments. In patient 39 the MFECP1 had 
cleared successfully on previous infusions (on the 1
st and 2
nd MFECP1 
infusions the time interval between the end of the MFECP1 infusion and 
prodrug was 18.4 hours and 14.1 hours respectively). Patient 39 
developed grade 2 neutropaenia and therefore the cohort was expanded. 
Patient 40 and 41 both received 3 treatments of 50 mg/m
2 x3 without 
DLT.  
 
An unplanned interim analysis of efficacy for patients 32 to 41 identified 
that efficacy was only seen at a TPD ≥ 900mg/m
2. A substantial protocol 
amendment therefore increased the TPD to 900mg/m
2 (3 treatments at 
100 mg/m
2 x3). In addition the definition of DLT relating to 
thrombocytopaenia was redefined as < 20 x10
9/l. Patient 42 received 3 
treatments at a prodrug dose of 100 mg/m
2 x 3  ( T P D  9 0 0 m g / m
2) and 
developed a DLT (platelets were 19 x10
9/l). Patient 43 only received the 
first of three planned prodrug bolus injections on day 9 (3
rd treatment) 
because of thrombocytopaenia. The patient subsequently developed a 
DLT on Day 19 (platelets were 18 x10
9/l).  
 
3.4 Time interval between MFECP1 and prodrug 
A total of 33 ADEPT treatments (MFECP1 followed by prodrug) were 
given, including 2 additional treatments given to patient 32. The median 
time interval from the end of the MFECP1 infusion to the start of prodrug 
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3.4). 
 
 
Table 3.4 
Time interval (hours) from end of MFECP1 infusion to start of BIP 
prodrug administration in repeat-treatment ADEPT phase I/II trial 
 
Patient  Treatment 1  Treatment 2  Treatment 3 
32 (cycle 1)  15.2 14.3  NA 
32 (cycle 2)  14.2 14.3  NA 
33  15.8 13.7  NA 
34  13.9 14.8  NA 
35  14.3 14.1 14.5 
36  22.3  18.3  BIP not given * 
37  14.5 14.7 14.8 
38  14.5 14.7 14.5 
39  18.4  14.1  BIP not given ** 
40  14.4 14.5 14.6 
41  14.8 14.4 14.1 
42  14.8 14.7  17 
43  18.6 17.4 16.8 
NA: not applicable. ** Patient 36 did not complete the 3
rd treatment; MFECP1 
was administered but prodrug was not given because the patient developed a 
symptomatic pulmonary embolus. **serum CPG2 enzyme activity did not fall 
<0.005U/ml until 59.5 hours after the end of the infusion, therefore BIP prodrug 
not given. 
 
 
  883.5 Pharmacokinetics of BIP prodrug 
Pharmacokinetic data was recorded after the 3
rd prodrug bolus i.e. when 
patients had already received 2 bolus administrations of BIP prodrug. 
Despite the possibility that BIP prodrug could accumulate following each 
bolus, previous clinical data using the same prodrug found no evidence of 
significant prodrug accumulation (Francis et al, 2002). Measurement after 
the 3
rd prodrug bolus allowed collection of data at 60 minutes that would 
not have been meaningful after the 1
st or 2
nd boli because of the 
administration of more prodrug i.e. the 2
nd or 3
rd bolus. 
 
Initially pharmacokinetic data was recorded after the 3
rd prodrug bolus of 
every treatment. However data from patient 32, 33, 34 and 35 suggested 
that repeat treatments did not significantly affect BIP prodrug 
pharmacokinetics. Consequently the protocol was modified so that from 
patient 36 onwards pharmacokinetic data was only recorded after the 3
rd 
prodrug bolus of the first and last treatments. 
 
Pharmacokinetic data was recorded on all patients and included 24 
treatments (Table 3.5). The median half life of the BIP prodrug was 13.6 
minutes (range 9.8 minutes to 18.2 minutes). This is similar to the median 
half life of 10.0 minutes reported in the single treatment ADEPT trial 
(Mayer et al., 2006). Median half life varied little during the 1
st, 2
nd or 3
rd 
treatments (13.6, 11.8 and 13.9 minutes respectively). 
 
3.6 Safety 
Toxicities that were deemed at least possibly related to ADEPT  are 
shown in Table 3.6.  Thrombocytopaenia and neutropaenia were the 
principal toxicities. A higher TPD was associated with increased grades of 
thrombocytopaenia and neutropaenia (Table 3.7). 
 
The median time of platelet nadir was day 25 (range 17 – 30). Patient 35 
experienced grade 4 thrombocytopaenia and was given a platelet 
transfusion as prophylaxis against haemorrhage. A patient with lung 
metastases (patient 37) developed a clinically small haemoptysis during a 
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period of grade 3 thrombocytopaenia and was therefore given a platelet 
transfusion. The median time taken for platelet recovery following platelet 
nadir was 13 days (range 7 to 41). 
 
In patients who developed grade 3 or 4 neutropaenia the median time of 
the nadir was Day 32 (range day 27 to 37). One patient with grade 3 
neutropaenia (patient 37) and one patient with grade 4 neutropaenia 
(patient 35) developed neutropaenic fever. The median time taken for 
neutrophil recovery in patients with grade 3 or 4 neutropaenia was 14 
days (range 7 to 46). The most frequent non-laboratory adverse events 
were nausea and fatigue.  
 
Patient 39 was diagnosed with acute myeloid leukaemia (AML) 8 months 
after commencing ADEPT. The patient had received 2 ADEPT treatments 
with a TPD of 300mg/m
2. In addition to ADEPT the patient had received 2 
other cytotoxic regimes i.e. ECX (epirubicin, cisplatin, capecitabine) and 
gemcitabine with carboplatin. The patient’s first cancer was an anaplastic 
large cell carcinoma of unknown primary. The time interval between the 
patient’s first exposure to a cytotoxic drug and the development of AML 
was 15 months. 
 
Adverse events that were considered to be caused by MFECP1 are 
discussed in detail in Chapter 5. Table 3.5 
BIP prodrug pharmacokinetics in repeat treatment ADEPT phase I/II trial 
Patient   Treatment 
number 
TPD per 
treatment 
(mg/m
2) 
Elimination 
half-life (min) 
C0 (μg/ml) AUCINF 
(μg.ml.min) 
Clearance 
(ml/min) 
Vss (ml) 
1  600 10.0  44.2  432 778 9493 
2  600 10.8  53.0  539 624 8038 
3  600 12.8  60.0 
32 
502 645 8647 
4  600   9.3 49.9  438 740 8488 
1  600 10.3  55.4  557 707 8894  33 
2  600 10.4  62.6  617 638 7926 
1  600 11.7  53.9  562 544 7587  34 
2  600 12.8  59.9  551 555 8165 
1  600 13.5  257 1100  351 4070 
2  600 14.6  54.1  805 480 8277 
35 
3  600 13.9  48.0  963 401 7741 
36  1  450 14.8  46.8  530 509 8582 
1 450  18.2  63.5  1389.5  180.6  4348.4  37 
3 450  18.1  71.6  1615.4  155.4  3803.8 
1 300  9.8 24.9  333.0  615.6  8264.8  38 
3 300  19.5  41.3  853.2  240.3  5963.5 
39  1 150  16.7  18.0  358.1  279.3  5999.0 
1 150  13.7  27.5  260.5  383.8  5706.6  40 
3 150  12.9  17.2  267.9  373.3  6285.0 
1 150  13.6  15.3  190.8  445.6  6827.0  41 
3 150  10.8  32.6  316.4  268.7  3388.4 
1 300  17.4  32.0  628.4  350.1  8135.4  42 
3 300  14.8  29.4  520.1  423.0  7506.6 
43  1 300  13.0  32.6  446.2  403.4  6218.0 
Two minute post-dose value in treatment 1 of patient 35 was extremely high. This was probably an artefact due to inadequate flushing of the central venous cannula resulting in 
contamination of the sample with prodrug. TPD: total prodrug dose. 
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Table 3.6 
The percentage of patients experiencing adverse events in repeat treatment ADEPT phase I/II trial 
 
Adverse event  Grade 1 – 4  Grade 1  Grade 2  Grade 3  Grade 4 
Leucocytes (total WBC)  92  8  42 25 17 
Neutrophils/Granulocytes  75 8 25 8 33 
Lymphopaenia  67 0  0 67 0 
Platelets  92 8 25  50 8 
Haemoglobin  50 25 25  0  0 
Bilirubin  25 17  8  0  0 
ALT  33 17  8  8  0 
AST  33 25  8  0  0 
GGT  8 0 8 0 0 
Febrile neutropaenia  17 NA NA 17  0 
Nausea  75 42 33  0 NA 
Vomiting  50 42  8  0  0 
Diarrhoea  8 8 0 0 0 
Fatigue  50 42  0  8  0 
Fever (no neutropaenia)  17 17  0  0  0 
Rigors/chills  17 17  0  0 NA 
Taste disturbance  17 17  0 NA  NA 
Haemoptysis  8 0  NA  8 0 
Secondary malignancy  8 NA  NA  NA 8 
Supraventricular arrhythmia  8 0 0 8 0 
 
Adverse events (AEs) shown were possibly, probably or almost certainly related to ADEPT. AEs defined according to Common Toxicity Criteria (CTC); 
version 2. NA: not applicable i.e. no such category exists in CTC version 2. Data from CRUK database. All data on patient 32 relates to cycle 1 only i.e. 
2 scheduled treatments. 
WBC: white blood cells, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma glutamyl transpeptidase 
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Table 3.7 
Thrombocytopaenia and neutropaenia in relation to number of 
treatments and total prodrug dose in repeat treatment ADEPT phase 
I/II trial 
 
 
Patient 
 
Number of 
treatments 
 
Total 
prodrug 
dose 
(mg/m
2) 
 
Thrombocytopaenia 
(CTC grade) 
 
 
Neutropaenia 
(CTC grade) 
 
39 300  1 2 
36 900  2 0 
32 1200  1  1 
33 1200  3 2 
34 
2 
 
1200  3 1 
40 450  2 2 
41 450  2 0 
43 700  3  4 
38 900  3  3 
42 900  3  4 
37 1350  3  4 
35 
3 
 
1800  4  4 
CTC: common toxicity criteria. 
All data on patient 32 relates to cycle 1 only i.e. 2 scheduled treatments. 
 
 
 
  933.7 Maximum tolerated TPD for repeat ADEPT treatments 
The definition of DLT in relation to thrombocytopaenia was changed during 
the study by protocol amendment. Definition 1 (patients 32 to 35 inclusive) 
was grade 4 thrombocytopaenia with 1 or more of the following: duration ≥ 5 
days, bleeding or requiring platelet transfusion. In April 2006 the definition 
was changed: Definition 2 (patients 36 to 41 inclusive) was ≥ grade 3 
thrombocytopaenia. The final protocol amendment (July 2007) increased the 
minimum TPD to 900mg/m
2. Since it was anticipated that grade 3 
thrombocytopaenia could occur at this dose, the definition of DLT was 
changed: Definition 3 (patients 42 and 43) was platelet count < 20x10
9/l. 
 
On study completion a single definition of DLT was applied to all patients to 
determine the MTD. The definition regarding thrombocytopaenia was 
Definition 3 (platelet count < 20x10
9/l), all other criteria were as defined in 
Materials and Methods (Chapter 2). Details of DLTs are shown in Table 3.8. 
 
The maximum tolerated TPD with 2 treatments was 1200mg/m
2. Three 
patients (patients 32, 33, 34) received this dose. Two patients experienced 
grade 3 thrombocytopaenia (platelet nadir was 33 x10
9/l in patient 33 and 48 
x10
9/l in patient 34). There were no grade 4 adverse events 
 
The maximum tolerated TPD with 3 treatments was 450mg/m
2. This 
schedule was received by patients 40 and 41. Complete follow up data is 
only available on patient 40 because patient 41 died on day 25 due to 
disease progression. Patient 40 experienced no grade 3 or 4 adverse 
events. 
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Table 3.8 
Dose limiting Toxicity (DLT) in repeat treatment ADEPT phase I/II 
trial 
 
Number of 
completed 
ADEPT 
treatments 
Total 
prodrug 
dose 
(mg/m
2) 
DLT* Patient 
300 No  39 
900 No  36 
1200 No 32** 
1200 No  33 
2 
 
1200 No  34 
450 No  40 
450 No  41 
Yes: 
700 
Platelets < 20 x10
9/l 
43 
900 No  38 
Yes: 
900 
Platelets < 20 x10
9/l 
42 
1350 
Yes: 
1. Febrile neutropaenia 
2. Platelets < 20 x10
9/l 
37 
3 
 
Yes: 
1800  1. Febrile neutropaenia 
2. Platelets < 20 x10
9/l 
35 
* The definition of DLT with regard to thrombocytopaenia was a platelet count < 20 
x10
9/l. 
** All data on patient 32 relates to cycle 1 only i.e. 2 scheduled treatments. 
  953.8 Combined analysis of toxicity in single and repeat treatment 
patients 
A combined analysis of the results from all 43 patients who have received 
ADEPT with MFECP1 was performed. Thirty one patients received 1 
treatment, 5 patients received 2 treatments and 7 patients received 3 
treatments. The toxicity results of the single ADEPT treatment phase I trial 
have previously been published (Mayer et al., 2006). The combined analysis 
in this MD (Res) thesis represents a novel analysis of all available data. 
 
3.8.1 Combined analysis of myelosuppression 
Myelosuppression was seen in single and repeat treatment patients. Severity 
of myelosuppression increased as the TPD increased (Table 3.9). 
 
In addition, as the number of treatments increased the dose of prodrug 
necessary to cause myelosuppression decreased. For example in patients 
who received MFECP1 3000U/m
2 the lowest TPD that was associated with ≥ 
grade 3 thrombocytopaenia after 1, 2 or 3 treatments was 1613mg/m
2, 
1200mg/m
2 and 700mg/m
2 respectively (Table 3.9). 
 
There is some evidence that myelosuppression is increased when prodrug is 
given at higher serum enzyme levels. Forty three patients received a total of 
64 ADEPT treatments (including 2 additional treatments given to patient 32). 
Prodrug was given when serum enzyme activity was ≤ 0.005U/ml in 63 of 64 
treatments. However in 1 treatment (patient 3) prodrug was administered 
when serum enzyme activity was 0.017U/ml. Patient 3 developed grade 3 
neutropaenia and grade 3 thrombocytopaenia despite being in the lowest 
prodrug dose cohort (Table 3.10). 
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Table 3.9 
Thrombocytopaenia and neutropaenia in relation to number of 
treatments and total prodrug dose in patients that received MFECP1 
3000U/m
2 
 
 
Patient 
 
Number of 
treatments 
 
Total 
prodrug 
dose 
(mg/m
2) 
 
Thrombocytopaenia 
(CTC grade) 
 
 
Neutropaenia 
(CTC grade) 
 
26 806.4  0  0 
27 806.4  1  2 
28 806.4  0  0 
24 1612.8  3  4 
25 
1 
 
1612.8 1  3 
39 300  1 2 
36 900  2 0 
32 1200  1  1 
33 1200  3 2 
34 
2 
 
1200  3 1 
40 450  2 2 
41 450  2 0 
43 700  3  4 
38 900  3  3 
42 900  3  4 
37 1350  3  4 
35 
3 
 
1800  4  4 
CTC: common toxicity criteria. ** All data on patient 32 relates to cycle 1 only i.e. 2 
scheduled treatments. 
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At a fixed TPD of 1613mg/m
2 a reduction in MFECP1 dose permitted earlier 
prodrug administration but was associated with greater myelosuppression 
(Table 3.11). The increase in myelosuppression, despite serum CPG2 
activity being < 0.002U/ml, was probably caused by CPG2 activity in non-
tumour tissue other than plasma e.g. liver, lung. 
 
 
 
 
 
Table 3.10 
Serum enzyme activity at time of prodrug administration and 
thrombocytopaenia / neutropaenia. Data on 6 patients who each 
received a total prodrug dose of 37.3mg/m
2 with MFECP1 5000U/m
2.
 
Patient number
  Serum CPG2 
activity (U/ml)
 
Thrombocytopaenia
CTC grade
 
Neutropaenia 
CTC grade
 
1
  ≤ 0.005
  2
  0
 
2
  ≤ 0.005
  1
  0
 
3
  0.0167
  3
  3
 
5
  ≤ 0.005
  0
  0
 
6
  ≤ 0.005
  0
  0
 
7
  ≤ 0.005
  0
  0
 
CTC: common toxicity criteria 
 
 
  
 
 
Table 3.11 
MFECP1 to prodrug time interval and myelosuppression 
 
Patient  MFECP1 
dose (U/m
2) 
Serum CPG2 
activity* 
(U/ml) 
MFECP1-prodrug 
interval (hours) 
Neutropaenia 
CTC 
Thrombocytopaenia
CTC 
21 5000 <0.002  17.0  0  0  mean 
22 5000 <0.002  16.0  = 16.5 0 1 
24 3000 <0.002  9.7  4  3  mean 
25 3000 <0.002  13.8  = 11.8 3 1 
*serum CPG2 activity at time of BIP prodrug administration. 
MFECP1-prodrug interval was time from end of MFECP1 infusion to BIP prodrug administration. 
CTC: Common Toxicity Criteria (version 2) 
 
  993.8.2 Combined analysis of hepatic toxicity 
Two patients (patient 23 and 25) experienced grade 4 elevation of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST). A liver 
biopsy in patient 23 revealed hepatic necrosis. The liver dysfunction resolved 
completely. Grade 4 hepatic impairment was only seen in patients who 
received a TPD per treatment of ≥ 1613mg/m
2. Grade 4 hepatic impairment 
did not occur in patients who received repeat ADEPT; the highest TPD per 
treatment in repeat ADEPT patients was 600mg/m
2. 
 
3.8.3 Combined analysis of renal toxicity 
Grade 4 renal dysfunction occurred in one patient (patient 23). This patient 
experienced grade 4 elevation of serum creatinine and uric acid. A renal 
biopsy revealed acute tubular necrosis. Temporary haemofiltration was 
required and the renal toxicity subsequently resolved. This patient also 
experienced grade 4 elevations of serum ALT and AST. The patient had 
received a single ADEPT treatment of MFECP1 5000U/m
2 followed by a 
TPD of 3225.6mg/m
2. This was the largest TPD per treatment given to any 
patient. No other patient had any elevation of serum creatinine or uric acid.  
 
3.9 Conclusions 
This chapter had two aims. Firstly to investigate treatment delivery and 
safety of repeat ADEPT treatments with MFECP1 and BIP prodrug. 
Secondly to identify risk factors for toxicity by examining all available clinical 
data i.e. single and repeat treatment patients. 
 
Twelve patients were treated in a phase I/II clinical trial of repeat ADEPT 
treatment. The median time interval between the end of the MFECP1 
infusion and prodrug administration was 14.6 hours. Dose limiting toxicity 
(thrombocytopaenia and febrile neutropaenia) prevented the number of 
treatments being increased above 3. The maximum tolerated TPD was 
1200mg/m
2 for 2 treatments and 450mg/m
2 for 3 treatments. The most 
  100frequent adverse events (any grade) were leucopaenia, thrombocytopaenia, 
neutropaenia and nausea. The most frequent grade 3 or 4 adverse events 
were lymphopaenia, thrombocytopaenia and leucopaenia. 
 
Combined analysis of all data identified risk factors for myelosuppression 
and hepatic toxicity. Grade 4 hepatic toxicity only occurred in patients who 
received a TPD per treatment ≥ 1613mg/m
2. Increased TPD or number of 
treatments was positively associated with an increase in myelosuppression. 
Myelosuppression may also be associated with increased serum CPG2 
activity at time of prodrug and reduced MFECP1-prodrug interval. 
 
These results indicate that repeat ADEPT can be given safely and have 
identified clinically relevant risk factors for toxicity. In the following chapter 
the efficacy of repeat ADEPT treatment is investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  101Chapter 4 
 
Efficacy of repeat ADEPT 
treatment with MFECP1 and BIP 
prodrug (Phase I/II trial). 
 
4.1 Introduction  
The primary objective of the phase I/II clinical trial was to determine the 
maximum number of tolerated treatments and the maximum tolerated TPD. 
Whilst formal assessment of efficacy is performed at a later stage in drug 
development (phase II and phase III), a phase I trial offers an opportunity to 
obtain early data on tumour response. Evidence of tumour response in a 
phase I trial would favour a drug’s continued development. Furthermore if 
responses do occur then these responses may provide early evidence of 
which drug doses are associated with response. This information may help 
in the selection of the recommended phase II dose. 
 
This chapter aims to examine evidence of efficacy in repeat treatment 
ADEPT patients. In addition a combined analysis of all available efficacy 
data is performed i.e. single and repeat treatment patients. This combined 
analysis includes FDG-PET results from single-treatment patients, data that 
was not included in the published data on the single-treatment trial (Mayer et 
al., 2006). 
 
4.2 Tumour response by CT imaging 
Eleven of 12 patients (92%) were evaluated for response with a Day 29 and 
Day 57 CT scan. No complete or partial responses were seen. The results of 
  102disease assessment by CT are shown in Table 4.1. Patients are listed 
according to TPD received. Patient 35 had a 10% reduction in tumour size 
(RECIST criteria) on Day 29 imaging (Figure 4.1) and a 4% reduction on Day 
57 imaging.  
 
 
Figure 4.1 
Reduction in the size of a metastasis following ADEPT. The images were taken before (Day - 
3) and after ADEPT (Day 28). The images in row A are taken at a different anatomical level to 
the images in row B. The location of a metastasis in the right lung is indicated with pink 
arrowheads. Images are from patient 35 who received 3 ADEPT treatments with a total 
prodrug dose of 1800mg.m2. By RECIST criteria reduction in longest diameter was 10% i.e. 
stable disease. 
A 
B 
Day  -3 Day +28 
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Table 4.1 
Disease assessment by CT imaging in repeat treatment ADEPT phase I/II 
trial 
 
 
Patient 
 
Total prodrug 
dose 
(mg/m
2) 
CT Day 29 
 
RECIST criteria 
(% change or 
new lesion) 
 
CT Day 57 
 
RECIST criteria 
(% change or 
new lesion) 
 
39 300 SD 
(13% increase) 
PD 
(28% increase) 
40 450 SD 
(4% increase) 
SD 
(7% increase) 
41  450  Not examined  Not examined 
43 700 SD 
(18% increase) 
SD 
(18% increase) 
36 900 SD 
(3% increase) 
SD 
(12% increase) 
38 900 SD 
(3% increase) 
SD 
(7% increase) 
42 900 
PD 
(New enlarged 
lymph node) 
PD 
(New enlarged 
lymph node) 
32 1200 SD 
(5% increase) 
SD 
(16% increase) 
33 1200 SD 
(10% increase) 
PD 
(29% increase) 
34 1200  PD (New bone 
lesion) 
PD (New bone 
lesion) 
37 1350 SD 
(1% decrease) 
SD 
(2% decrease) 
35 1800 SD  SD 
(10% decrease)  (4% decrease) 
Percentage change in measured target lesions relative to the pre-ADEPT CT scan. CT: 
computerized tomography. RECIST: response evaluation criteria in solid tumours. PD 
(progressive disease) is an increase in the sum of longest diameters of target lesions of 
≥ 20% or the appearance of one or more new lesions. SD (stable disease) is defined as 
neither sufficient shrinkage to qualify for PR (≥30% decrease in the sum of the longest 
diameters of target lesions) nor a sufficient increase to qualify for PD.  
  1044.3 FDG-PET imaging 
Eleven patients chose to undergo an optional FDG-PET scan prior to 
treatment. Post-treatment imaging was performed on Day 23 and Day 54 in 
10 and 8 patients respectively. Three patients were unable to have post 
treatment imaging due to symptomatic deterioration. The results of disease 
assessment by FDG-PET coincidence imaging are shown in Table 4.2. A 
significant reduction in tumour activity (>15%) was seen in 3 patients at Day 
23. 
 
4.4 Serum CA19-9 measurement 
The serum tumour marker CA19-9 was elevated at baseline in 8 patients. 
Following ADEPT the serum CA19-9 fell in 3 patients, all of whom received a 
TPD  ≥ 900 mg/m
2. Reductions in serum CA19-9 of 64%, 63% and 27% 
occurred in patients 32, 35 and 38 respectively (Figure 4.2). These 3 
patients are the same patients that responded on FDG-PET. 
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Figure 4.2 
Reduction in serum CA19-9 in patients 32, 35 and 38 following ADEPT. All patients 
commenced treatment on Day 1. Data shown on patient 32 represents the response to the 
first 2 treatments that patient 32 received. 
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Table 4.2 
Disease assessment by FDG-PET imaging in repeat treatment ADEPT 
phase I/II trial 
 
Patient 
Total prodrug 
dose 
(mg/m
2) 
Response by FDG-PET 
coincidence imaging on 
Day 23 
(% change) 
Response by FDG-PET 
coincidence imaging on 
Day 54 
(% change) 
39 300  SD (7.0% increase)  N.Q. 
450  SD (8.5% increase)  PD (45.2% increase)  40 
41 450  NE  NE 
43 700  NQ  NQ 
36 900  NQ  NQ 
38 900  PR (15.2% decrease)  SD (5.4% increase) 
42 900  PD (60.6% increase)  PD (68.6% increase) 
32 1200  PR (20.7% decrease)  SD (6.1% increase) 
33 1200  PD (36.6% increase)  NE 
34 1200  PD (692% increase)  NE 
37 1350  NE  NE 
35 1800  PR (27.2% decrease)  PD (48.6% increase) 
Response defined according to the method described by Green (Green et al., 2008). 
Partial response (PR) is a reduction >15%, progression of disease (PD) is an increase 
>10%, stable disease (SD) relates to values between PR and PD. PR, SD and PD shaded 
in green, blue and pink respectively. Percentage change is relative to the pre-ADEPT 
baseline FDG-PET coincidence scan. Patient 37 declined FDG coincidence imaging. 
Patient 41 was unable to undergo follow up imaging due to symptomatic deterioration. 
Patients 33 and 34 were unable to undergo the Day 53 scan due to symptomatic 
deterioration. NQ: not quantifiable. NE: not examined. 
 
 
  1064.5 Combined analysis of efficacy in single and repeat treatment 
patients 
A combined analysis of the results from all 43 patients who have received 
ADEPT (with MFECP1 and BIP prodrug) was performed. The median 
number of previous chemotherapy regimes received prior to ADEPT 
(including adjuvant therapy) was 2 (range 1 to 5). 
 
No objective response (complete response or partial response on RECIST) 
was seen on CT imaging. Two patients had minor CT responses i.e. 9% 
reduction in patient 24 and 10% reduction in patient 35.  
 
Quantification of FDG-PET tumour response was performed in 22 patients. 
Tumour activity on FDG-PET imaging reduced significantly (> 15%) in 4 
patients. The primary site of tumour in these patients was peritoneal serous 
carcinoma (patient 24), adenocarcinoma of the pancreas (patient 32) and 
adenocarcinoma of the colon (patients 35 and 38). 
 
In 3 of the 4 patients who had a significant response on FDG-PET imaging, 
data from a subsequent FDG-PET was available. In all 3 of these patients 
the significant reduction in tumour activity was seen on the Day 23 scan. 
However in each of these patients tumour activity had increased above the 
pre-ADEPT imaging on the Day 54 scan. The median interval in days 
between the 2 scans was 35 days (range 28 to 38). 
 
Responses on FDG-PET were only seen in patients that received a TPD ≥ 
900 mg/m
2.
 There was a significant correlation between percentage change 
of tumour activity on FDG-PET and TPD (p=0.031, Spearman Rank 
correlation test).
 
 
Serum CA19-9 was elevated at baseline in 30 patients. Following ADEPT 
serum CA19-9 fell in 9 patients. The 3 largest falls in serum CA19-9 (64% in 
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patient 32, 63% in patient 35 and 27% in patient 38) all occurred in patients 
that received a TPD ≥ 900 mg/m
2. A summary of adverse events and 
efficacy in patients who received a TPD ≥ 900mg/m
2 is shown in Table 4.3. 
 
4.6 Efficacy with 2 ADEPT treatments given at maximum tolerated TPD 
Using an MFECP1 dose of 3000U/m
2 the maximum tolerated TPD was 
450mg/m
2 with 3 treatments, 1200mg/m
2 with 2 treatments and 806.4mg/m
2 
with 1 treatment. (In the single ADEPT treatment trial MFECP1 3000U/m
2 
was only examined at 2 TPD levels: 806.4mg/m
2 and 1612.8mg/m
2). 
Combined analysis of efficacy indicated that efficacy was only seen when 
TPD ≥ 900mg/m
2.  
 
There was evidence of efficacy with 2 ADEPT treatments given at maximum 
tolerated TPD (1200mg/m
2). Three patients were treated with this regime 
(patients 32, 33 and 34). Efficacy was seen in one of these patients (patient 
32) on FDG-PET (21% reduction in activity) and serum CA19-9 (64% 
reduction). The FDG-PET response appeared short lived and tumour activity 
had increased above baseline 35 days later i.e. on the Day 54 scan. With 
this regime both grade 3 lymphopaenia and grade 3 thrombocytopaenia 
occurred in 2 patients (66%). One patient (33%) had grade 2 neutropaenia. 
Non-laboratory adverse events were grade 1 only. The most frequently 
occurring non-laboratory adverse events were nausea (66%), vomiting 
(66%) and fatigue (66%).  
 
Table 4.3 
Adverse events and efficacy (CT and FDG-PET) with TPD ≥ 900mg/m
2 
 
Grade of Toxicity (CTC)  Number of 
treatments 
Patient 
Number 
TPD 
(mg/m
2)  CT 
Creatinine Platelets Neutrophils ALT  AST
FDG-PET 
21 1613  0  0  0  1  0  SD    NQ 
22  1613  0  1  0  1  1  SD   Disease progression 
24 1613  0  3  4 2  2  SD    Response 
25 1613  0  1  3  4  4 PD    NE 
1 
23 3226  4 3  2  4  4  PD   Disease progression 
32  1200  0  1  1  2  1  SD   Response 
33  1200  0  3  2  0  0  SD   Disease progression  2 
34  1200  0  3  1  0  0  PD   Disease progression 
42 900  0  3  4  3  1  PD   Disease progression 
38 900  0  3  3  1  1 SD    Response 
36 900  0  2  0  0  0 SD    NQ 
37 1350  0  3  4 2  1  SD    NE 
3 
35 1800  0  4  4 0  0  SD    Response 
No grade 4 toxicity occurred following 2 treatments with a TPD of 1200mg/m2 (shaded green). CT is Day 29 result. FDG-PET is Day 23 result. 
Response on FDG-PET defined according to the method described by Green (Green et al., 2008). ALT: alanine transaminase, AST: aspartate 
transaminase, SD: stable disease, PD: progression of disease, NQ: not quantifiable, NE: not examined: TPD: total prodrug dose, CTC: common 
toxicity criteria. 
  1094.7 Conclusions 
The aim of this chapter was to investigate evidence of efficacy with repeat 
ADEPT treatments. This was achieved by assessment of CT, FDG-PET and 
serum CA19-9. No complete responses or partial responses were seen on 
CT imaging. One patient had a 10% reduction of tumour size on CT by 
RECIST criteria. Clinically significant responses on FDG-PET imaging 
occurred in 3 patients.  
 
Combined analysis of data from single and repeat ADEPT treatments 
indicated that FDG-PET responses only occurred in patients who received a 
TPD  ≥ 900mg/m
2. Efficacy was seen in 1 of 3 patients that received 2 
ADEPT treatments given at the maximum tolerated TPD. 
 
 
 
 
  
 
 
 
 
  110Chapter 5 
 
The immune response to MFECP1 
 
5.1 Introduction 
MFECP1 is a non-human, recombinant fusion protein. Hence administration 
of MFECP1 to patients could cause activation of elements of the immune 
system e.g. Th lymphocytes and B-lymphocytes. The aim of the work 
presented in this chapter was to increase understanding of the immune 
response to MFECP1. The immune response to MFECP1 is important 
because antibodies to MFECP1 could reduce patient safety and adversely 
affect the function of MFECP1. 
 
The first question asked was whether increasing the number of MFECP1 
infusions would increase the incidence of immunological adverse events. 
This is possible because data from the single-treatment ADEPT trial 
indicated that patients could become HACPA positive as early as day 7. 
Since a patient receiving 3 ADEPT treatments would receive the 3
rd 
MFECP1 infusion on day 8, HACPA could be present at the time of MFECP1 
administration. 
 
The second question was whether patients receiving repeat MFECP1 
infusions were more likely to become HACPA positive than those who 
received a single treatment. 
 
Finally the nature of the Th lymphocyte response to MFECP1 was 
investigated. Since Th lymphocyte activation is required for the development 
of high affinity, long-lived antibody responses the possibility of identifying 
and mutating clinically relevant T-cell epitopes was investigated. The focus 
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was placed on addressing the CPG2 component of MFECP1 since this was 
likely to be the most immunogenic sequence within MFECP1. Th 
lymphocytes were isolated from healthy volunteers and a patient receiving 
ADEPT, as well as from mice transgenic for human MHC class II, in order to 
investigate the role of Th  lymphocytes in the development of immune 
responses against MFECP1. 
 
5.2 Safety of MFECP1 
During the single-treatment and repeat-treatment ADEPT trials a total of 66 
MFECP1 infusions were administered to 43 patients (including 2 additional 
treatments given to patient 32). Adverse events related to MFECP1 occurred 
in 8 of 43 patients (19%) and were grade 1 only (Table 5.1). 
 
MFECP1 infusion reactions, defined as MFECP1-related adverse event(s) 
that started after MFECP1 administration but before BIP prodrug, occurred in 
11% (7/66) of infusions and were grade 1 only. Infusion reactions occurred 
with 12% of 1
st-dose infusions and 9% of non-1
st dose infusions. Hence the 
results indicated that prior administration of MFECP1 did not increase the 
risk of an infusion reaction (Table 5.2). 
 
 
 
 
 Table 5.1 
Adverse events related to MFECP1 in single and repeat treatment ADEPT patients 
 
Patient  CTC 
grade  Day  Comments  MFECP1 infusion reaction 
‡  Adverse  event 
rigors/chills 1 
fatigue 1 
1 
 
1 
1  50 minutes after starting MFECP1 
allergy/immunology – other* 
Yes 
2 headache  1  1  Day  1  Yes 
11  hypertension  1  1  2 hours after starting MFECP1  Yes 
fever (no neutropaenia)  1  2  5 hours after BIP prodrug   No 
12 
1  3 
Day 3 i.e. after MFECP1 and BIP 
prodrug 
No  fever (no neutropaenia) 
nausea 1 
14 
vomiting 1 
1  4 hours after starting MFECP1  Yes 
28  constitutional – other**  1  2  3 hours after BIP prodrug   No 
fever 
1 
(no neutropaenia) 
1  1 hour after starting MFECP1  Yes 
35 
rigors/chills 1  8  After  3
rd MFECP1 infusion  Yes 
36 nausea  1  3  After  2
nd MFECP1 infusion  Yes 
Adverse events listed were considered possibly, probably or almost certainly related to MFECP1. CTC: Common Toxicity Criteria (CTC), version 2. 
* Patient felt cold / shivery and felt “heat” in throat. Looked pale and had cool peripheries. ** Pyrexia. ‡ MFECP1 infusion reaction defined as MFECP1-related adverse event(s) 
that started after MFECP1 administration but before BIP prodrug administration. 
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Table 5.2 
MFECP1 infusion reactions and number of MFECP1 infusions received; 
results from single and repeat treatment ADEPT patients 
 
 
1
st MFECP1 
administration
(n=43) 
2nd MFECP1 
administration
(n=12) 
3rd MFECP1 
administration 
(n=10) 
4th MFECP1 
administration
(n=1) 
Number (%) 
of infusions 
complicated 
by infusion 
reaction 
5 
(12%) 
1  1  0 
(8%)  (10%)  (0%) 
 
 
5.3 HACPA production  
HACPA formation was measured by ELISA before treatment and weekly 
during follow up period. The cut-off value for a positive result was obtained 
by assaying 50 pre-treatment serum samples at 1:100 dilutions and taking 
the cut-off as 3x the standard deviation above the mean absorbance.  
 
HACPA data was obtained from all repeat-treatment patients. These results 
were combined with those from single-treatment patients to provide a 
combined data set from 42 patients. No follow up HACPA data was available 
on patient 31 due to clinical deterioration. The combined HACPA results 
(Table 5.3) showed that all patients became HACPA positive during the 58 
day follow-up period. In patients who received repeat MFECP1 infusions the 
median day of becoming HACPA positive was day 16 (range 15 to 58).  
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Table 5.3 
HACPA production in relation to number of MFECP1 infusions; results 
from single and repeat treatment ADEPT patients 
 
Day of HACPA onset 
or median day of 
HACPA onset (range), 
in HACPA positive 
patients 
Number of MFECP1 
infusions 
Number of HACPA 
positive patients (%) 
1*  12/30 (40%)   day 14 (7 to 42) 
2  2/2 (100%)  day 16 and day 19 
3  9/9 (100%)  day 16 (15 to 37) 
4  1/1 (100%)  day 58 
* Data updated from single ADEPT treatment study (Mayer et al, 2006) 
 
 
One patient received a total of 4 MFECP1 infusions (2 scheduled infusions 
plus 2 additional infusions) and became HACPA positive on day 58. This 
patient was able to receive the 2 additional infusions (on day 43 and 45) as 
per protocol. 
 
Four patients received ciclosporin immunosupression in an attempt to 
reduce HACPA formation. Ciclosporin was given to patients 36, 37, 38 and 
39 who became HACPA positive on day 18, 15, 23 and 15 respectively. 
Patient 36 had a grade 4 allergic reaction (anaphylaxis) to intravenous 
ciclosporin shortly after beginning the infusion. This allergic reaction resolved 
completely the same day after supportive treatment. The patient was 
switched from ciclosporin to alternative immunosupression (oral tacrolimus). 
  115Ciclosporin was also considered responsible for grade 2 nausea in patient 
37 and grade 1 elevation of creatinine in patient 39. Since ciclosporin 
appeared to increase toxicity without producing any delay in HACPA 
formation, it was not given after patient 39. 
 
Patients who received more than 1 MFECP1 infusion were significantly more 
likely to become HACPA positive (Log-rank p = 0.001) than patients who 
received a single infusion (Figure 5.1). A significant positive relationship was 
also found between total MFECP1 dose and HACPA formation (p=0.013, 
Cox Regression analysis).  
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Figure 5.1 
Kaplan Meier curves for probability of being HACPA positive following a single or repeat 
MFECP1 infusion. Single infusion = blue line, repeat infusion = green line. Data based on 
results of 42 patients. (+ = data censored) 
 
  1165.4 Human Th lymphocyte response to MFECP1: healthy volunteers 
The in vitro response to MFECP1 was studied using Th lymphocytes from 6 
healthy volunteers none of whom had received MFECP1. PBMCs were 
incubated for 5 days with MFECP1 in T-cell proliferation assays. SEB and 
PPD were used as positive controls. The results of these experiments are 
illustrated in Figure 5.2 and showed that significant lymphocyte stimulation, a 
stimulation index (SI) of ≥ 2, occurred in 83% i.e. 5 of the 6 volunteers.  
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Figure 5.2 
In vitro response of peripheral blood mononuclear cells (PBMCs) from healthy volunteers to 
MFECP1. T-cell proliferation assays using PBMCs from 6 healthy volunteers. Cells were 
incubated with MFECP1, SEB, PPD or negative control (medium only). Results are shown as 
stimulation indices (S.I.). Significant proliferation (S.I. ≥ 2) occurred in 5 of 6 donors when 
incubated with MFECP1. 
 
 
 
  1175.5 Human Th lymphocyte response to MFECP1: ADEPT patient 
PBMCs from an ADEPT patient were incubated with MFECP1 in a T-cell 
proliferation assay. The PBMCs were prepared from a blood sample taken 
from patient 43 on day 80. Due to a low yield of PBMCs the concentration of 
cells added to wells was 1.5 x10
6 cells/ml rather than the usual concentration 
of 3.5 x10
6 cells/ml. The patient received 3 MFECP1 infusions and became 
HACPA positive on day 16. The patient did not receive ciclosporin and had 
not experienced any adverse events related to MFECP1. Results from the T-
cell proliferation assay showed that incubation of PBMCs with MFECP1 
produced a SI of 2.5, consistent with significant stimulation (Figure 5.3).  
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Figure 5.3 
In vitro response of peripheral blood mononuclear cells (PBMCs) from an ADEPT patient to 
MFECP1. A T-cell proliferation assay using PBMCs from patient 43. Cells were incubated 
with MFECP1, SEB, PPD or negative control (medium only). Results are shown as 
stimulation indices (S.I.). Significant proliferation (S.I. ≥ 2) occurred following incubation of 
PBMCs with MFECP1. 
 
 
 
  1185.6 Human Th lymphocyte response: IFN- secretion assay 
Secondary immune responses are characterized by rapid, large responses 
to an antigen that an organism has previously been exposed to. In section 
5.4 it was demonstrated that Th lymphocytes from 5 of 6 healthy volunteers 
responded after a 5 day in vitro incubation with MFECP1. Th lymphocyte 
proliferation at 5 days suggested that the reaction was a secondary immune 
response. Further experiments were therefore conducted to investigate 
whether there was evidence of lymphocyte activation earlier than 5 days. 
 
Blood was taken from 3 healthy volunteers. All 3 volunteers (volunteer 2, 3 
and 6) had given a previous blood sample for the T-cell proliferation 
experiments (see Figure 5.4) and had responded to MFECP1. Whole blood 
was incubated for 13 hours at 37
oC with MFECP1, SEB (positive control) or 
media only (negative control). The red blood cells were then lysed and T-cell 
stimulation was measured by using an IFN- secretion assay. T-cells were 
first labelled with a catch reagent specific for IFN- (this is a proprietary mAb-
mAb complex that binds to the cell surface at one end and binds to IFN- at 
the other). Cells were incubated at 37
oC to allow IFN- secretion from 
stimulated cells. IFN- that bound to the catch reagent was then labelled 
using a second IFN- specific mAb that was conjugated to R-phycoerythrin 
(PE) for detection by flow cytometry. In addition cells were labelled for CD3 
and CD4. Cells were then fixed and flow cytometry performed.  
 
Results showed that incubation of PBMCs with MFECP1 increased IFN- 
release compared to incubation with medium alone in CD3 positive cells 
(Figure 5.4).  
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Figure 5.4 
Response of CD3+ cells (measured by IFN- release) from 3 healthy volunteers after 
incubation with MFECP1, negative control (media only) or positive control (SEB). A. 
Percentage of CD3 positive cells releasing IFN- after incubation for 13 hours with MFECP1, 
negative control or positive control. B. IFN- release in CD3 positive cells from volunteer 3 
after incubation with MFECP1 (blue line), negative control (red line) or positive control (green 
line). 
 
 
To identify which CD3+ cells were responding to MFECP1 subset analysis 
was performed on CD4+ and CD4- cells.  
 
Results from the CD4+ subset suggested that IFN- secretion is increased 
by incubation with MFECP1 compared with medium. The apparent increase 
in IFN- secretion from CD4+ cells following incubation with MFECP1 is 
shown in Figure 5.5. Incubation with MFECP1 did not appear to increase 
IFN- secretion in CD4- cells (Figure 5.6 and Figure 5.7). 
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A  B
Figure 5.5 
Response of CD4+ cells (measured by IFN- release) from 3 healthy volunteers after 
incubation with MFECP1, negative control (medium only) or positive control (SEB). A. 
Percentage of CD4 positive cells releasing IFN- after incubation for 13 hours with MFECP1, 
negative control or positive control. B. IFN- release in CD4 positive cells from volunteer 3 
after incubation with MFECP1 (blue line), negative control (red line) or positive control (green 
line). 
 
 
The stimulation of CD4+ cells from healthy volunteers by MFECP1 is 
particularly significant because it occurred after a short incubation i.e. 13 
hours. Stimulation of CD4+ cells after such a short incubation would strongly 
suggest that healthy donors were pre-primed against components of 
MFECP1 and generate T cell memory which can produce rapid T-
lymphocyte responses upon challenge with MFECP1 in vitro. 
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Figure 5.6 
Response of CD4- cells (measured by IFN- release) from 3 healthy volunteers after 
incubation with MFECP1, negative control (medium only) or positive control (SEB). A. 
Percentage of CD4 negative cells releasing IFN- after incubation for 13 hours with MFECP1, 
negative control or positive control. B. IFN- release in CD4 negative cells from volunteer 3 
after incubation with MFECP1 (blue line), negative control (red line) or positive control (green 
line) 
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  1225.7 Mapping T-cell epitopes on CPG2: healthy volunteers 
Experiments shown in section 5.7 were performed by Biovation Ltd. as part 
of a collaboration between the ADEPT development team at UCL and 
Biovation Ltd. (a biotechnology company with expertise in de-immunization 
of proteins and now known as Antitope Ltd.). 
 
In order to identify amino acid sequences on CPG2 that induce Th 
lymphocyte proliferation, PBMCs from 20 healthy volunteers were incubated 
with 128 different overlapping 15mer peptides that spanned the entire 
sequence of CPG2. Th  lymphocyte activation was assessed using T-cell 
proliferation assays. The results of these T-cell proliferation assays are 
summarized in Figure 5.8. Full results are shown in Appendix 2. Whilst 
81/128 peptides did not cause significant proliferation of PBMCs from any of 
the 20 donors, 47/128 peptides caused significant proliferation in at least one 
donor. 
 
 
 
 
 
3 peptides reacted with 3 volunteers 
1 peptide reacted with 4 volunteers 
12 peptides reacted with 2 volunteers 
31 peptides reacted with 1 volunteer 
Figure 5.8 
Cartoon to illustrate the results of T-cell proliferation assays using peripheral blood 
mononuclear cells from 20 healthy volunteers incubated with 15 mer peptides spanning 
sequence of carboxypeptidase G2.  
 
  123The data from these T-cell proliferation assays was analysed by Biovation in 
conjunction with the known structure of CPG2. Eight Th lymphocyte epitopes 
were identified. The predicted binding of these 8 epitopes with HLA was 
analysed in silico and 23 amino acid substitutions were proposed to disrupt 
peptide/HLA binding. The proposed mutations are shown in Table 5.4. A 
model indicating the position of individual mutations for a single epitope is 
shown in Figure 5.9. 
 
 
 
Table 5.4 
Identification of 8 Th lymphocyte epitopes on CPG2 
and proposed amino acid substitutions 
 
Epitope  Mutation 
identity 
Amino acid 
and location 
Substitution Secondary 
structure 
information 
 
1  I 74  T  B-sheet exposed 
2  L 83  A / G  B-sheet exposed  A 
3  M 85  K  B-sheet exposed 
4  Y 110  T  B-sheet exposed 
5  I 114  A / G  Loop, cleft, partly 
exposed 
6  V 123  A / G  A-helix interior 
B 
7  L 125  A / G  A-helix interior 
C  8  L 145  G or T   B-sheet interior 
9  V 171  A / G  B-sheet interior 
10  L 172  T   B-sheet interior 
11  F 174  A / G  B-sheet interior 
D 
12  L 184  A / G  B-sheet interior 
13  L 211  A / G  Loop exterior 
14  V 213  A   Loop exterior  E 
15  L 216  A  A-helix exterior 
16  L 236  A / G  Loop partly exposed 
17  W 240  A (H)  B-sheet interior 
18  I 242  A, T  B-sheet exterior 
F 
19  V 248  T  Loop exterior 
20  V 291   A / G  B-sheet  G 
21  V 293  A / G  B-sheet 
22  L 311  A / G  a-helix  H 
23  V 312  A / G  a-helix 
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Figure 5.9 
Model of CPG2 monomer with amino acid substitutions at 3 locations designed to disrupt T-
cell epitope A. Amino acid 74 (isoleucine) shown in red has been changed to threonine. 
Amino acid 83 (leucine) shown in green has been changed to alanine. Amino acid 85 
(methionine) shown in yellow has been changed to lysine. 
 
 
5.8 MFECP1 response of Th lymphocytes from transgenic mice 
Human and particularly patient blood is a resource of limited availability. It 
was hypothesized that mice transgenic for human MHC could offer a viable 
alternative; particularly as the mice could be immunized with MFECP1. The 
in vitro response of Th lymphocytes from a transgenic mouse strain (HLA-
DRB1*0101 mice) to MFECP1 was investigated. The experiment was 
performed using 20 male DRB1*0101 mice; 10 were immunized with 
MFECP1 plus adjuvant, 10 were immunized with PBS plus adjuvant. Mice 
that were injected with MFECP1 received 16.5μg of MFECP1 each. On days 
12 to 13 the mice were culled and lymphocytes extracted from the popliteal 
lymph node adjacent to the immunization site. The cells were incubated for 5 
days in T-cell proliferation assays with MFECP1, SEB or medium.  
 
  125The results from these experiments indicated that Th lymphocytes from 
control immunized DRB1*0101 mice did not respond to MFECP1 (SI < 2) 
whilst Th lymphocytes from 9 of the 10 MFECP1-immunized DRB1*0101 
mice responded. These results are shown in Figure 5.10. 
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Figure 5.10 
Stimulation indices of Th lymphocytes from DRB1*0101 transgenic mice incubated with 
MFECP1 in T-cell proliferation assays. Mice 1-10 had been immunized with control 
immunization (PBS and TiterMax adjuvant). Mice 11-20 had been immunized with MFECP1 
immunization (MFECP1 and TiterMax adjuvant). Twelve to 13 days after immunization the 
mice were culled and lymphocytes extracted from the popliteal lymph node adjacent to the 
immunization site. Cells were incubated for 5 days with medium, MFECP1 or SEB. Th 
lymphocytes from control immunized mice did not proliferate in vitro when incubated with 
MFECP1 i.e. stimulation indices <2. Th lymphocytes from 9 of 10 MFECP1 immunized mice 
did proliferate in vitro when incubated with MFECP1 i.e. stimulation indices ≥ 2. Off scale data 
for mice 11, 14, 15, 17 and 19 were 9.6, 23.4, 57.1, 36.4 and 11.3 respectively. 
 
  1265.9 Conclusions 
The aim of this chapter was to increase understanding of the immune 
response to MFECP1. 
 
Data from 66 MFECP1 infusions indicated that infusion reactions were mild 
(grade 1 only) and occurred in 11% of infusions. Repeat administration of 
MFECP1 did not increase the risk of an infusion reaction but significantly 
increased the risk of a patient becoming HACPA positive. 
 
In vitro MFECP1 induced proliferation of Th lymphocytes in 83% of healthy 
volunteers. The induction of IFN- release from Th lymphocytes by MFECP1 
after an incubation of only 13 hours strongly suggested that the response 
was a secondary immune response. Healthy volunteers may have been 
previously exposed to T-cell epitopes on MFECP1 through natural exposure 
to CPG2 from Pseudomonas bacteria. 
 
In collaboration with Biovation, 8 possible T-cell epitopes on CPG2 were 
identified by incubating PBMCs from 20 healthy donors with overlapping 15 
mer peptides spanning the sequence of CPG2. Suggested mutations to 
remove the T-cell epitopes were proposed. 
 
In view of the limited availability of donor and patient blood investigations 
were made into whether transgenic mice may be suitable candidates for 
epitope mapping. Although Th lymphocytes from control immunized mice did 
not respond to MFECP1 in vitro, Th lymphocytes from 90% of MFECP1-
immunized mice did respond. The results indicate that MFECP1-immunized 
mice may provide an alternative source of Th lymphocytes for T-cell epitope 
mapping experiments. 
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Discussion 
 
6.1 Introduction 
The aim of ADEPT is to produce significant clinical efficacy with low toxicity 
and low immunogenicity. The results presented in this MD (Res) thesis 
provide new data that increases understanding of the safety of ADEPT, risk 
factors for adverse events, the immune response to ADEPT and efficacy. In 
the light of this new data two important questions can be discussed. What 
are the conditions required for successful ADEPT? Were these conditions 
achieved?  
 
6.2 The conditions required for successful ADEPT  
An ideal ADEPT system would: 
 
  Use a safe antibody-enzyme 
  Deliver sufficient enzyme to tumour 
  Deliver sufficient prodrug to tumour 
  Have very low toxicity (in particular antibody-enzyme would not be 
present in non-tumour tissue at time of prodrug administration) 
 Be  non-immunogenic 
  Be suitable for repeat treatment  
  Have high clinical efficacy 
 
  128Pre-clinical and clinical ADEPT trials have aimed to achieve these 
conditions. Pre-clinical investigations of ADEPT with MFECP1 and BIP 
prodrug have produced positive results (Sharma et al., 2005). A single 
ADEPT treatment caused significant tumour growth delay in LS174T and 
SW1222 xenografts. Furthermore efficacy was significantly increased when 
repeat treatments were given. In LS174T tumours there was prolonged 
growth delay and in SW1222 tumours there was complete regression of 
tumours. 
 
Were the conditions that were achieved in these pre-clinical investigations 
achieved in patients? How do the characteristics of ADEPT with MFECP1 
and BIP prodrug compare to an ideal ADEPT system? 
 
6.2.1 Safety of MFECP1 
The clinical results demonstrated that repeat administration of MFECP1 was 
well tolerated and prior administration of MFECP1 did not increase the risk of 
an infusion reaction. This compares favourably with streptokinase (a 
licensed non-human enzyme) in which 50% of non-1
st dose infusions were 
associated with allergic reactions (White et al., 1990). In total 66 MFECP1 
infusions were administered and all infusion reactions were mild (grade 1). It 
appears based on the current evidence that repeat administration of 
MFECP1 is safe. It is possible that more serious infusion reactions may have 
occurred if MFECP1 had been given to a larger number of patients. However 
since the rate of grade 3/4 infusion reactions is currently 0% (0/66) it is 
unlikely that such reactions are common. It should be noted that MFECP1 
was given under very specific safety conditions i.e. only administered to 
HACPA negative patients. MFECP1 has never been given to a HACPA 
positive patient and therefore we do not know the safety of MFECP1 in such 
circumstances. It is probable that administration of MFECP1 to a HACPA 
positive patient would increase the risk of an infusion reaction. For example 
a significantly increased risk of infusion reactions was reported when the 
  129chimeric mAb infliximab (used to treat inflammatory bowel disease) was 
given to patients with anti-infliximab antibodies (Miele et al., 2004). The 
administration of MFECP1 to HACPA positive patient is therefore not 
advised. 
 
6.2.2 Targeting and delivery of CPG2 activity to tumour 
In mice bearing LS174T xenografts co-localization of CPG2 with CEA in 
tumour tissue was demonstrated by immunohistochemistry (Sharma et al., 
2005). This co-localization was also demonstrated in tumour biopsies from 
single-treatment patients following MFECP1 infusion (Mayer et al., 2006). 
 
In mice the mean tumour CPG2 activity at time of prodrug administration (6 
hours after MFECP1) was 1.55U/g in LS174T xenografts and 1.29U/g in 
SW1222 xenografts. Was this level of tumour CPG2 activity achieved in 
patients at the time of prodrug administration? In the single-treatment 
ADEPT trial CPG2 activity within tumour was estimated by the administration 
of radiolabelled MFECP1 followed by single photon emission computed 
tomography (SPECT) imaging. In two patients, the SPECT scan was 
performed within 1 hour of prodrug administration; this is the best available 
data with which to assess tumour CPG2 activity at time of prodrug. At times 
within an hour of prodrug administration, estimated median tumour CPG2 
activities in patients (0.007U/g and 0.006U/g in patients 18 and 21 
respectively) were significantly less than the tumour CPG2 activities 
achieved in mice (1.55U/g and 1.29U/g in LS174T and SW1222 xenografts 
respectively). Details are shown in Table 6.1. 
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Table 6.1 
Tumour CPG2 activity at time of prodrug in mice and patients 
 
  Mice Mice  Patient 18
◊ Patient  21
◊ 
Tumour type 
LS174T*  SW1222* 
 
adenocarcinoma 
of colon 
adenocarcinoma 
of colon   
1000U/kg 1000U/kg  5000U/m
2 5000U/m
2  MFECP1 dose 
Time of 
prodrug** 
6, 7 and 8 
hours 
6, 7 and 8 
hours 
20.6, 21.6 and 
22.6 hours 
18.4, 19.4 and 
20.4 hours 
Serum CPG2 
activity at 
time of 
prodrug 
(U/ml) 
0.0011 
(SD=0.0004)
0.0038 
(SD=0.0005) 
<0.002 <0.002 
Tumour CPG2 
activity at 
time of 
prodrug (U/g) 
1.55
*** 
(SD = 0.20) 
1.29
***  0.07
‡  0.06
‡ 
(SD = 0.22)  (0.06 to 0.10)  (0.03 to 0.08) 
* human colonic adenocarcinoma xenograft, ** time after start of MFECP1, *** mean value, ‡ median 
and range of CPG2 activity values from >1 tumour in each patient, 
◊ in patients 18 and 21 time interval 
between prodrug and single photon emission computed tomography (SPECT) imaging was ≤ 1hour..  
CPG2 activity in mice measured on tumour tissue using high-performance liquid chromatography 
assay. CPG2 activity in patient tumour estimated using radiolabelled MFECP1 and SPECT. Patient 17 
received 123Iodine radiolabel; patient 18 received 131Iodine radiolabel. Mice data from Sharma et al, 
2005. Patient data from CRUK database. Both patient 18 and 21 received a single treatment of 
ADEPT. CPG2 = carboxypeptidase G2. SD = standard deviation. 
  131Mice CPG2 activity was measured on tumour tissue by an indirect high-
performance liquid chromatography assay (HPLC) whereas in patients 
CPG2 activity was estimated using a non-invasive technique i.e. SPECT. 
However tumour CPG2 activity results obtained by SPECT analysis have 
previously been shown to correlate well with direct measurement of CPG2 
activity in tumour tissue measured by HPLC (Napier et al., 2000). Hence the 
available evidence suggests that tumour CPG2 activity at time of prodrug 
administration was significantly less in patients compared to mice. 
 
Furthermore even at much earlier time points following MFECP1 
administration, the tumour CPG2 activity in patients was still significantly less 
than the values associated with efficacy in mice (Table 6.2). 
 
 
 
Table 6.2 
Estimated CPG2 activity in patient tumour 3 - 4 hours after start of 
MFECP1 infusion 
 
Patient 
MFECP1 
dose 
(U/m
2) 
Time interval from 
radiolabel to SPECT 
(hours) 
Estimated CPG2 activity 
in tumour (U/g). 
17 5000  3.2  0.13 
0.13* 
18 5000  4.4 
(0.11 - 0.15) 
Estimation of CPG2 activity was performed by single photon emission computed tomography 
analysis. Patient 17 received MFECP1 radiolabelled with 123Iodine and patient 18 received 
MFECP1 radiolabelled with 131Iodine. *Median value (and range) from 4 separate tumours 
assessed in patient 18. Data from CRUK database. 
  132Why was tumour CPG2 activity less in patients compared to mice? The 
answer does not appear to be due to differences in plasma half life since the 
alpha half life of MFECP1 (approximately 30 minutes) is very similar in mice 
and patients (Sharma et al., 2005; Mayer et al., 2006). It is possible that 
delivery of MFECP1 into tumour was greater in mice than patients. Since 
CPG2 localization following MFECP1 administration occurs in viable tumour 
(as opposed to necrotic tumour) it is possible that the difference observed 
was due to a greater proportion of viable tumour tissue in mice compared to 
patients.  
 
6.2.3 Prodrug and activated prodrug in tumour 
Activated prodrug is effective in vitro against proliferating LoVo colorectal 
tumour cells following a 1 hour (IC50 0.34μM ) or 1 minute incubation (IC50 
1.57μM ) (Blakey et al., 1996). Activated prodrug is also effective in vitro 
against quiescent LoVo cells (IC50 1.9μM after one hour incubation). 
Exposure of tumour cells to activated prodrug causes DNA interstrand 
crosslinks (Webley et al., 2001) and apoptosis (Monks et al., 2001). 
 
Ideally the concentration of BIP prodrug and activated prodrug would be 
measured in tumour and non-tumour tissue. In mice the half life of BIP 
prodrug following a TPD of 45mg/kg given intraperitoneally was 9 minutes 
(Astra Zeneca data, 1998). This is similar to the half life measured in patients 
after intravenous administration i.e. 14.5 minutes after a TPD of 47mg/m
2 
(Francis et al., 2002) and 10.3 minutes (mean value) after TPDs ranging 
from 37mg/m
2 to 3225mg/m
2 (Mayer et al., 2006). 
 
It is also desirable to know what quantity of activated prodrug was being 
produced in tumour and in non-tumour tissue. However due to the very short 
half life of activated prodrug it was not possible for this to be measured in 
clinical trials. However it was possible to measure the biological effects of 
activated prodrug i.e. DNA interstrand crosslinks.  
  133Single cell gel electrophoresis (comet) assay can be used to assess DNA 
interstrand crosslinks. The method is based on the observation that when a 
cell is irradiated (to provide a fixed quantity of random DNA strand 
breakage), the cell membrane lysed and the cell placed in an electric field, 
the smaller fragments of DNA produced by DNA strand breakage move 
towards the anode. These smaller DNA fragments form a structure that 
resembles the tail of a comet. DNA interstrand crosslinks can be detected 
because (in contrast to DNA strand breakage) they reduce the size of the tail 
moment. 
 
Comet assays have been used in pre-clinical and clinical ADEPT studies 
(Webley et al., 2001; Francis, 2002, Mayer, 2006). In pre-clinical studies 
tumour tissue from treated mice was compared with tumour tissue from 
untreated mice. In clinical studies comet assays were performed on 
circulating lymphocytes before and after prodrug and on tumour tissue which 
was biopsied after prodrug. Tumour biopsies taken from patients after 
prodrug were compared with pre-prodrug circulating lymphocytes, since no 
pre-prodrug biopsy was available as a control. The absence of a pre-prodrug 
tumour control means that some caution needs to be applied when 
interpreting comet assays performed on tumour from patients. 
 
What TPD was required to produce DNA interstrand crosslinks or clinical 
efficacy? The doses of BIP prodrug associated with pharmacodynamic effect 
on tumour in pre-clinical and clinical ADEPT studies are shown in Table 6.3. 
ADEPT using BIP prodrug has been investigated in nude mice bearing 
human xenografts (Blakey et al., 1996, Webley et al., 2001, Sharma et al., 
2005). In these pre-clinical investigations BIP prodrug was given 
intraperitoneally and the TPD was expressed in mg/kg. It is possible to 
calculate the human equivalent TPD (for details see 
www.fda.gov/cder/cancer/animalframe.htm). First the mouse mg/kg dose is 
converted into the mouse mg/m
2 dose by multiplying the mouse mg/kg dose 
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by 3. Second, doses in mg/m
2 are assumed to scale 1:1 between mice and 
humans when normalized to body surface area i.e. mouse mg/m
2 dose 
assumed to equal human mg/m
2 dose. The bioavailability of intraperitoneal 
BIP prodrug was assumed to be 100%. 
 
In pre-clinical investigations human equivalent TPDs of 630mg/m
2 and 
675mg/m
2 were associated with tumour regression and DNA interstrand 
crosslinks respectively. In clinical trials using MFECP1 a TPD of 806mg/m
2 
was associated with DNA interstrand crosslinks and a TPD ≥ 900mg/m
2 
produced efficacy on FDG-PET. 
 
It has been reported that a TPD of 37mg/m
2 produced DNA interstrand 
crosslinks in tumour tissue in a clinical trial with a F(ab’)2 - CPG2 chemical 
conjugate and BIP prodrug (Francis et al., 2002). This TPD is significantly 
less than the other pre-clinical and clinical results. This low result does not 
appear to be secondary to a high tumour CPG2 activity because a tumour 
biopsy on day of prodrug in the same patient showed a CPG2 activity of 
0.010U/g (PhD thesis of Francis RJ, 2005, UCL). The DNA interstrand 
crosslinks may have been secondary to extensive prodrug activation in non-
tumour since the serum CPG2 activity at time of prodrug was 0.025U/ml. 
This was approximately 10 times higher than the serum CPG2 at time of 
prodrug in the clinical trials using MFECP1. 
 
Hence it appears that in the phase I trials of ADEPT with BIP prodrug and 
MFECP1, effective prodrug dose conditions were achieved in patients 
provided that the TPD was 806mg/m
2  (to produce DNA interstrand 
crosslinks) or ≥ 900mg/m
2 (to produce efficacy on FDG-PET). 
 
 Table 6.3 
Doses of BIP prodrug associated with pharmacodynamic effect on tumour in pre-clinical and clinical ADEPT studies 
Study 
setting  Data Source  TPD  Route 
Human 
equivalent 
TPD* 
(mg/m
2) 
Number of 
treatments 
Antibody-
enzyme  Tumour 
Pharmacodynamic 
effect 
on tumour 
Blakey et al., 
1996  210mg/kg ip 630mg/m
2 Single 
F(ab’)2 
conjugated 
to CPG2 
LoVo xenograft  Tumour regression 
Webley et al., 
2001  225mg/kg ip 675mg/m
2 Single  “”  LS174T  xenograft  Tumour DNA 
interstrand crosslinks 
Pre-
clinical 
mice 
studies 
 
Sharma et 
al., 2005  210mg/kg ip 630mg/m
2  Repeat   MFECP1  SW1222 xenograft  Tumour regression 
Francis et al., 
2002  37mg/m
2  iv 37mg/m
2 Single 
F(ab’)2 
conjugated 
to CPG2 
Carcinoma colon**  Tumour DNA 
interstrand crosslinks 
Mayer et al., 
2006 
806mg/m
2 
(patient 26) 
iv 806mg/m
2 Single  MFECP1  Carcinoma  colon  Tumour DNA 
interstrand crosslinks 
Clinical 
 
Wilkins 2010 
MD(Res) 
thesis 
≥ 900mg/m
2 iv 
carcinoma colon 
(#35, #38), pancreas 
(# 32), peritoneal 
(#24). 
Responses on  Single and 
repeat  ≥ 900mg/m
2  MFECP1 
FDG-PET  
* Conversion from mg/kg to mg/m
2 in mice by multiplying mg/kg x3. Doses assumed to scale 1:1 between mice and humans when normalized to 
body surface area (www.fda.gov/cder/cancer/animalframe.htm). BIP prodrug assumed to have 100% bioavailability when given ip. ** Data from 
PhD thesis of Francis RJ, 2005, UCL. TPD = total prodrug dose, ip = intraperitoneal, iv = intravenous, CPG2 = carboxypeptidase G2.  
  1366.2.4 Toxicity 
Myelosuppression was the principal toxicity of repeat ADEPT treatments and 
was the cause of all DLTs. It is not possible to attribute the frequency or 
severity of ADEPT induced thrombocytopaenia to poor patient 
characteristics e.g. low performance status or prior chemotherapy. For 
example the patient with the most severe thrombocytopaenia after 2 ADEPT 
treatments given at the maximum tolerated TPD (patient 33, platelet nadir 
33x10
9/l) had a good overall health status (WHO performance status of 1) 
and had only received one previous line of chemotherapy. 
 
In principle the myelosuppression could have been caused by any of the 3 
drugs administered or generated during ADEPT i.e. MFECP1, BIP prodrug 
or activated prodrug 
 
MFECP1 is a recombinant fusion protein of a scFv plus CPG2 and is unlikely 
to have caused myelosuppression. In contrast there is evidence that the 
severity of myelosuppression was positively associated with TPD. However 
this data does not clarify whether it is BIP prodrug or activated prodrug that 
caused the myelosuppression (or possibly a combination of the two). 
 
The only data on the effects of BIP prodrug given alone come from an earlier 
ADEPT trial (Francis et al., 2002; PhD thesis of Francis RJ, 2005, UCL). 
Three patients received BIP prodrug alone at TPDs of 15mg/m
2, 47mg/m
2 
and
  56mg/m
2. One patient (15mg/m
2) had grade 1 nausea, one patient 
(47mg/m
2) had grade 1 leucopaenia plus grade 1 neutropaenia and one 
patient (56mg/m
2) had no drug-related toxicities. In the current trial the TPD 
per treatment was significantly higher (150mg/m
2 to 600mg/m
2) and the TPD 
over all treatments ranged from 300mg/m
2 to 1800mg/m
2. Hence it is 
possible that BIP prodrug caused some myelosuppression. 
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activated prodrug. Two lines of evidence support this hypothesis. Firstly 
activated prodrug is an alkylating agent, a class of drugs well known to 
cause myelosuppression. Secondly at a fixed dose of MFECP1 and BIP 
prodrug, administration of prodrug at a higher serum CPG2 activity was 
associated with greater myelosuppression (Table 3.10). The most likely 
explanation for these findings is that when prodrug was given at higher 
serum CPG2 activity, greater amounts of activated prodrug was generated 
and this caused increased myelosuppression. 
 
However if activated prodrug was the principal cause of myelosuppression 
and if it is assumed that activated prodrug would need to be present in the 
bone marrow to cause myelosuppression, how does activated prodrug come 
to be in the bone marrow? One possibility is that some activated prodrug 
was generated in bone marrow due to the presence of MFECP1 in the bone 
marrow at the time of prodrug administration. Although pre-clinical testing of 
the glycosylated fusion protein did measure CPG2 activity in plasma, liver, 
kidney, lung and spleen, CPG2 activity was not measured in bone marrow. 
CPG2 activity in bone marrow was also not measured in the single or repeat-
treatment ADEPT trials. Hence it is not known whether activation of BIP 
prodrug within bone marrow is clinically significant. 
 
An alternative cause of myelosuppression is the possibility that BIP prodrug 
is activated away from the bone marrow but then travels to it in the systemic 
circulation. This mechanism would require the activated prodrug to be stable 
long enough to travel from the site of generation to the bone marrow. The 
exact half life of the activated prodrug is not known although it is considered 
to be very short. During development of BIP prodrug 16 novel potential 
prodrugs (and their corresponding activated prodrugs) were assessed 
(Springer et al., 1995). The shortest measured half-life of any of the 
activated prodrugs was 0.6 minutes (36 seconds). Several activated 
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rates that were too fast to measure accurately. Hence the half-life of the 
activated cytotoxic drug generated during the current ADEPT trial is 
considered < 36 seconds. Therefore although the half life of activated 
prodrug is short it may be long enough to allow some drug to reach the bone 
marrow. 
 
Hence activated cytotoxic drug probably travels to the bone marrow after 
being produced in tumour and in non-tumour tissue e.g. plasma. Although 
CPG2 activity (U/g) is relatively low in non-tumour tissue the total mass of 
non-tumour tissue is high. There is clinical evidence to support the 
hypothesis that generation of activated prodrug in non-tumour tissues is a 
significant cause of myelosuppression. For example administration of 
prodrug when serum CPG2 activity > 0.005U/ml was associated with 
increased severity of myelosuppression. The increased myelosuppression 
was probably caused by increased production of activated prodrug in the 
plasma. 
 
It is also possible that CPG2 activity in viscera (non-tumour tissue other than 
plasma) was a significant cause of myelosuppression. In mice CPG2 activity 
was detected in liver, lung, kidneys and spleen following administration of 
MFECP1 (Sharma et al., 2005). Furthermore at 6 hours, when MFECP1 had 
cleared from plasma (CPG2 activity 0.001U/ml), enzyme activity in lung was 
4 times higher (0.004U/g). 
 
CPG2 activity in viscera may be a significant cause of myelosuppression in 
patients. When the time interval between MFECP1 and prodrug was reduced 
(as a result of a lower MFECP1 dose) myelosuppression increased even 
though prodrug was administered when serum CPG2 activity < 0.002U/ml 
(Table 3.11). The most likely explanation for this is that at earlier time points 
there was increased total CPG2 activity in organs e.g. liver, lung. 
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clinically significant. The first was the possibility that some BIP prodrug was 
activated in the lumen of the central venous catheter (used to obtain large-
bore venous access in patients). All patients had a central venous catheter 
inserted since BIP prodrug can cause venous irritation. The central venous 
catheter was used to administer the MFECP1 and the BIP prodrug. The line 
was thoroughly flushed with normal saline at the end of the MFECP1 
infusion. Furthermore the BIP prodrug was typically given around 14 hours 
after the end of the MFECP1 infusion. However if some MFECP1 adhered to 
the plastic lumen of the central venous catheter and retained enzymatic 
activity, it is possible that some activated prodrug could have been 
generated in the lumen of the central venous catheter when BIP prodrug was 
administered. 
 
The second possibility was that some BIP prodrug was activated by CPG2 in 
Pseudomonas bacteria which are occasionally present in gut flora. For this 
to occur there would need to be: i) movement of BIP prodrug into the lumen 
of the colon ii) activation of BIP prodrug by CPG2 iii) movement of activated 
prodrug across the colonic epithelium and into the portal circulation iv) 
movement of activated prodrug from the portal circulation to the bone 
marrow. Two pieces of evidence make this hypothesis unlikely. Firstly the 
half life of the activated prodrug is < 36 seconds and therefore there is 
unlikely to be time for activated prodrug to travel from the lumen of the colon 
to the bone marrow. Secondly the toxicity profile of ADEPT does not support 
the hypothesis. Contact between activated prodrug and the wall of the colon 
would potentially cause diarrhoea. However diarrhoea only occurred in 2 of 
the 43 ADEPT (grade 1 in patient 35 and grade 2 in patient 30). 
 
The combined data from all 43 patients has identified clinical factors that 
modify the risk of myelosuppression (Table 6.4).  
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Table 6.4 
Clinical factors and myelosuppression 
 
 
Myelosuppression is positively associated with: 
● Total prodrug dose 
● Serum CPG2 activity at time of prodrug administration 
● Number of ADEPT treatments 
 
Myelosuppression can be negatively associated with: 
● Time interval between MFECP1 and prodrug 
 
 
 
The combined analysis of all patients identified that grade 4 hepatic toxicity 
only occurred in patients who received a TPD per treatment ≥ 1613mg/m
2. 
This toxicity is probably caused by a high peak concentration of BIP prodrug.  
 
One patient was diagnosed with AML 8 months after commencing ADEPT 
treatment. This event could be i) an unrelated chance event ii) caused by the 
patient having an independent risk factor (genetic or environmental) that 
increased the risk of both cancers iii) caused by treatment (or investigational 
procedures) undertaken during the management of the first cancer. 
 
There is clear evidence that some chemotherapy regimes increase the risk 
of AML (Kirova et al., 2008; Schaapveld et al., 2008). However since many 
chemotherapy regimes contain more than one drug (and patients may 
receive several different chemotherapy regimes) it can be difficult to know 
the carcinogenic potential of individual drugs. 
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chemotherapy before being diagnosed with AML: i) ECX (epirubicin, 
cisplatin, capecitabine) ii) ADEPT iii) gemcitabine with carboplatin. 
 
An increased risk of AML has also been reported with epirubicin and 
cisplatin (Pedersen-Bjergaard et al., 1992) and carboplatin (Travis et al., 
1999). Gemcitabine and capecitabine are not known to increase the risk of 
AML. 
 
The activated form of BIP prodrug is an alkylating agent, a class of drugs 
known to increase the risk of AML (Curtis et al., 1992). It is possible that 
activated prodrug produced during ADEPT was associated with the 
subsequent development of AML. In total 70 patients have received ADEPT 
using BIP prodrug; 27 in the trial by Francis and coworkers (Francis et al., 
2002), 31 in the trial by Mayer and colleagues (Mayer et al., 2006) and 12 in 
the current trial of repeat ADEPT treatments. The patient reported here is the 
only one of these patients to have been reported to have developed acute 
leukaemia. 
 
6.2.5 Immunogenicity 
Following repeat MFECP1 infusions 100% of patients developed HACPA 
whereas only 40% of patients who received a single MFECP1 infusion 
developed HACPA. The significant increase in ADA formation with multiple 
MFECP1 infusions compared to a single infusion (Log-rank p = 0.001) is 
consistent with pre-clinical ADEPT data and data from other therapeutic 
proteins.  
 
In pre-clinical experiments 8 Balb/c mice were immunized repeatedly with 
MFECP-his (Mayer et al., 2004). None of the mice produced anti-CPG2 after 
1 immunization (day 15) whereas 4 of the 8 mice produced anti-CPG2 after 
4 immunizations (day 57). 
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dose of IFN-α was given once, twice or three times per week, an increased 
frequency of administration was associated with higher titres of ADA i.e. 
frequency of administration increased ADA production independent of the 
total dose (Braun et al., 1997). Furthermore patients with multiple sclerosis 
who received IFNβ-1a three times per week were significantly more likely to 
develop ADAs compared to patients who were treated once per week (Ross 
et al., 2000).  
 
A significant positive relationship was also found between total MFECP1 
dose and HACPA formation. This result is probably because patients that 
received a higher total MFECP1 dose did so by receiving multiple MFECP1 
infusions.  
 
Since activation of T-lymphocytes is likely to be involved in the 
immunological response to MFECP1, the in vitro response of T- lymphocytes 
to MFECP1 and CPG2 was investigated. PBMCs from 83% of healthy 
volunteers proliferated in response to MFECP1. The most likely cause of a 
T-lymphocyte response after 5 days of incubation is a memory response i.e. 
the healthy volunteers had previously been exposed to T-cell epitopes on 
MFECP1. 
 
To investigate whether in vitro stimulation could occur after a much shorter 
incubation PBMCs from 3 healthy volunteers were incubated with MFECP1 
for 13 hours. Th lymphocyte stimulation was assessed using an IFN- 
secretion assay. This experiment demonstrated that Th lymphocytes were 
stimulated by MFECP1 after only 13 hours of incubation. The result is 
consistent with the response to MFECP1 being a secondary immune 
response rather than a primary immune response. This suggests that the 
healthy volunteers had been previously exposed to T-cell epitopes on CPG2. 
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bacteria. 
 
The in vitro response of PBMCs from a treated ADEPT patient to incubation 
with MFECP1 was investigated. After 5 days of incubation MFECP1 induced 
significant stimulation (SI = 2.5). The magnitude of proliferation was similar 
to the results from healthy volunteers (median SI = 3.0, range 1.6 to 3.9). 
The blood sample from the treated ADEPT patient was taken on day 80. It is 
possible that proliferation would have been greater if the blood had been 
taken nearer to ADEPT treatment. Evidence to support this comes from 
similar experiments conducted on the non-human therapeutic protein 
streptokinase. Squire and colleagues demonstrated that compared to pre-
streptokinase blood samples, lymphocytes taken 6 days after treatment 
showed a statistically significant elevation in stimulation indices (Squire et 
al., 1999). However by 6 weeks the stimulation indices had returned to 
baseline values.  
 
The activation of Th lymphocytes implies that certain sequences within 
MFECP1 were behaving as T-cell epitopes. Since CPG2 is bacterial in origin 
it was considered that the amino acid sequence of CPG2 was probably the 
most immunogenic portion of MFECP1. The aim of the next experiment was 
therefore to find possible T-cell epitopes within CPG2. In collaboration with 
Biovation overlapping 15 mer peptides spanning the sequence of CPG2 
were incubated with PBMCs (containing Th lymphocytes and antigen 
presenting cells) from healthy volunteers. This in vitro data was used to 
identify 8 possible T-cell epitopes.  
 
Since blood from healthy volunteers, and particularly patients, was a very 
limited resource it was considered desirable to have a non-human model to 
investigate the immune response to MFECP1. Mice transgenic for human 
MHC provide a possible alternative source of pre-clinical data. First the in 
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DRB1*0101 to MFECP1 were investigated. Half of the mice were pre-
immunized with MFECP1 plus adjuvant, the other half were immunized with 
PBS plus adjuvant. Th lymphocytes activation was measured in T-cell 
proliferation assays. Nine of the 10 mice that had been pre-immunized with 
MFECP1 responded in vitro to MFECP1 whereas none of the mice pre-
immunized with control responded in vitro to MFECP1. Since mice that were 
not immunized with MFECP1 did not respond in vitro to MFECP1, it appears 
that the mice had not been in contact with epitopes on MFECP1 during the 
course of their lives. However by pre-immunizing the mice with MFECP1 the 
mice produced Th lymphocytes that respond to MFECP1 in vitro. It may be 
possible therefore for pre-immunized DRB1*0101 transgenic mice to be 
used in epitope mapping experiments on CPG2. 
 
The results demonstrate that MFECP1 is immunogenic although infusions 
reactions to date have been mild. Production of HACPA limits the treatment 
window for MFECP1 to approximately 2 weeks. Strategies to reduce HACPA 
formation are discussed in section 6.3.1. 
 
6.2.6 Delivery of repeat ADEPT treatments 
In the pre-clinical investigation of repeat ADEPT (with MFECP1 and BIP 
prodrug) mice with LS174T xenografts received treatment 5 times in week 1 
and then twice per week in weeks 2 and 3. Mice bearing SW1222 xenografts 
were given a different regime; 4 times in week 1 and then twice per week in 
weeks 2, 3 and 4.  
 
In the repeat treatment phase I/II trial the first cohort of patients received 2 
treatments. The protocol permitted the number of treatments to be 
progressively increased so that in theory 8 treatments could have been 
scheduled over an 11 day period. This would have achieved a schedule 
similar to that performed in pre-clinical experiments. However in the phase 
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increased above 3 due to myelosuppression. Repeat ADEPT was 
significantly more toxic in patients than in mice. Hence the repeat treatment 
ADEPT phase I/II trial was unable to achieve the number and frequency of 
treatments performed in pre-clinical investigations. 
 
6.2.7 Evidence of efficacy 
In patients with metastatic cancer new treatments aim to improve patient 
survival. Consequently survival is the ideal end-point in a phase III trial. In 
contrast the primary objectives of a phase I trial are to investigate safety, 
pharmacokinetics and relevant pharmacodynamic end-points. As part of 
pharmacodynamic evaluation it is desirable to obtain information on whether 
there is any effect on key aspects of tumour behaviour e.g. survival and 
growth. This information may be useful when choosing which drugs should 
be taken into phase II trials. Furthermore responses may allow preliminary 
assessment of which tumour types are most sensitive. This information 
would be helpful when deciding which tumour types to treat in a phase II 
trial. 
 
The most frequently used technique to assess tumour response is to 
measure the size of the tumour before and after treatment. The method is 
relatively simple and results can be presented in a standardized format using 
RECIST criteria. A revised edition of RECIST (version 1.1) has recently been 
produced (Eisenhauer et al., 2009). 
 
However the use of tumour size to measure efficacy has weaknesses. For 
example some effective drugs may be cytostatic rather than cytotoxic and 
hence deliver significant clinical benefit without reducing the size of the 
tumour. This principle is demonstrated by a phase III randomized trial that 
compared sorafenib (an oral multi-kinase inhibitor) with placebo in patients 
with advanced previously untreated hepatocellular carcinoma (Llovet et al., 
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survival even though sorafenib only produced tumour shrinkage in 2% of 
patients (objective response by RECIST). However in a clinical trial 
investigating a cytotoxic drug e.g. ADEPT, measurement of tumour size 
appears appropriate since an effective cytotoxic drug would be expected to 
cause tumour shrinkage.  
 
Changes in tumour metabolism following treatment can also provide 
clinically relevant information on efficacy. FDG-PET is the most frequently 
used technique to measure changes in tumour metabolism. For example in 
patients with gastrointestinal stromal tumours treated with imatinib, 
reductions in tumour metabolism on FDG-PET after 8 days of treatment 
were associated with a significantly increased progression free survival 
(Stroobants et al., 2003). FDG-PET has also been useful in measuring the 
response of gastrointestinal carcinomas to cytotoxic chemotherapy (Ott et 
al., 2006). A draft framework for PET Response Criteria in Solid Tumours 
(PERCIST) has recently been proposed (Wahl et al., 2009). 
 
In the single-treatment and repeat-treatment ADEPT trials efficacy was 
measured using CT and FDG-PET. Response on FDG-PET was measured 
using a semi-automatic technique to quantify total activity within a tumour 
volume of interest. Tumour response defined according to this technique has 
been positively associated with prolonged survival in patients receiving 
cytotoxic chemotherapy for solid tumours (Green et al., 2008; Francis et al., 
2007). 
 
Four of the 22 ADEPT patients who underwent FDG-PET had significant 
reductions in tumour activity on functional imaging. Three observations 
suggest that the changes measured by FDG-PET reflected significant 
biological change in the tumours. Firstly the 4 patients that responded on 
FDG-PET include the 2 patients that had small reductions on CT (10% and 
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also include the 3 patients with the largest falls in serum CA19-9. Thirdly 
there was a significant correlation between percentage change of tumour 
activity on FDG-PET and TPD.  
 
6.3 Challenges to ADEPT  
It is apparent from an examination of the current ADEPT system that only 
some of the conditions required for successful ADEPT are being achieved. 
Positive features have been the development of a safe antibody-enzyme 
(MFECP1), adequate delivery of BIP prodrug to tumour and some evidence 
of clinical efficacy. However three important characteristics need to be 
improved: 
 
1) Antibody-enzyme  immunogenicity 
 
2) Myelosuppression 
 
3)  Tumour CPG2 activity at time of prodrug 
 
 
Since the 2
nd and 3
rd points are intimately entwined they are discussed 
together in section 6.3.2. 
 
6.3.1 Reduction of antibody-enzyme immunogenicity 
In patients who received repeat ADEPT treatments HACPA developed at a 
median of day 16 and the earliest time that any patient became HACPA 
positive was day 15. Hence the time period in which ADEPT can safely be 
given is approximately 2 weeks. During this time it would be possible in 
theory to give 8 treatments. In practice however the number of treatments 
was limited by myelosuppression not immunogenicity. 
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in a patient that received 2 ADEPT treatments with a TPD of 1200mg/m
2, the 
final MFECP1 infusion would be given on day 3, i.e. before HACPA 
develops. 
 
However taking a broad perspective, immunogenicity remains an important 
independent challenge to clinical ADEPT development. Future developments 
to reduce myelosuppression may re-expose immunogenicity as the rate-
limiting factor in the delivery of repeat treatments. 
 
There are a number of potential strategies to reduce immunogenicity in 
ADEPT. One option is to pre-treat patients with an immunosuppressant drug. 
Administration of ciclosporin (an inhibitor of activated Th lymphocytes) to 
ADEPT patients delayed HACPA production but increased adverse events 
(Bagshawe and Sharma, 1996). Corticosteroids may provide an alternative 
less toxic means of transient immunosupression. In a randomized double-
blind, placebo controlled trial of patients with Crohn’s disease who were 
receiving the chimeric monoclonal antibody infliximab, pre-treatment with 
intravenous hydrocortisone significantly reduced ADA titres at 8 and 16 
weeks (Farrell et al., 2003). However the percentage of patients who were 
considered ADA positive was not significantly reduced. 
 
In a randomized trial of patients receiving intravenous radiographic contrast 
medium, pre-treatment with oral corticosteroid 12 hours and 2 hours before 
the administration of contrast, significantly reduced the incidence of allergic 
reactions (Lasser et al., 1987). The effectiveness and safety of corticosteroid 
pre-treatment in ADEPT has not been investigated. 
 
Identification and removal of T-cell epitopes on a bacterial enzyme is 
technically challenging but remains the most elegant solution. One group 
has achieved limited success with efforts to eliminate Th lymphocyte 
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combination of in silico techniques and in vitro assays to identify an 
immunodominant T-cell epitope on staphylokinase (Warmerdam et al., 
2002). PBMCs from 10 healthy volunteers (covering 95% of HLA-DR 
haplotypes in European and North American populations) were used to 
generate T-cell clones specific for staphylokinase. Incubation with individual 
17 mer peptides (overlapping by 12 amino acids) revealed a peptide (C3) 
that stimulated T-cell clones derived from 9 of the 10 donors. The 
promiscuous binding of this peptide with multiple HLA types suggested that 
this peptide contained an immunodominant epitope. To identify precisely the 
epitope(s) within C3, the binding of 11 mer peptides (derived from C3) to 
HLA-DR1 was analysed in silico. This identified two overlapping 11 mer 
peptides within the C3 region that bound strongly to HLA-DR1. The effect of 
single alanine substitutions at each amino acid location on these 2 peptides 
was assessed by measuring proliferation of T cell clones in response to the 
variant peptides and by in-silico calculation of binding to HLA. This 
information was used to produce 3 variant staphylokinase proteins 
containing 2, 3 or 4 amino acid substitutions which retained biological 
activity. Although the immunogenicity of the C3 region was eliminated, 
proliferation assays on one of the staphylokinase variants demonstrated that 
the intact protein continued to stimulate T-cells primed with the 
staphylokinase variant. There was no evidence for the creation of a new 
epitope in the C3 region and therefore the persistent immunogenicity is 
almost certainly caused by other epitopes outside the C3 region. 
 
Interestingly Harding and colleagues have identified four CD4 positive T-cell 
epitopes on the bacterial enzyme β-lactamase, an enzyme that can be used 
in ADEPT systems (Harding et al., 2005). They used 117 15-mer peptides 
(overlapping by 12 amino acids) that spanned the entire sequence of β-
lactamase. Individual peptides were incubated with PBMCs from 65 
community donors in T-cell proliferation assays. The 4 peptides that caused 
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T-cell epitopes. For each of the 4 peptides variants with a single alanine 
replacement at each amino acid location were produced. Each of these 
variant peptides was incubated with PBMCs from 66 community donors. By 
selection of the peptides that produced the least in vitro response, four 
alanine substitutions were chosen for each epitope. Complete enzyme 
mutants were produced incorporating these mutations and 2 mutant epitopes 
were identified that did not significantly interfere with enzyme function or 
stability. Both of these modified epitopes were incorporated into a novel B-
lactamase. The novel B-lactamase was expressed at high levels and 
retained enzyme function. Novel B-lactamase produced significantly less 
stimulation than wild-type B-lactamase when incubated with PBMCs from 30 
community donors. This is the first report of successful identification and 
removal of T-cell epitopes from a bacterial enzyme used in ADEPT systems. 
This novel B-lactamase can be incorporated into a fusion protein but has not 
been used in an ADEPT clinical trial. 
 
6.3.2 Reducing myelosuppression and increasing CPG2 activity in 
tumour  
A successful ADEPT system requires that at the time of prodrug 
administration tumour CPG2 is high and non-tumour CPG2 activity is low / 
absent. Failure to achieve the former would be expected to reduce efficacy; 
failure of the latter would be expected to increase myelosuppression. 
 
There is evidence that the current ADEPT system may be failing in both of 
these requirements.  
 
In pre-clinical ADEPT studies MFECP1 achieved the required design 
characteristics. Tumour CPG2 activity at time of prodrug (1.29U/g in 
SW1222 xenografts) was sufficient to produce significant tumour regression 
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ADEPT therapy caused less than 2% weight loss in mice. 
 
However in patients, when MFECP1 had cleared from the circulation (serum 
CPG2 activity <0.002U/ml) tumour CPG2 activity was 0.006U/ml to 
0.007U/ml i.e. significantly less than in mice. It is possible that the rapid 
clearance of MFECP1 from the systemic circulation may be an explanation 
for the apparent sub-optimal retention of MFECP1 on tumour. MFECP1 was 
designed to clear rapidly from the circulation so that a clearing antibody 
would not be required. Rapid clearance of MFECP1 was achieved by post-
translational mannose glycosylation (a consequence of production in 
P.pastoris). MFECP1 binds to mannose receptors on liver sinusoidal 
endothelial cells and is taken into the cells (Kogelberg et al., 2007).  
 
Clinical data also suggests that CPG2 on non-tumour may be a significant 
cause of myelosuppression. In summary, at the time of prodrug 
administration the available evidence suggests that tumour CPG2 activity in 
patients was probably too low and total non-tumour CPG2 activity was too 
high.  
 
It is important at this point to comment on the concept of tumour to non-
tumour ratios. This concept is often included in ADEPT publications e.g. ratio 
of CPG2 activity in tumour compared to plasma. Despite its frequent use this 
concept could be misleading and should probably be avoided. It is likely that 
absolute values are more important than ratios. For example a CPG2 activity 
ratio of 500:1 (tumour versus plasma) may appear desirable but if the 
absolute value of plasma CPG2 activity is too high then there will probably 
be unacceptable myelosuppression. Similarly a CPG2 activity ratio of 500:1 
may not produce efficacy if the absolute CPG2 activity in tumour is 
inadequate. 
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CPG2 distribution at the time of prodrug administration? The effect of 
MFECP1 dose on tumour CPG2 was examined in pre-clinical investigations 
in mice bearing LS174T xenografts. When the MFECP1 dose was increased 
from 600U/kg to 1200U/kg tumour CPG2 activity at 6 hours increased from 
0.31U/g to 1.6U/g (Sharma et al., 2005). Similarly plasma CPG2 activity at 6 
hours increased from 0.0009U/ml to 0.0017U/ml. At this dose schedule 
tumour CPG2 activity increased approximately 5 times while serum CPG2 
increased 2 times (and remained < 0.002U/ml). 
 
The effect of MFECP1 dose on tumour CPG2 activity in patients is unknown. 
Six single-treatment ADEPT patients had quantification of tumour CPG2 by 
SPECT analysis (1 received MFECP1 3000U/m
2 and 5 received MFECP1 
5000U/m
2). Although the scans were taken at different times, making 
comparison difficult, no obvious effect on tumour CPG2 was seen (Table 
6.5).  
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Table 6.5 
Estimated tumour CPG2 activity and MFECP1 dose 
 
Patient 
MFECP1 dose 
(U/m
2) 
Time of scan 
after radiolabel 
(hours) 
Median estimated 
CPG2 activity on 
SPECT (range) 
17 5000 3.2 0.13* 
18  5000  4.4  0.13 (0.11 – 0.15) 
26  3000  11.1  0.07 (0.05 – 0.007)
21  5000  17.4  0.06 (0.03 – 0.08) 
19  5000  19.6  0.04 (0.03 – 0.06) 
20  5000  20.6  0.12 (0.12 – 0.16) 
18  5000  21.3  0.07 (0.06 – 0.10) 
* single tumour assessed. Tumour CPG2 activity estimated using radiolabelled MFECP1 and single 
photon emission computed tomography. Patient 17 received 123Iodine radiolabel; patient 18, 19, 20, 
21, 26 received 131Iodine radiolabel. Data from CRUK database.  
 
 
It is possible that a MFECP1 dose significantly > 5000U/m
2 may increase 
tumour CPG2. However such a dose may also increase plasma CPG2 
activity and could therefore increase myelosuppression 
 
Similarly there may also be no simple method to reduce total non-tumour 
CPG2 activity without compromising other ADEPT characteristics. For 
example increasing the time interval from the end of the MFECP1 infusion to 
the administration of prodrug would be expected to reduce total non-tumour 
  154CPG2 activity. However it would also be expected to reduce tumour CPG2 
activity.  
 
Hence there is unlikely to be a new dose/schedule of MFECP1 that would 
significantly increase tumour CPG2 activity and significantly reduce total 
non-tumour CPG2 activity.  
 
Should repeat ADEPT with MFECP1 and BIP prodrug be recommended to 
enter phase II trials? This decision requires a balanced view of the current 
evidence, weighing the positive and negative aspects. The most positive 
finding was a response on FDG-PET in 1 of the 3 patients that received 2 
ADEPT treatments at the maximum tolerated TPD. 
 
However there were also a number of significant negative considerations: 
 
1)  FDG-PET responses were short-lived. 
 
2)  None of the 13 patients who received a TPD ≥ 900mg/m
2 had a PR 
on CT imaging by RECIST criteria. 
 
3) At the only schedule in which the maximum tolerated TPD was ≥ 
900mg/m
2 (2 ADEPT treatments with a TPD of 1200mg/m
2) 66% of 
patients developed grade 3 thrombocytopaenia. This frequency of 
grade 3 thrombocytopaenia appeared higher than in conventional out-
patient cytotoxic drug regimes. For example FOLFOX 6 (oxaliplatin, 
fluorouracil, folinic acid) produced G3/4 thrombocytopaenia in 1% of 
patients when used as 2
nd line treatment of metastatic colorectal 
cancer (Tournigand et al., 2004). 
 
4)  Tumour CPG2 activity associated with efficacy in mice may not have 
been achieved in patients. 
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5) Due to instability of reconstituted BIP prodrug the time interval from 
the start of reconstitution to expiry of the reconstituted BIP prodrug 
product was 20 minutes. Reconstitution and labeling required 
approximately 5 minutes and drug administration to the patient was 
over 5 minutes. Hence there was a maximum of 10 minutes to 
transport the reconstituted BIP prodrug from pharmacy to the patient. 
This would be logistically difficult in routine medical practice. 
 
 
After consideration of all available evidence concerning ADEPT with 
MFECP1 and BIP, the most appropriate conclusion was that the current 
system should not be recommended to enter a phase II clinical trial. 
 
6.4 ADEPT in perspective 
Currently the most frequently adopted strategy in oncology drug 
development is to attempt to disrupt signaling pathways using small 
molecule enzyme inhibitors or mAbs. These non-cytotoxic drugs have added 
to the previous gains made by cytotoxic drugs (e.g. trastuzumab in breast 
cancer) and transformed the management of some tumours in which 
cytotoxic drugs were ineffective (e.g. sunitinib in renal cell carcinoma). 
However in many tumour types cytotoxic drugs are likely to remain an 
important part of systemic drug therapy. Therefore efforts to optimize 
cytotoxic delivery remain very relevant. In this context ADEPT can be seen 
as an incorporation of recombinant technology into a cytotoxic-based 
strategy. Despite the difficulties associated with the current ADEPT system 
(MFECP1 and BIP prodrug) ADEPT as a generic system continues to offer 
appealing characteristics and pre-clinical development of ADEPT is likely to 
continue. 
 
  156The challenges faced in ADEPT and the techniques used to address them 
are issues that affect many areas of drug development in oncology. For 
example the issues of immunogenicity and mechanistic trial design are 
relevant to the development of many new compounds. 
 
For example immunogenicity is potentially important in the development of 
any new protein therapeutic. Both wholly/partially foreign proteins and 
therapeutic proteins that are designed to replace an absent or deficient 
endogenous protein can be significantly affected by immunogenicity. The 
immunological reactions to these two types of therapeutic proteins however 
can be quite different. In the case of non-human proteins/sequences the 
consequences of ADA formation are primarily hypersensitivity, altered 
clearance and neutralization of the therapeutic protein. In contrast 
administration of recombinant endogenous proteins e.g. erythropoietin, can 
lead to breaking of tolerance and ADAs that neutralize both the therapeutic 
protein and any endogenous protein. This situation is rare but can have very 
serious clinical effects (Casadevall et al., 2002). Hence the consequences of 
ADA formation can vary widely in clinical type and severity. Consequently a 
risk-based approach to the evaluation of immunogenicity in clinical trials has 
been proposed (Shankar et al., 2007). For example the administration of a 
human recombinant protein to replace an endogenous protein with a unique 
and essential function, is regarded as higher risk because of the possibility of 
ADAs leading to neutralization of the endogenous counterpart. In contrast 
the administration of a non-human protein (e.g. CPG2) that is not designed 
to interfere with human protein function is regarded as lower risk. It should 
be noted however that anaphylaxis can occur even with lower risk 
therapeutic proteins. 
 
Just as immunogenicity is a widespread issue in oncological drug 
development, so too are the changes in phase I trial design that have taken 
place since the first ADEPT clinical trial. The adoption of a mechanistic trial 
  157design in ADEPT phase I trials (i.e. the use of biomarkers) mirrors 
widespread changes in the design of phase I trials in oncology. Recent 
ADEPT phase I trials have incorporated multiple biomarkers including 
biomarkers of MFECP1 delivery (e.g. SPECT), biological effect biomarkers 
(e.g. tumour COMET assays) and efficacy biomarkers (e.g. FDG-PET). 
Biomarker data is essential to understand a complex drug system. 
Furthermore biomarker data can be combined with pharmacokinetic data to 
build a computer model of ADEPT (Fang and Sun, 2008). 
 
The use of multiple biomarkers in ADEPT clinical trials reflects a sea-change 
of phase I trial design in oncology. A review of over 2000 American Society 
of Clinical Oncology phase I trial abstracts reported that the proportion of 
studies incorporating one or more biomarkers increased significantly over 
time; 14% in 1991  compared with 26% in 2002 (Goulart et al., 2007). In 39% 
of journal articles reporting on phase I trials, a biomarker supported the 
proposed drug mechanism of action. However only 25% of phase I trials 
reported in journal articles used multiple (4 or 5) biomarkers.  
 
Biomarkers require close collaboration between the laboratory and clinic, 
add expense and may require patients to undergo additional investigations. 
However the data they provide can assist in both trial design and pre-clinical 
investigations. The data can allow trial investigators to know whether a drug 
achieved the desired effects. When the system deviates from the desired 
path it may be possible to rapidly adjust the trial design to correct deviations. 
For example during the repeat-treatment ADEPT phase I/II trial, detection by 
FDG-PET (an imaging biomarker) that efficacy only occurred when TPD ≥ 
900mg/m
2 led to modification of the trial protocol to adjust the dose of 
prodrug. Hence mechanistic trial design has been integral to the 
development of ADEPT. 
 
 
  1586.5 Conclusions 
The aim of this MD (Res) thesis was to investigate the conditions required 
for successful repeat ADEPT treatments. In particular the thesis aimed to 
increase understanding of toxicity, efficacy and immunogenicty. ADEPT 
consisted of a recombinant antibody-enzyme (MFECP1) that targeted CEA 
followed by BIP prodrug. 
 
A phase I/II clinical trial of repeat ADEPT treatments was conducted to 
obtain clinical and mechanistic data. This data was combined with the results 
of a single-treatment ADEPT phase I trial (also using MFECP1 and BIP 
prodrug) to provide a dataset on 43 patients. 
 
The toxicity profile was defined and risk factors for adverse events identified. 
Myelosuppression was the principal toxicity and was probably caused by 
activated prodrug travelling to the bone marrow after production in tumour 
and non-tumour tissue. The maximum number of tolerated treatments was 
three. MFECP1 appeared to be safe and repeat MFECP1 administration did 
not increase the risk of infusion reactions. Repeat MFECP1 infusions 
significantly increased the incidence of HACPA. In vitro investigations 
indicated that MFECP1 causes activation and proliferation of T-lymphocytes. 
 
Four patients had significant reductions in tumour activity on FDG-PET 
following ADEPT treatment. Response on FDG-PET only occurred in 
patients who received a TPD ≥ 900mg/m
2. One of three patients treated with 
2 ADEPT treatments at the maximum tolerated TPD responded on FDG-
PET. 
 
This MD (Res) thesis has significantly increased understanding of the 
conditions required for successful ADEPT treatment. 
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Appendix 1 
 
Table 9.1 
Planned treatment schedule for the administration of repeat ADEPT. 
 
  Number of treatments 
  2 3 4 5 6 7 
Day  Cohort 1  Cohort 2  Cohort 3  Cohort 4  Cohort 5  Cohort 6 
1  MFECP1 MFECP1 MFECP1 MFECP1 MFECP1 MFECP1 
2  Prodrug x3  Prodrug x3  Prodrug x3 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
3  MFECP1 MFECP1 MFECP1 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
4  Prodrug x3  Prodrug x3  Prodrug x3  Prodrug x3  Prodrug x3 
Prodrug x3 
MFECP1 
5        Prodrug  x3 
6        
7   MFECP1  MFECP1  MFECP1 MFECP1 MFECP1 
8    Prodrug x3  Prodrug x3  Prodrug x3 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
9     MFECP1  MFECP1 
Prodrug x3 
MFECP1 
Prodrug x3 
MFECP1 
10      Prodrug x3  Prodrug x3  Prodrug x3  Prodrug x3 
On days where prodrug and MFECP1 are shown on the same day it was planned that prodrug 
would be given in the morning and MFECP1 in the evening. 
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Table 9.2 
Results of T-cell proliferation assays using PBMCs from 20 healthy 
donors incubated with overlapping 15mer peptides from CPG2.  
 
 
Peptide 
 
 
 
Identity of 
responding donor 
(volunteer number) 
 
 
 
 
Epitope 
Peptide sequence 
 
 
1 5    QKRDNVLFQAATDEQ 
2       DNVLFQAATDEQPAV 
3       LFQAATDEQPAVIKT 
4       AATDEQPAVIKTLEK 
5       DEQPAVIKTLEKLVN 
6       PAVIKTLEKLVNIET 
7       IKTLEKLVNIETGTG 
8 5    LEKLVNIETGTGDAE 
9       LVNIETGTGDAEGIA 
10       IETGTGDAEGIAAAG 
11       GTGDAEGIAAAGNFL 
12       DAEGIAAAGNFLEAE 
13       GIAAAGNFLEAELKN 
14       AAGNFLEAELKNLGF 
15       NFLEAELKNLGFTVT 
16       EAELKNLGFTVTRSK 
17 18    LKNLGFTVTRSKSAG 
18       LGFTVTRSKSAGLVV 
19       TVTRSKSAGLVVGDN 
20       RSKSAGLVVGDNIVG 
21       SAGLVVGDNIVGKIK 
22       LVVGDNIVGKIKGRG 
23 5    GDNIVGKIKGRGGKN 
24       IVGKIKGRGGKNLLL 
25  1, 6, 16, 18  KIKGRGGKNLLLMSH 
26 1,  9 
A 
GRGGKNLLLMSHMDT 
27       GKNLLLMSHMDTVYL 
28 9    LLLMSHMDTVYLKGI 
29  1, 18, 19    MSHMDTVYLKGILAK 
30       MDTVYLKGILAKAPF 
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Peptide 
 
 
 
Identity of 
responding donor 
(volunteer number) 
 
 
 
 
Epitope 
Peptide sequence 
 
 
31       VYLKGILAKAPFRVE 
32 1    KGILAKAPFRVEGDK 
33       LAKAPFRVEGDKAYG 
34       APFRVEGDKAYGPGI 
35       RVEGDKAYGPGIADD 
36       GDKAYGPGIADDKGG 
37 5,  10  AYGPGIADDKGGNAV 
38 10  PGIADDKGGNAVILH 
39 1  ADDKGGNAVILHTLK 
40 1,  18  KGGNAVILHTLKLLK 
41 1,  18  NAVILHTLKLLKEYG 
42 1,  18 
B 
ILHTLKLLKEYGVRD 
43 18    TLKLLKEYGVRDYGT 
44       LLKEYGVRDYGTITV 
45       EYGVRDYGTITVLFN 
46       VRDYGTITVLFNTDE 
47       YGTITVLFNTDEEKG 
48 10  ITVLFNTDEEKGSFG 
49 10,  18 
C 
LFNTDEEKGSFGSRD 
50 10    TDEEKGSFGSRDLIQ 
51       EKGSFGSRDLIQEEA 
52 10    SFGSRDLIQEEAKLA 
53       SRDLIQEEAKLADYV 
54       LIQEEAKLADYVLSF 
55 1    EEAKLADYVLSFEPT 
56 5,  7    KLADYVLSFEPTSAG 
57       DYVLSFEPTSAGDEK 
58 7  LSFEPTSAGDEKLSL 
59 5,  7  EPTSAGDEKLSLGTS 
60 7,  15 
D 
SAGDEKLSLGTSGIA 
61       DEKLSLGTSGIAYVQ 
62       LSLGTSGIAYVQVNI 
63 4    GTSGIAYVQVNITGK 
64       GIAYVQVNITGKASH 
65       YVQVNITGKASHAGA 
66 9,  16    VNITGKASHAGAAPE 
67       TGKASHAGAAPELGV 
68 18  ASHAGAAPELGVNAL 
69 16  AGAAPELGVNALVEA  E 
70  9, 16, 20  APELGVNALVEASDL 
 
  182 
Peptide 
 
 
 
Identity of 
responding donor 
(volunteer number) 
 
 
 
 
Epitope 
Peptide sequence 
 
 
71       LGVNALVEASDLVLR 
72       NALVEASDLVLRTMN 
73       VEASDLVLRTMNIDD 
74       SDLVLRTMNIDDKAK 
75       VLRTMNIDDKAKNLR 
76       TMNIDDKAKNLRFNW 
77 18  IDDKAKNLRFNWTIA 
78 1,  18  KAKNLRFNWTIAKAG 
79 10,  18 
F 
NLRFNWTIAKAGNVS 
80       FNWTIAKAGNVSNII 
81 18    TIAKAGNVSNIIPAS 
82 1    KAGNVSNIIPASATL 
83 18    NVSNIIPASATLNAD 
84       NIIPASATLNADVRY 
85       PASATLNADVRYARN 
86       ATLNADVRYARNEDF 
87       NADVRYARNEDFDAA 
88       VRYARNEDFDAAMKT 
89       ARNEDFDAAMKTLEE 
90       EDFDAAMKTLEERAQ 
91       DAAMKTLEERAQQKK 
92       MKTLEERAQQKKLPE 
93       LEERAQQKKLPEADV 
94       RAQQKKLPEADVKVI 
95       QKKLPEADVKVIVTR 
96       LPEADVKVIVTRGRP 
97  1, 3, 18  G  ADVKVIVTRGRPAFN 
98       KVIVTRGRPAFNAGE 
99       VTRGRPAFNAGEGGK 
100 3    GRPAFNAGEGGKKLV 
101 16    AFNAGEGGKKLVDKA 
102 9    AGEGGKKLVDKAVAY 
103 18    GGKKLVDKAVAYYKE 
104 16    KLVDKAVAYYKEAGG 
105       DKAVAYYKEAGGTLG 
106       VAYYKEAGGTLGVEE 
107       YKEAGGTLGVEERTG 
108 5    AGGTLGVEERTGGGT 
109       TLGVEERTGGGTDAA 
110       VEERTGGGTDAAYAA 
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Peptide 
 
 
 
Identity of 
responding donor 
(volunteer number) 
 
 
 
 
Epitope 
Peptide sequence 
 
 
111       RTGGGTDAAYAALSG 
112 3    GGTDAAYAALSGKPV 
113       DAAYAALSGKPVIES 
114       YAALSGKPVIESLGL 
115       LSGKPVIESLGLPGF 
116 3    KPVIESLGLPGFGYH 
117       IESLGLPGFGYHSDK 
118       LGLPGFGYHSDKAEY 
119       PGFGYHSDKAEYVDI 
120       GYHSDKAEYVDISAI 
121       SDKAEYVDISAIPRR 
122       AEYVDISAIPRRLYM 
123       VDISAIPRRLYMAAR 
124 18    SAIPRRLYMAARLIM 
125       PRRLYMAARLIMDLG 
126       LYMAARLIMDLGAGK 
127 11    AARLIMDLGAGKHHH 
  128     LIMDLGAGKHHHHHH 
 
A responding donor (to a particular peptide) was a donor whose PBMCs 
proliferated significantly more to peptide than negative control i.e. 
stimulation index ≥ 2. Peptides that reacted with 1 donor are shown in 
blue. Peptides that reacted with 2 donors are shown in yellow. Peptides 
that reacted with 3 donors are shown in orange. Peptides that reacted with 
4 donors are shown in pink. Experiments performed at Biovation Ltd. 
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